SEARCH
検索詳細
清田 尚臣医学部附属病院 腫瘍センター准教授
研究者基本情報
■ 学位■ 研究ニュース
■ 研究キーワード
■ 研究分野
■ 委員歴
研究活動情報
■ 受賞- 2022年 神戸大学医学部附属病院臨床研究推進センター, 優秀論文賞
- 2020年12月 Japan Clinical Oncology Group (JCOG), JCOG下山正徳賞, JCOG1008研究
- 2014年12月 JCOGデータセンター, Best Study Coordinator賞, JCOG研究者その他の賞
- 2025年07月, Journal of Clinical Oncology研究論文（学術雑誌）
- 2025年07月, EJC Skin Cancer研究論文（学術雑誌）
- 2025年04月, Japanese Journal of Clinical Oncology, 英語[査読有り]研究論文（学術雑誌）
- PURPOSE: Hypoparathyroidism (HypoPT) is one of the most common complications of surgical treatment for thyroid cancer and afflicated patients often report symptoms or impairments in quality of life (QoL). We aimed to investigate differences in various QoL domains between thyroid cancer survivors with and without permanent hypoparathyroidism. METHODS: Thyroid cancer survivors with a minimum of 1.5 years post-diagnosis completed the EORTC core questionnaire (EORTC QLQ-C30) and the EORTC thyroid module (QLQ-THY34). Sociodemographic and clinical information were obtained from the patients themselves and their medical charts. Analysis of covariance was used to compare QoL between survivors with and without hypoparathyroidism (adjusting for age, gender, time since diagnosis, and comorbidity). RESULTS: Of the 126 participants, 21 (17%) were diagnosed with permanent HypoPT. There was no evidence of differences regarding any QoL domain between survivors due to hypoparathyroidism. The symptoms with the highest burden for both groups were fatigue (hypoPT: 24.9; non-hypoPT: 32.8; p = 0.151) and insomnia (hypoPT: 22.2; non-hypoPT: 30.8; p = 0.213). Thyroid cancer specific impairments were observed for joint pain (hypoPT: 28.6; non-hypoPT: 34.0; p = 0.480), worry about important others (hypoPT: 25.8; non-hypoPT: 27.9; p = 0.765), exhaustion (hypoPT: 23.8; non-hypoPT: 27.9; p = 0.482), and lacking social support (hypoPT: 36.5; no-hypoPT: 23.0; p = 0.070). CONCLUSION: The present study appears to show that QoL in thyroid cancer survivors may be unrelated to hypoparathyroidism, further suggesting a more complex relationship between these two aspects.2025年04月, Hormones (Athens, Greece), 英語, 国際誌[査読有り]研究論文（学術雑誌）
- 2025年03月, European Thyroid Journal, 英語[査読有り][招待有り]研究論文（学術雑誌）
- BACKGROUND: Platinum and anti-PD-1 antibodies are the front-line systemic therapy for recurrent or metastatic head and neck squamous cell carcinoma (RM-HNSCC). However, limited data are available on clinical outcomes and appropriate regimens for patients with RM-HNSCC following treatment failure with these agents. PATIENTS AND METHODS: We retrospectively analyzed the clinical data of patients with RM-HNSCC from 10 Japanese institutions in whom platinum and nivolumab treatment failed. RESULTS: Of the 480 patients included in the study, 236 were treated with the best supportive care and had a median overall survival of 3.1 months. The remaining 244 patients received salvage-line chemotherapy, which was paclitaxel + cetuximab in 72 (30%), paclitaxel or docetaxel in 89 (36%), and tegafur/gimeracil/oteracil in 48 (20%); the respective objective response rates were 54.9%, 27.9%, and 25.5%, with median progression-free survival of 5.4 months and median overall survival of 13.0 months. Multivariable analysis identified disease stabilization or response on prior nivolumab and paclitaxel + cetuximab as salvage-line chemotherapy to be associated with encouraging progression-free and overall survival. CONCLUSION: This study sheds light on clinical outcomes and prognostic factors in patients with RM-HNSCC after failure of platinum and anti-PD-1 antibody therapy. The findings provide essential baseline data for future therapeutic development in salvage-line settings.2025年03月, The oncologist, 30(3) (3), 英語, 国際誌[査読有り]研究論文（学術雑誌）
- 2025年, Endocrine Journal, 英語[査読有り]研究論文（学術雑誌）
- AIM: Although immune checkpoint inhibitors (ICPi) for salivary gland cancer (SGC) have been investigated in clinical trials, details of the tumor immune microenvironment (TIME) remain unclear. This research aimed to elucidate the TIME of SGC and its relationship with tumor mutation burden (TMB) and to explore the rationale for the applicability of ICPi. MATERIALS AND METHODS: We selected five pathological types, namely adenoid cystic carcinoma (ACC); adenocarcinoma, not otherwise specified (ANOS); salivary duct carcinoma (SDC); and low/high-grade mucoepidermoid carcinoma (MEClow/high). We investigated the TIME and TMB of each pathological type. TIME was evaluated by multiplexed fluorescent immunohistochemistry. TMB was measured by next-generation sequencing. RESULTS: ACC and MEChigh showed the lowest and highest infiltration of immune effector and suppressor cells in both tumor and stroma. ANOS, SDC, and MEClow showed modest infiltration of immune effector cells in tumors. Correlation analysis showed a positive correlation between CD3+CD8+ T cells in tumor and TMB (r = 0.647). CD3+CD8+ T cells in tumors showed a positive correlation with programmed cell death-ligand 1 expression in tumor cells (r = 0.513) and a weak positive correlation with CD3+CD4+Foxp3+ cells in tumors (r = 0.399). However, no correlation was observed between CD3+CD8+ T cells and CD204+ cells in tumors (r = -0.049). CONCLUSION: The TIME of ACC was the so-called immune desert type, which may explain the mechanisms of the poor response to ICPi in previous clinical trials. On the other hand, MEChigh was the immune-inflamed type, and this may support the rationale of ICPi for this pathological subtype.2024年12月, Asia-Pacific journal of clinical oncology, 20(6) (6), 779 - 788, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- 2024年11月, The Lancet. Oncology, 25(12) (12), 1513 - 1514, 英語, 国際誌[査読有り][招待有り]研究論文（学術雑誌）
- Background: Health economic appraisals often rely on the assessment of health utilities using preference-based measures (PBM). The cancer-specific PBM, European Organisation for Research and Treatment of Cancer Quality of Life Utility - Core 10 Dimensions (EORTC QLU-C10D), was developed recently, and now needs to be validated in various clinical populations. Methods: In a multicenter, multinational prospective cohort study, we longitudinally collected EORTC QLQ-C30 and EQ-5D-5L data from patients with thyroid cancer. We applied seven country-specific value sets to the QLQ-C30 data to derive country-specific utility values and used the EQ-5D-5L as a comparator PBM. Criterion validity was assessed by correlating index scores and Bland-Altman plots. Construct validity was investigated by correlating domain scores. Known-group comparisons and responsiveness were assessed using external clinical criteria. Results: A total of 181 patients with thyroid cancer from nine countries (three continents) provided analyzable data. Patients were included if they had differentiated, medullary, or anaplastic thyroid cancer. Mean utility values of both instruments were generally lower compared to general population norms. No floor or ceiling effects were present for the QLU-C10D. The intra-class correlation for EQ-5D-5L and QLU-C10D index values ranged from 0.761 to 0.901 across the measurement timepoints, supporting criterion validity. Spearman's correlation coefficients ranged from 0.289 to 0.716 for theoretically corresponding domain pairs. The QLU-C10D detected differences in 9 of 15 known-group comparisons, supporting sensitivity. Clinically important changes were detected by all QLU-C10D country specific value sets, supporting responsiveness. Further, the QLU-C10D had higher statistical efficiency than the EQ-5D-5L in 74.7% of comparisons. Conclusions: The QLU-C10D is a valid PBM for health economic evaluations in thyroid cancer studies. We recommend its use to estimate health utilities in economic evaluations of thyroid cancer therapies.2024年11月, Thyroid : official journal of the American Thyroid Association, 34(11) (11), 1356 - 1370, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- INTRODUCTION: Minimal important change estimates (MIC) are useful for interpreting results of clinical research with quality of life (QoL) as an endpoint. For the European Organisation for Research and Treatment of Cancer head and neck cancer module, the EORTC QLQ-HN43, no such thresholds are established. METHODS: Head and neck cancer patients under active treatment (n = 503) from 15 countries completed the EORTC QLQ-HN43 three times (t1: before treatment, t2: three months after t1, t3: six months after t1). A subgroup completed a Subjective Significance Questionnaire (SSQ), indicating experienced change from the previous time point in four QoL domains. QoL was assumed to deteriorate after t1 and improve again until t3. The MIC was established using the average of mean differences in SSQ groups (MICmean) and estimates based on logistic regressions (MICpredict). Additionally, minimal detectable changes (MDC) were computed using 0.5 standard deviation and standard error of the mean. RESULTS: For swallowing, speech, dry mouth, and global QoL, the MIC for deterioration were 13, 14, 26, and 10 respectively. The MIC for improvement were 8 (swallowing), 6 (dry mouth), and 5 (global QoL); no MIC for speech improvement can be presented because of insufficient correlation between change score and anchor. The MDC estimates for deterioration were 15, 14, 15, and 11. For improvement, the MDC estimates were 13, 14, 14, and 11. CONCLUSIONS: Our results underline that no single MIC or MDC can be applied to all EORTC QLQ-HN43 scales, and that the MIC for deterioration seems larger than those for improvement.2024年11月, European journal of cancer (Oxford, England : 1990), 212, 115062 - 115062, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- Abstract Background Over the last decade, novel anticancer drugs have improved the prognosis for recurrent or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN). However, this has increased healthcare expenditures and placed a heavy burden on patients and society. This study investigated the frequency of use and costs of select palliative chemotherapy regimens in Japan. Methods From July 2021 to June 2022 in 54 healthcare facilities, we gathered data of patients diagnosed with RM-SCCHN and who had started first-line palliative chemotherapy with one of eight commonly used regimens. Patients with nasopharyngeal carcinomas were excluded. The number of patients receiving each regimen and the costs of each regimen for the first month and per year were tallied. Results The sample comprised 907 patients (674 were < 75 years old, 233 were ≥ 75 years old). 330 (36.4%) received Pembrolizumab monotherapy, and 202 (22.3%) received Nivolumab monotherapy. Over 90% of patients were treated with immune checkpoint inhibitors as monotherapy or in combination with chemotherapy. Treatment regimens’ first-month costs were 612 851–849 241 Japanese yen (JPY). The cost of standard palliative chemotherapy until 2012 was about 20 000 JPY per month. The incremental cost over the past decade is approximately 600 000–800 000 JPY per month, a 30- to 40-fold increase in the cost of palliative chemotherapy for RM-SCCHN. Conclusion First-line palliative chemotherapy for RM-SCCHN exceeds 600 000 JPY monthly. Over the last decade, the prognosis for RM-SCCHN has improved, but the costs of palliative chemotherapy have surged, placing a heavy burden on patients and society.Oxford University Press (OUP), 2024年10月, Japanese journal of clinical oncology, 54(10) (10), 1115 - 1122, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- BACKGROUND AND PURPOSE: Hypothyroidism is a recognized late adverse event following radiotherapy for head and neck cancer (HNC). In the JCOG1008 trial, we treated patients with high-risk HNC with postoperative chemoradiotherapy. We aimed to elucidate factors associated with hypothyroidism by analyzing the JCOG1008 data. MATERIALS AND METHODS: In 2012-2018, 261 patients from 28 institutions were enrolled in JCOG1008. Thyroid function tests were conducted to assess hypothyroidism, including free thyroxine (FT4) and thyroid-stimulating hormone assays. Hypothyroidism was defined as Grade 2 or higher in CTCAE v4.0. Various clinical and dosimetric parameters were analyzed. In radiotherapy, there were no dose constraints for the thyroid. Multivariable analysis was conducted on these variables to identify predictive factors for hypothyroidism. RESULTS: The analysis included 162 patients (57 with 3D-CRT and 105 with IMRT), with a median follow-up of 4.7 years (0.3-9.3 years). Among these, 27 (16.7 %) developed hypothyroidism within 2 years after radiotherapy. In a multivariable analysis, the weekly cisplatin [OR=7.700 (CI: 1.632-36.343, p = 0.010)] and baseline FT4 [OR=0.009 (CI: <0.001-0.313, p = 0.010)] were significantly associated with hypothyroidism in the IMRT group. Regarding dosimetric characteristics, V60Gy [OR=1.069 (CI: 0.999-1.143, p = 0.054)] was potentially associated with the development of hypothyroidism. CONCLUSION: The study revealed that the incidence of hypothyroidism within 2 years after postoperative chemoradiotherapy for high-risk HNC was 16.7 % based on analytical results from prospective clinical trials.2024年10月, Oral oncology, 157, 106976 - 106976, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- BACKGROUND: In a randomized phase II/III trial (JCOG1008), weekly cisplatin (40 mg/m2) was non-inferior to 3-weekly cisplatin (100 mg/m2) for postoperative high-risk head and neck cancer. We investigated how acute kidney injury (AKI), a major dose-limiting toxicity effect of cisplatin, affects overall survival (OS). METHODS: We analyzed 251 patients from JCOG1008 receiving chemoradiotherapy. AKI was defined based on AKI Network criteria (serum creatinine increase of ≥0.3 mg/dL or ≥1.5-fold [≥ stage I]) within 30 days after completing chemoradiotherapy. OS in the two arms was compared according to AKI development using the log-rank test. RESULTS: The total incidence of AKI was lower in the weekly arm than in the 3-weekly arm (38/122 [31.1%] vs. 56/129 [43.4%]). Additionally, stage II/III AKI occurred less frequently in the weekly arm than in the 3-weekly arm (8/122 [6.6%] vs. 19/129 [14.7%]). Cisplatin doses were similar in the weekly arm for patients with and without AKI (median, 238.6 mg/m2 vs. 239.2 mg/m2; p = 0.94), but lower in the 3-weekly arm for those who developed AKI (median, 276.3 mg/m2 vs. 297.4 mg/m2; p = 0.007). In the weekly arm, there was no difference in OS between patients with and without AKI (hazard ratio [HR], 1.06; 95% confidence interval [CI], 0.53 to 2.10). However, in the 3-weekly arm, patients with AKI had poorer OS than those without AKI (HR, 1.83; 95% CI, 1.04 to 3.21). CONCLUSIONS: In this supplementary analysis of JCOG1008 data, AKI impacted the OS of patients with head and neck cancer undergoing postoperative chemoradiotherapy in the 3-weekly arm but not in the weekly arm. Our results further endorse the utilization of weekly cisplatin at 40 mg/m2 in this setting.2024年09月, Cancer medicine, 13(18) (18), e70235, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- Monovalent Omicron XBB.1.5 mRNA vaccines were newly developed and approved by the FDA in Autumn 2023 for preventing COVID-19. However, clinical efficacy for these vaccines is currently lacking. We previously established the quantification of antigen-specific antibody sequence (QASAS) method to assess the response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination at the mRNA level using B-cell receptor (BCR) repertoire assay and the coronavirus antibody database (CoV-AbDab). Here, we used this method to evaluate the immunogenicity of monovalent XBB.1.5 vaccines. We analyzed repeated blood samples of healthy volunteers before and after monovalent XBB.1.5 vaccination (BNT162b2 XBB.1.5 or mRNA-1273.815) for the BCR repertoire to assess BCR/antibody sequences that matched SARS-CoV-2-specific sequences in the database. The number of matched unique sequences and their total reads quickly increased 1 week after vaccination. Matched sequences included those bound to the Omicron strain and Omicron XBB sublineage. The antibody sequences that can bind to the Omicron strain and XBB sublineage revealed that the monovalent XBB.1.5 vaccines showed a stronger response than previous vaccines or SARS-CoV-2 infection before the emergence of XBB sublineage. The QASAS method was able to demonstrate the immunogenic effect of monovalent XBB.1.5 vaccines for the 2023-2024 COVID-19 vaccination campaign.2024年08月, EJHaem, 5(4) (4), 661 - 668, 英語, 国際誌研究論文（学術雑誌）
- 2024年08月, ESMO Open, 9(8) (8)研究論文（学術雑誌）
- (有)科学評論社, 2024年07月, 腫瘍内科, 34(1) (1), 59 - 66, 日本語【周術期薬物療法の成果と今後の課題】頭頸部がんに対する周術期治療
- OBJECTIVES: Acute kidney injury (AKI) represents a major toxicity associated with cisplatin. We developed a risk prediction model for cisplatin-induced AKI in patients with postoperative high-risk head and neck cancer who received chemoradiotherapy during a randomized phase II/III trial, JCOG1008. MATERIALS AND METHODS: Two hundred and fifty-one patients received radiotherapy with weekly cisplatin at 40 mg/m2 (weekly arm) or 3-weekly cisplatin at 100 mg/m2 (3-weekly arm). AKI was defined using the AKI Network classification/staging system as increased serum creatinine of ≥0.3 mg/dL or a ≥1.5-fold increase from baseline 30 days after completing chemoradiotherapy. The Akaike information criterion was used to explore the optimal model by combining explanatory variables at registration. RESULTS: Among the 251 patients (210 men and 41 women (median age; 62 years)), 94 (37.5 %) developed cisplatin-induced AKI. The optimal cisplatin-induced AKI risk prediction model comprised four factors, including a primary site of hypopharynx/larynx (vs. oral cavity/oropharynx), 3-weekly arm (vs. weekly arm), serum albumin of ≤3.5 g/dL (vs. >3.5 g/dL) and creatinine clearance (CCr) of <90 mL/min (vs. ≥90 mL/min). The incidence of cisplatin-induced AKI rose with cumulative count of the four factors. When the cumulative count was ≥2, the positive predictive value for cisplatin-induced AKI was 50.3 %. CONCLUSIONS: We developed a risk prediction model for cisplatin-induced AKI in patients with head and neck cancer who received postoperative chemoradiotherapy using primary site, cisplatin administration method, serum albumin, and CCr. Patients with risk factors unrelated to the cisplatin administration method should adopt a weekly cisplatin regimen.2024年07月, Oral oncology, 154, 106868 - 106868, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- (一社)日本内分泌外科学会, 2024年06月, 日本内分泌外科学会雑誌, 41(2) (2), 100 - 104, 日本語
- Background Since the larynx and pharynx are vital for respiration, swallowing, and speech, chemoradiotherapy (CRT) has been widely applied for T3 hypopharyngeal cancer (HPC) as an organ-preserving treatment. However, CRT can lead to severe late adverse events such as dysphagia and aspiration pneumonia, especially in patients who have difficulty swallowing and/or aspiration at the time of initial diagnosis. Patients and methods Between 2012 and 2020, 86 patients with T3 HPC treated with curative intent at Kobe University Hospital were included in this study. The average age was 69 years old, ranging from 43 to 89. Diseases were classified as Stage III in 29 patients, Stage IVA in 52 patients, and Stage IVB in five patients. Thirty-five (41%) patients were treated by CRT, and 51 (59%) patients were treated by surgery. Patients were followed up for at least two years, and the follow-up period ranged from four to 128 months (median: 45 months). Results Three-year progression-free survival (PFS) rates of patients treated by CRT and patients treated by surgery were 56.2% and 60.3%, respectively. Three-year disease-specific survival (DSS) rates of patients treated by CRT and surgically treated patients were 79.0% vs. 70.8%, respectively. Three-year overall survival (OS) rates of patients treated by CRT and surgically treated patients were 64.5% and 69.0%, respectively. Of note, a significant difference was observed between three-year DSS and three-year PFS (79.0% vs. 56.2%, p = 0.0014) in the patients treated by CRT but not in the patients treated by surgery. Conclusions No significant differences were observed between the PFS, DSS, and OS rates of patients treated by CRT and those of surgically treated patients. Locoregional recurrences after CRT were significantly successfully salvaged by surgical intervention. These results suggest that CRT can be applied as an alternative to surgery without reducing survival, especially for patients without severe clinical symptoms. Meticulous follow-up is mandatory for early detection of recurrence to salvage by surgery and for the management of late adverse events.2024年06月, Cureus, 16(6) (6), e62553, 英語, 国際誌研究論文（学術雑誌）
- Head and neck cancer (HNC) patients suffer from a range of health-related quality of life (HRQoL) issues, but little is known about their long-term HRQoL. This study explored associations between treatment group and HRQoL at least 5 years' post-diagnosis in HNC survivors. In an international cross-sectional study, HNC survivors completed the European Organization for Research and Treatment of Cancer (EORTC) quality of life core questionnaire (EORTC-QLQ-C30) and its HNC module (EORTC-QLQ-H&N35). Meaningful HRQoL differences were examined between five treatment groups: (a) surgery, (b) radiotherapy, (c) chemo-radiotherapy, (d) radiotherapy ± chemotherapy and neck dissection and (e) any other surgery (meaning any tumour surgery that is not a neck dissection) and radiotherapy ± chemotherapy. Twenty-six sites in 11 countries enrolled 1105 survivors. They had a median time since diagnosis of 8 years, a mean age of 66 years and 71% were male. After adjusting for age, sex, tumour site and UICC stage, there was evidence for meaningful differences (10 points or more) in HRQoL between treatment groups in seven domains (Fatigue, Mouth Pain, Swallowing, Senses, Opening Mouth, Dry Mouth and Sticky Saliva). Survivors who had single-modality treatment had better or equal HRQoL in every domain compared to survivors with multimodal treatment, with the largest differences for Dry Mouth and Sticky Saliva. For Global Quality of Life, Physical and Social Functioning, Constipation, Dyspnoea and Financial Difficulties, at least some treatment groups had better outcomes compared to a general population. Our data suggest that multimodal treatment is associated with worse HRQoL in the long-term compared to single modality.2024年05月, International journal of cancer, 154(10) (10), 1772 - 1785, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- The Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data (SISAQOL) initiative was established in 2016 to assess the quality and standardization of patient-reported outcomes (PRO) data analysis in randomized controlled trials (RCTs) on advanced breast cancer. The initiative identified deficiencies in PRO data reporting, including nonstandardized methods for handling missing data. This study evaluated the reporting of health-related quality of life (HRQOL) in Japanese cancer RCTs to provide insights into the state of PRO reporting in Japan. The study reviewed PubMed articles published from 2010 to 2018. Eligible studies included Japanese cancer RCTs with ≥50 adult patients (≥50% were Japanese) with solid tumors receiving anticancer treatments. The evaluation criteria included clarity of the HRQOL hypotheses, multiplicity testing, primary analysis methods, and reporting of clinically meaningful differences. Twenty-seven HRQOL trials were identified. Only 15% provided a clear HRQOL hypothesis, and 63% examined multiple HRQOL domains without adjusting for multiplicity. Model-based methods were the most common statistical methods for the primary HRQOL analysis. Only 22% of the trials explicitly reported clinically meaningful differences in HRQOL. Baseline assessments were reported in most trials, but only 26% reported comparisons between the treatment groups. HRQOL analysis was based on the intention-to-treat population in 19% of the trials, and 74% reported compliance at follow-up; however, 41% did not specify how missing values were handled. Although the rates of reporting clinical hypotheses and clinically meaningful differences were relatively low, the current state of HRQOL evaluation in the Japanese cancer RCT appears comparable to that of previous studies.2024年05月, Cureus, 16(5) (5), e60804, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- Background: Driver mutations at BRAF V600 are frequently identified in papillary thyroid cancer and anaplastic thyroid cancer (ATC), in which BRAF inhibitors have shown clinical effectiveness. This Japanese phase 2 study evaluated the efficacy and safety of a BRAF inhibitor, encorafenib, combined with an MEK inhibitor, binimetinib, in patients with BRAF V600-mutated thyroid cancer. Methods: This phase 2, open-label, uncontrolled study was conducted at 10 institutions targeted patients with BRAF V600-mutated locally advanced or distant metastatic thyroid cancer not amenable to curative treatment who became refractory/intolerant to ≥1 previous vascular endothelial growth factor receptor-targeted regimen(s) or were considered ineligible for those. The primary endpoint was centrally assessed objective response rate (ORR). The secondary endpoints included duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety. Results: We enrolled 22 patients with BRAFV600E-mutated thyroid cancer: 17 had differentiated thyroid cancer (DTC), and 5 had ATC. At data cutoff (October 26, 2022), the median follow-up was 11.5 (range = 3.4-19.0) months. The primary endpoint of centrally assessed ORR was 54.5% (95% confidence interval [CI] 32.2-75.6; partial response in 12 patients and stable disease in 10). The ORRs in patients with DTC and ATC were 47.1% (8 of 17) and 80.0% (4 of 5), respectively. The medians for DOR and PFS by central assessment and for OS were not reached in the overall population, the DTC subgroup, or the ATC subgroup. At 12 months, the rate of ongoing response was 90.9%, and the PFS and OS rates were 78.8% and 81.8%, respectively. All patients developed ≥1 adverse events (AEs): grade 3 AEs in 6 patients (27.3%). No patients developed grade 4-5 AEs. The most common grade 3 AE was lipase increased (4 patients [18.2%]). Those toxicities were mostly manageable with appropriate monitoring and dose adjustment. Conclusions: Treatment with encorafenib plus binimetinib met the primary endpoint criteria and demonstrated clinical benefit in patients with BRAFV600E-mutated thyroid cancer regardless of its histological type, such as DTC or ATC, with no new safety concerns identified. Encorafenib plus binimetinib could thus be a new treatment option for BRAF V600-mutated thyroid cancer. Clinical Trial Registration number: Japan Registry of Clinical Trials: jRCT2011200018.2024年03月, Thyroid : official journal of the American Thyroid Association, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- Surgery remains a foundation of treatment for locally advanced squamous cell carcinoma of the head and neck. For postoperative patients at high risk of recurrence, however, surgery by itself is not enough, and improvement in survival requires postoperative treatment. Unlike the case with most other malignancies, the standard postoperative treatment for locally advanced squamous cell carcinoma of the head and neck patients with high-risk factors for recurrence is radiotherapy or chemoradiotherapy with cisplatin. However, chemoradiotherapy with cisplatin at a dose of 100 mg/m2 once every 3 weeks has raised discussion over insufficient cisplatin delivery due to high-dose-related toxicity. As a possible solution, a recent randomized trial of the JCOG1008 has proved the non-inferiority of postoperative chemoradiotherapy with weekly cisplatin at a dose of 40 mg/m2 to 3-weekly cisplatin in terms of overall survival. Here, this review article focuses on current evidence and future perspectives of postoperative treatment for locally advanced squamous cell carcinoma of the head and neck.2024年03月, Japanese Journal of Clinical Oncology, 英語, 国際誌[査読有り][招待有り]研究論文（学術雑誌）
- The expression of EGFR and p16 in the external auditory canal squamous cell carcinoma (EACSCC) and their impacts on oncological outcomes were not well studied. Seventeen-one consecutive patients who were treated for EACSCC at Kobe University Hospital from 1995 to 2018 were enrolled in this study. The expression of EGFR, and p16 were evaluated and their impacts on oncological outcomes were statistically analyzed. Positive expression of EGFR was observed in 62 patients (87%). Strong positive expression of p16 were observed in 18 patients (32.4%), and weakly positive expression in 30 patients (42.3%), respectively. While the number of the patients with negative EGFR expression were limited, all the surgically treated patients with negative EGFR expression have been alive without disease. In the patients with T3 & T4a EACSCC, prognosis of the patients with positive p16 expression EACSCC tended to be better than those with negative p16 expression. These results suggest the clinical significance of EGFR and p16 expressions in the patients with advanced EACSCC to predict oncological outcomes.2024年01月, The Kobe journal of medical sciences, 69(4) (4), E144-E150, 英語, 国内誌研究論文（学術雑誌）
- INTRODUCTION: Chemoradiation therapy (CRT) with concurrent high-dose cisplatin (CDDP) is one of the standard treatment options for locally advanced head and neck cancer. Since the indications specific to the older population have not been reported, we conducted a multicenter survey on the indications. METHODS: In April and May 2023, a questionnaire survey was emailed to all institutions belonging to the JCOG-HNCSG, consisting of 37 institutions. RESULTS: The major factors influencing the indications for high-dose CDDP were renal function and performance status (PS). The majority agreed that the treatment is administered to patients aged 65-74 years with PS 0-1 and 65-74 years with eGFR ≥60 (ml/ min/1.73m2), and not in patients aged ≥75 years with PS 2, ≥80 years with PS 1, and ≥65 years with eGFR <60. Regarding weekly CDDP, the majority agreed that the treatment is not conducted in patients aged ≥75 years with PS 2, ≥65 years with eGFR <40, and ≥70 years with eGFR <50. DISCUSSION: In Japan, where CRT is actively performed even among older people, a survey was conducted to determine its indications. Renal function and PS were considered important, and comorbidities, such as heart failure, were considered while determining the indication. These results will help define the eligibility criteria for prospective studies on CRT in older patients.2024年, Frontiers in oncology, 14, 1441056 - 1441056, 英語, 国際誌研究論文（学術雑誌）
- A monovalent Omicron XBB.1.5 mRNA RBD analogue vaccine, MAFB-7256a (DS-5670d), was newly developed and approved in Japan in the Spring of 2024 for the prevention of COVID-19. However, clinical efficacy data for this vaccine are currently lacking. We previously established the Quantification of Antigen-specific Antibody Sequence (QASAS) method to assess the response to SARS-CoV-2 vaccination at the mRNA level using B-cell receptor (BCR) repertoire assays and the Coronavirus Antibody Database (CoV-AbDab). Here, we used this method to evaluate the immunogenicity of MAFB-7256a. We analyzed repeated blood samples using the QASAS method from three healthy volunteers before and after MAFB-7256a vaccination. BCR response increased rapidly one week post-vaccination and then decreased, as with conventional vaccine. Notably, the matched sequences after MAFB-7256a vaccination specifically bound to the receptor-binding domain (RBD), with no sequences binding to other epitopes. These results validate that MAFB-7256a is an effective vaccine that exclusively induces antibodies specific for the RBD, demonstrating its targeted immunogenic effect.2024年, Frontiers in immunology, 15, 1468760 - 1468760, 英語, 国際誌研究論文（学術雑誌）
- PURPOSE: The purpose of this study was to investigate the impact of the type of data capture on the time and help needed for collecting patient-reported outcomes as well as on the proportion of missing scores. METHODS: In a multinational prospective study, thyroid cancer patients from 17 countries completed a validated questionnaire measuring quality of life. Electronic data capture was compared to the paper-based approach using multivariate logistic regression. RESULTS: A total of 437 patients were included, of whom 13% used electronic data capture. The relation between data capture and time needed was modified by the emotional functioning of the patients. Those with clinical impairments in that respect needed more time to complete the questionnaire when they used electronic data capture compared to paper and pencil (ORadj 24.0; p = 0.006). This was not the case when patients had sub-threshold emotional problems (ORadj 1.9; p = 0.48). The odds of having the researcher reading the questions out (instead of the patient doing this themselves) (ORadj 0.1; p = 0.01) and of needing any help (ORadj 0.1; p = 0.01) were lower when electronic data capture was used. The proportion of missing scores was equivalent in both groups (ORadj 0.4, p = 0.42). CONCLUSIONS: The advantages of electronic data capture, such as real-time assessment and fewer data entry errors, may come at the price of more time required for data collection when the patients have mental health problems. As this is not uncommon in thyroid cancer, researchers need to choose the type of data capture wisely for their particular research question.2023年12月, Endocrine, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- BACKGROUND: Total pharyngolaryngectomy (TPL) is standard treatment for hypopharyngeal cancer. However, extensive thyroidectomy and paratracheal nodal dissection (PTND) can cause hypoparathyroidism. We sought to determine the optimum extent of resection. METHODS: We analyzed the clinicopathological information of 161 pyriform sinus cancer patients undergoing TPL from 25 Japanese institutions. Rates of recurrence and risk factors for hypoparathyroidism, as well as incidence of pathological contralateral level VI nodal metastasis and stomal recurrence, were investigated. RESULTS: The extent of thyroidectomy and nodal dissection were not independent risk factors for recurrence. Incidences of contralateral level VI nodal involvement and stomal recurrence were 1.8% and 1.2%, respectively. Patients undergoing hemithyroidectomy/ipsilateral PTND did not develop stomal recurrence and had the lowest incidence of hypoparathyroidism. Prognosis in patients without tracheostomy prior to hemithyroidectomy/ipsilateral PTND was comparable to that with more extensive resections. CONCLUSIONS: Hemithyroidectomy/ipsilateral PTND may be sufficient for pyriform sinus cancer cases without tracheostomy.2023年11月, Head & neck, 46(2) (2), 269 - 281, 英語, 国際誌研究論文（学術雑誌）
- BACKGROUND: Chemoradiotherapy (CRT) with concurrent cisplatin is the standard of care as a nonsurgical definitive treatment for patients with locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). However, CRT is associated with increased severe late adverse events, including swallowing dysfunction, xerostomia, ototoxicity, and hypothyroidism. Few strategies aimed at less invasive CRT without compromising treatment outcomes have been successful. The purpose of this study is to confirm the non-inferiority of reduced dose prophylactic radiation with 40 Gy compared to standard dose prophylactic radiation with 56 Gy in terms of the time to treatment failure (TTF) among patients with clinical stage III-IVB LA-SCCHN. METHODS: This study is a multicenter, two-arm, open-label, randomized phase III trial. Patients with LA-SCCHN excluding p16 positive oropharynx cancer are randomized to the standard arm or experimental arm. A total dose of 70 Gy for tumors with concurrent cisplatin at 100 mg/m2 are administered in both arms. For prophylactic field, patients in the standard arm receive a total dose of 56 Gy in 35 fractions for 7 weeks using simultaneous integrated boost (SIB56) and those in the experimental arm receive 40 Gy in 20 fractions using two-step methods for 4 weeks (2-step40). A total of 400 patients will be enrolled from 52 Japanese institutions within 5 years. The primary endpoint is TTF, and the secondary endpoints are overall survival, complete response rate, progression-free survival, locoregional relapse-free survival, acute and late adverse events, quality of life score, and swallowing function score. DISCUSSION: If the experimental arm is non-inferior to the standard arm in terms of TTF and superior on the safety endpoints, the 2-step40 procedure is the more useful treatment than SIB56 for definitive CRT. TRIAL REGISTRATION: This trial has been registered in the Japan Registry of Clinical Trials as jRCTs031210100 ( https://jrct.niph.go.jp/latest-detail/jRCTs031210100 ). Date of Registration: May 2021.2023年11月, BMC cancer, 23(1) (1), 1068 - 1068, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- (有)科学評論社, 2023年09月, 腫瘍内科, 32(3) (3), 223 - 229, 日本語【各臓器がんに対する周術期(手術・放射線治療)薬物療法のState of the art】頭頸部がん
- BACKGROUND: Squamous cell carcinoma of the external auditory canal (EACSCC) is a rare condition. However, a standard treatment has not yet been established. We retrospectively evaluated the efficacy, adverse events, and feasibility of TPF-CCRT (concomitant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil) in patients with advanced EACSCC. METHODS: Thirty-five consecutive patients with advanced EACSCC (T3, T4) initially treated with TPF-CCRT at Kobe University Hospital were included. T4 diseases with invasion of the brain, internal carotid artery, or internal jugular vein were classified as T4b, and those without these features were classified as T4a. RESULTS: Five-year overall survival rates for T3 and T4 were 100% and 64.2%, respectively. A significant difference was observed between T4a and T4b (82.4% vs. 30%, p = 0.007). Five-year progression-free survival rates of T3, T4a, and T4b were 100%, 68%, and 20% (p = 0.022), respectively. CONCLUSIONS: TPF-CCRT should be considered as a plausible treatment option for advanced EACSCC.2023年07月, Head & neck, 英語, 国際誌研究論文（学術雑誌）
- The aim of the "Japanese Clinical Practice Guidelines for Head and Neck Cancer - 2022 Update" is to review the latest evidence regarding head and neck cancer and to present the current standard approaches for diagnosis and treatment. These evidence-based recommendations were created with the consensus of the Guideline Committee, which is composed of otorhinolaryngologists and head and neck surgeons, together with radiologists, radiation oncologists, medical oncologists, plastic surgeons, dentists, palliative care physicians, and rehabilitation physicians. These guidelines were created by the Clinical Practice Guideline Committee of the Japan Society for Head and Neck Cancer based on the "Head and Neck Cancer Treatment Guidelines 2018 Edition," and the revised draft was compiled after evaluation by the Assessment Committee and public comments. The 'Clinical questions and recommendations' section consists of 13 categories, and 59 clinical questions are described in total. Here we describe 6 clinical questions specific to other sets of guidelines with recommendations and comments.2023年07月, Auris, nasus, larynx, 英語, 国際誌研究論文（学術雑誌）
- The use of anti-SARS-CoV-2 antibody products like tixagevimab/cilgavimab represents an important strategy to protect immunocompromised patients with haematological malignancies from COVID-19. Although patients who receive these agents should still be vaccinated, the use of tixagevimab/cilgavimab can mask the production of anti-spike antibody after vaccination, making it hard to assess vaccine response. We have newly established a quantification method to assess the response to SARS-CoV-2 vaccination at the mRNA level using B-cell receptor (BCR) repertoire assay and the Coronavirus Antibody Database (CoV-AbDab). Repeated blood samples before and after vaccination were analysed for the BCR repertoire, and BCR sequences were searched in the database. We analysed the number and percentage frequency of matched sequences. We found that the number of matched sequences increased 2 weeks after the first vaccination and quickly decreased. Meanwhile, the number of matched sequences more rapidly increased after the second vaccination. These results show that the postvaccine immune response can be assessed at the mRNA level by analysing the fluctuation in matching sequences. Finally, BCR repertoire analysis with CoV-AbDab clearly demonstrated the response to mRNA SARS-CoV-2 vaccination even after tixagevimab/cilgavimab administration in haematological malignancy patients who underwent allogeneic haematopoietic stem cell transplantation.2023年06月, British journal of haematology, 202(3) (3), 504 - 516, 英語, 国際誌研究論文（学術雑誌）
- (NPO)日本緩和医療学会, 2023年06月, Palliative Care Research, 18(Suppl.) (Suppl.), S209 - S209, 日本語QOL/PRO研究に関する国際的取り組みに参画するための国内体制整備
- (NPO)日本緩和医療学会, 2023年06月, Palliative Care Research, 18(Suppl.) (Suppl.), S209 - S209, 日本語QOL/PRO研究に関する国際的取り組みに参画するための国内体制整備
- (一社)日本血栓止血学会, 2023年05月, 日本血栓止血学会誌, 34(2) (2), 195 - 195, 日本語進行・再発・転移の未治療固形がん患者における静脈血栓塞栓症の前向き観察研究の統合解析
- (一社)日本頭頸部癌学会, 2023年05月, 頭頸部癌, 49(2) (2), 137 - 137, 日本語白金製剤・ニボルマブ不応・不耐後の再発・転移頭頸部扁平上皮癌の臨床転帰に関する後方視的多施設共同研究
- (一社)日本頭頸部癌学会, 2023年05月, 頭頸部癌, 49(2) (2), 132 - 132, 日本語当院における甲状腺がんに対するがん遺伝子パネル検査の現状と課題
- (一社)日本頭頸部癌学会, 2023年05月, 頭頸部癌, 49(2) (2), 152 - 152, 日本語進行頭頸部扁平上皮がん患者における静脈血栓塞栓症 前向き観察研究サブ解析
- The long-term problems of head and neck cancer survivors (HNCS) are not well known. In a cross-sectional international study aimed at exploring the long-term quality of life in this population, 1114 HNCS were asked to state their two most serious long-term effects. A clinician recorded the responses during face-to-face appointments. A list of 15 example problems was provided, but a free text field was also available. A total of 1033 survivors responded to the question. The most frequent problems were 'dry mouth' (DM) (n = 476; 46%), 'difficulty swallowing/eating' (DSE) (n = 408; 40%), 'hoarseness/difficulty speaking' (HDS) (n = 169; 16%), and 'pain in the head and neck' (PHN) (n = 142; 14%). A total of 5% reported no problems. Logistic regression adjusted for age, gender, treatment, and tumor stage and site showed increased odds of reporting DM and DSE for chemo-radiotherapy (CRT) alone compared to surgery alone (odds ratio (OR): 4.7, 95% confidence interval (CI): 2.5-9.0; OR: 2.1, CI: 1.1-3.9), but decreased odds for HDS and PHN (OR: 0.3, CI: 0.1-0.6; OR: 0.2, CI: 0.1-0.5). Survivors with UICC stage IV at diagnosis compared to stage I had increased odds of reporting HDS (OR: 1.9, CI: 1.2-3.0). Laryngeal cancer survivors had reduced odds compared to oropharynx cancer survivors of reporting DM (OR: 0.4, CI: 0.3-0.6) but increased odds of HDS (OR: 7.2, CI: 4.3-12.3). This study provides evidence of the serious long-term problems among HNCS.2023年03月, Healthcare (Basel, Switzerland), 11(6) (6), 英語, パスワードが無い, 国際誌, 国際共著している[査読有り]研究論文（学術雑誌）
- Assessments of patient-reported outcomes and health-related quality of life in cancer clinical trials have been increasingly emphasized recently because patient and public involvement in cancer treatment development has been promoted by regulatory authorities and academic societies. To assess patient experiences during and after cancer treatment, there is interest in implementing patient-reported outcome and health-related quality of life assessments into cancer clinical trials. The Japan Clinical Oncology Group quality of life ad hoc committee previously created a version of the Quality of Life Assessment Policy in 2006. Recently, there has been increasing demand from Japan Clinical Oncology Group researchers to assess patient-reported outcome/health-related quality of life in clinical trials. Although guidelines are available regarding planning and reporting clinical trials that include patient-reported outcome/health-related quality of life as an endpoint, there are still issues regarding the lack of consensus on standardized methods for analysing and interpreting the results. Hence, it was considered necessary to reorganize the Japan Clinical Oncology Group patient-reported outcome/quality of life research committee and to revise the former patient-reported outcome/quality of life research policy to promote patient-reported outcome/health-related quality of life research in future Japan Clinical Oncology Group trials. The purpose of this Japan Clinical Oncology Group patient-reported outcome/quality of life research policy is to define patient-reported outcome/health-related quality of life research and provide guidelines for including patient-reported outcome/health-related quality of life as an endpoint in Japan Clinical Oncology Group trials.2023年03月, Japanese journal of clinical oncology, 53(3) (3), 195 - 202, 英語, パスワードが無い, 国際誌, 国際共著していない[査読有り]研究論文（学術雑誌）
- (一社)日本内分泌外科学会, 2023年03月, 日本内分泌外科学会雑誌, 40(1) (1), 29 - 32, 日本語【ゲノム医療時代の甲状腺癌治療】遺伝子異常に基づく薬物療法時代の検体処理
- (一社)日本内科学会, 2023年02月, 日本内科学会雑誌, 112(臨増) (臨増), 163 - 163, 日本語がん関連静脈血栓塞栓症に対するアピキサバン療法の出血リスク予測 多施設共同第2相臨床試験副次的解析
- CONTEXT: The occurrence of multiple endocrinopathies due to immune checkpoint inhibitors (ICIs) is a relatively common adverse event. However, the occurrence of a combination of hypophysitis and type 1 diabetes mellitus (T1DM) is extremely rare, and its clinical features are unclear. OBJECTIVE: We comparatively analyzed the clinical features of this combination and each individual ICI-induced endocrinopathy. METHODS: We reported 3 cases that we encountered and reviewed previously reported cases of patients with combined hypophysitis and T1DM due to ICIs. RESULTS: Anti-programmed cell death-1 (anti-PD-1) antibodies were prescribed to all 3 cases. The duration from ICI initiation to the onset of endocrine disease was 12 to 48 weeks. Several human leukocyte antigen (HLA) haplotypes that have disease susceptibility to hypophysitis were detected in all 3 patients. With the 17 previously reported cases, combined endocrinopathies were more common in men (85%). The onset age was in the 60s for both combined and single endocrinopathies. Anti-PD-1 antibodies were used in most of the cases (90%). The time from ICI initiation to the onset of endocrinopathies was 24 (8-76) weeks for hypophysitis and 32 (8-76) weeks for T1DM in patients with combined endocrinopathies, which was not significantly different from that for each single endocrinopathy. CONCLUSION: We presented 3 cases of patients with combined endocrinopathies of hypophysitis and T1DM that may have been caused by anti-PD-1 antibodies. There was no difference in the time from ICI initiation to the onset of endocrinopathies between combined and single endocrinopathies. Further case accumulation and pathogenic investigations are required.2023年01月, Journal of the Endocrine Society, 7(3) (3), bvad002, 英語, 国際誌研究論文（学術雑誌）
- INTRODUCTION: Adoptive cell transfer of genetically engineered T cells is a promising treatment for malignancies; however, there are few ideal cancer antigens expressed on the cell surface, and the development of chimeric antigen receptor T cells (CAR-T cells) for solid tumour treatment has been slow. CAR-T cells, which recognise major histocompatibility complex and peptide complexes presented on the cell surface, can be used to target not only cell surface antigens but also intracellular antigens. We have developed a CAR-T-cell product that recognises the complex of HLA-A*02:01 and an epitope of the MAGE-A4 antigen equipped with a novel signalling domain of human GITR (investigational product code: MU-MA402C) based on preclinical studies. METHODS AND ANALYSIS: This is a dose-escalation, multi-institutional, phase 1 study to evaluate the tolerability and safety of MU-MA402C for patients with MAGE A4-positive and HLA-A*02:01-positive unresectable advanced or recurrent solid cancer. Two dose cohorts are planned: cohort 1, MU-MA402C 2×108/person; cohort 2, MU-MA402C 2×109/person. Prior to CAR-T-cell infusion, cyclophosphamide (CPA) and fludarabine (FLU) will be administered as preconditioning chemotherapy. Three evaluable subjects per cohort, for a total of 6 subjects (maximum of 12 subjects), will be recruited for this clinical trial. The primary endpoints are safety and tolerability. The severity of each adverse event will be evaluated in accordance with Common Terminology Criteria for Adverse Events V.5.0. The secondary endpoint is efficacy. Antitumour response will be evaluated according to Response Evaluation Criteria in Solid Tumours V.1.1. ETHICS AND DISSEMINATION: This clinical trial will be conducted in accordance with the current version of Good Clinical Practice. The protocol was approved by the Clinical Research Ethics Review Committee of Mie University Hospital (approval number F-2021-017). The trial results will be published in peer-reviewed journals and/or disseminated through international conferences. TRIAL REGISTRATION NUMBER: jRCT2043210077.2022年11月, BMJ open, 12(11) (11), e065109, 英語, 国際誌研究論文（学術雑誌）
- (一社)日本癌治療学会, 2022年10月, 日本癌治療学会学術集会抄録集, 60回, O48 - 3, 英語切除不能進行/転移・再発固形癌に対するePROモニタリングの有用性を検証する比較試験
- 2022年09月, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 40(26) (26), 3096 - 3097, 英語, パスワードが無い, 国際誌研究論文（学術雑誌）
- PURPOSE: Anaplastic thyroid cancer (ATC) is a rare and highly aggressive cancer for which effective systemic therapy has long been sought. Here, we assessed the efficacy and safety of lenvatinib in patients with unresectable ATC. PATIENTS AND METHODS: The study was investigator-initiated and conducted under a multicenter, open-label, nonrandomized, phase II design. Eligibility criteria included pathologically proven ATC; unresectable measurable lesion as defined by RECIST 1.1; age 20 years or older; ECOG PS 0-2; and adequate organ function. The primary end-point was overall survival. Secondary end-points were progression-free survival, objective response rate, disease control rate, clinical benefit rate, and safety. RESULTS: Of 52 patients enrolled from 17 institutions, 42 patients who were confirmed to have ATC were included for efficacy analysis, and 50 patients were included for safety analysis. The estimated 1-year overall survival rate was 11.9% (95% CI, 4.4%-23.6%). One patient (2.4%) achieved complete response, four patients (9.5%) partial response, and 26 patients (61.9%) stable disease, including nine patients (21.4%) who demonstrated durable stable disease, giving an objective response rate of 11.9%, disease control rate of 73.8%, and clinical benefit rate of 33.3%. Adverse events of any grade were observed in 45 patients (90.0%), the most common of which of any grade included loss of appetite (48.0%), fatigue (48.0%), hypertension (44.0%), and palmar-plantar erythrodysesthesia syndrome (26.0%). CONCLUSION: Lenvatinib treatment resulted in disappointing survival for unresectable ATC patients. Although the number of responders was small, responses were durable, indicating that lenvatinib may be beneficial for selected patients. Further investigation to identify suitable candidates for lenvatinib monotherapy is needed.Elsevier BV, 2022年09月, European journal of cancer (Oxford, England : 1990), 173, 210 - 218, 英語, 国際誌研究論文（学術雑誌）
- It was not until around 2000 that human papillomavirus-related oropharyngeal carcinoma was recognized as carcinoma with clinical presentations different from nonrelated head and neck carcinoma. Twenty years after and with the revision of the tumor-node-metastasis classification in 2017, various clinical trials focused on human papillomavirus-related oropharyngeal carcinoma to improve the prognosis and quality of life of patients with this disease. However, the incidence of human papillomavirus-related cancers is increasing, which is expected to be particularly prominent in Japan, where human papillomavirus vaccination is not widely available. In this review, we describe the current status of clinical trials (mainly focused on initial surgery and radiation dose reduction) for, primary and secondary prevention of, and the present status of human papillomavirus-related oropharyngeal carcinoma in Japan.2022年07月, Japanese journal of clinical oncology, 52(7) (7), 700 - 706, 英語, 国際誌研究論文（学術雑誌）
- PURPOSE: The standard treatment for postoperative high-risk locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) is chemoradiotherapy with 3-weekly cisplatin (100 mg/m2). However, whether chemoradiotherapy with weekly cisplatin (40 mg/m2) yields comparable efficacy with 3-weekly cisplatin in postoperative high-risk LA-SCCHN is unknown. PATIENTS AND METHODS: In this multi-institutional open-label phase II/III trial, patients with postoperative high-risk LA-SCCHN were randomly assigned to receive either chemoradiotherapy with 3-weekly cisplatin (100 mg/m2) or with weekly cisplatin (40 mg/m2) to confirm the noninferiority of weekly cisplatin. The primary end point of phase II was the proportion of treatment completion, and that of phase III was overall survival. A noninferiority margin of hazard ratio was set at 1.32. RESULTS: Between October 2012 and December 2018, a total of 261 patients were enrolled (3-weekly cisplatin, 132 patients; weekly cisplatin, 129 patients). At the planned third interim analysis in the phase III part, after a median follow-up of 2.2 (interquartile range 1.19-3.56) years, chemoradiotherapy with weekly cisplatin was noninferior to 3-weekly cisplatin in terms of overall survival, with a hazard ratio of 0.69 (99.1% CI, 0.374 to 1.273 [< 1.32], one-sided P for noninferiority = .0027 < .0043). Grade 3 or more neutropenia and infection were less frequent in the weekly arm (3-weekly v weekly, 49% v 35% and 12% v 7%, respectively), as were renal impairment and hearing impairment. No treatment-related death was reported in the 3-weekly arm, and two (1.6%) in the weekly arm. CONCLUSION: Chemoradiotherapy with weekly cisplatin is noninferior to 3-weekly cisplatin for patients with postoperative high-risk LA-SCCHN. These findings suggest that chemoradiotherapy with weekly cisplatin can be a possible treatment option for these patients.2022年06月, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 40(18) (18), 1980 - 1990, 英語, パスワードが無い, 国際誌, 国際共著していない[査読有り]研究論文（学術雑誌）
- Anti-CD20 antibodies react with CD20 expressed not only on malignant B cells, but also on normal B cells. It has been reported that patients treated with anti-CD20 antibodies had an insufficient response to two-dose mRNA SARS-CoV-2 vaccination. To investigate the efficacy of a third dose in these patients, we investigated serum IgG antibody titers for the S1 protein after a third vaccination in 22 patients treated with the anti-CD20 antibody who failed two-dose vaccination. Results showed that overall, 50% of patients seroconverted. Although no patient who received the third dose within 1 year of the last anti-CD20 antibody administration showed an increase in S1 antibody titer, 69% of patients who received the third dose more than 1 year after the last anti-CD20 antibody administration seroconverted. Our data show that a third dose of vaccination is effective in improving the seroconversion rate in patients treated with the anti-CD20 antibody who failed standard two-dose vaccination.2022年06月, Vaccines, 10(6) (6), 英語, 国際誌研究論文（学術雑誌）
- Regorafenib is an oral multikinase inhibitor targeting several tyrosine kinase receptors including BRAF and epidermal growth factor receptor (EGFR) and is approved as a third-line treatment for metastatic gastrointestinal stromal tumor (GIST). While acneiform eruptions have been observed in patients receiving other BRAF and EGFR inhibitors, the commonly reported adverse reactions to regorafenib are fatigue and palmar-plantar erythrodysesthesia. Herein, we report, to the best of our knowledge, the first case who presented with a severe acneiform eruption 24 months after beginning regorafenib for the treatment of GIST. A 61-year-old woman developed GIST with multiple liver metastases, and she was treated with imatinib and sunitinib. However, these therapies were discontinued, and regorafenib was administered. Twenty-four months after beginning regorafenib, she developed an acneiform eruption on her back. Histopathologic analysis of a skin biopsy from the back revealed neutrophilic suppurative folliculitis. Therefore, she postponed regorafenib administration for 2 months and was treated with topical application of clindamycin phosphate hydrate, which was effective. Consistent with reported evidence that the presence of acneiform eruption and the efficacy of EGFR inhibitors are positively associated, regorafenib had good anticancer activity in our patient. Ultimately, we found that although regorafenib-associated skin toxicities usually appear within 1 month of treatment, patients potentially can present with delayed-onset acneiform eruptions even 24 months later.PAGEPress Publications, 2022年06月, Dermatology reports, 14(2) (2), 9303 - 9303, 英語, 国際誌研究論文（学術雑誌）
- BACKGROUND: Radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) is an aggressive form of thyroid cancer. Lenvatinib is a multikinase inhibitor approved for treatment of RAI-R DTC. The impact of tumor response and tumor burden on overall survival (OS) after lenvatinib treatment in patients with RAI-R DTC was assessed. METHODS: Data from patients treated with lenvatinib (N = 261) in SELECT were retrospectively analyzed. Patients were divided into lenvatinib responder or nonresponder subgroups and into low (≤40 mm) or high (>40 mm) tumor burden subgroups based on baseline sums of diameters of target lesions using Response Evaluation Criteria in Solid Tumors, version 1.1 (cutoff values were determined by receiver-operating characteristic analyses). Associations of tumor response and tumor burden with OS were assessed. RESULTS: Median OS was prolonged in lenvatinib responders versus nonresponders (52.2 vs 19.0 months; hazard ratio [HR], 0.32; 95% CI, 0.23-0.46). Patients with a lower tumor burden who received lenvatinib had prolonged OS versus those with a higher tumor burden (median OS, not reached vs 29.1 months, respectively; HR, 0.42; 95% CI, 0.28-0.63). Baseline tumor burden was associated with OS by multivariate analysis (HR, 0.56; 95% CI, 0.35-0.89; P = .0138). CONCLUSIONS: Patients with a lower tumor burden receiving lenvatinib had prolonged OS compared with those with a higher tumor burden receiving lenvatinib. Baseline tumor burden may be a prognostic factor for OS in patients with RAI-R DTC treated with lenvatinib.2022年06月, Cancer, 128(12) (12), 2281 - 2287, 英語, パスワードが無い, 国際誌[査読有り]研究論文（学術雑誌）
- (一社)日本頭頸部癌学会, 2022年05月, 頭頸部癌, 48(2) (2), 182 - 182, 日本語
- Although nivolumab is administered every two or four weeks, high programmed cell death-1 (PD-1) binding of nivolumab on T cells lasting for several months has been reported. A relationship between the PD-1 occupancy rate on T-cells and the efficacy of nivolumab is not yet fully understood. The present study used flow cytometric analyses to determine the time-dependence of PD-1 occupancy in five patients who discontinued nivolumab. The relationship between PD-1 occupancy at relapse and the efficacy of re-challenge was also studied. Occupancies after discontinuation were measured at a total of 32 points. The data indicated that it took 32.4 and 48.9 weeks to decrease occupancy by 50 and 70%, respectively. Subsequently, two patients had recurrence and were re-challenged with nivolumab. At that time, one patient had 70.8% occupancy while the other had 6.6%. Treatment was effective only for the patient with lower occupancy. Overall, the present study suggests that re-challenge with nivolumab may be efficacious in patients with low occupancy at recurrence.2022年05月, Molecular and clinical oncology, 16(5) (5), 104 - 104, 英語, 国際誌研究論文（学術雑誌）
- There are no established guidelines for managing older patients with head and neck cancer. Most clinical trials that define current standard therapy included few elderly patients. On the other hand, there is great variability in patients' comorbidities, physical functions, cognitive function, familial and financial background and values. The key point appears to be appropriate geriatric assessment, clarifying the patients' outcomes and a multidisciplinary team approach, including the treatment decision-making policy. Although these processes should be scientific in nature, the evidence for the treatment of elderly head and neck patients is very limited. This review summarizes the evidence available regarding the management of geriatric assessment, each treatment modality and the multidisciplinary team approach for older patients with head and neck cancers.2022年04月, Japanese journal of clinical oncology, 52(4) (4), 313 - 321, 英語, 国際誌[査読有り][招待有り]研究論文（学術雑誌）
- BACKGROUND: Although COVID-19 severity in cancer patients is high, the safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients undergoing chemotherapy for solid cancers in Japan have not been reported. METHODS: We investigated the safety and immunogenicity of BNT162b2 in 41 patients undergoing chemotherapy for solid cancers and in healthy volunteers who received 2 doses of BNT162b2. We evaluated serum IgG antibody titers for S1 protein by ELISA at pre-vaccination, prior to the second dose and 14 days after the second vaccination in 24 cancer patients undergoing cytotoxic chemotherapy (CC group), 17 cancer patients undergoing immune checkpoint inhibitor therapy (ICI group) and 12 age-matched healthy volunteers (HV group). Additionally, inflammatory cytokine levels were compared between the HV and ICI groups at pre and the next day of each vaccination. RESULTS: Anti-S1 antibody levels were significantly lower in the ICI and CC groups than in the HV group after the second dose (median optimal density: 0.241 [0.063-1.205] and 0.161 [0.07-0.857] vs 0.644 [0.259-1.498], p = 0.0024 and p < 0.0001, respectively). Adverse effect profile did not differ among the three groups, and no serious adverse event occurred. There were no differences in vaccine-induced inflammatory cytokines between the HV and ICI groups. CONCLUSION: Although there were no significant differences in adverse events in three groups, antibody titers were significantly lower in the ICI and CC groups than in the HV group. Further protection strategies should be considered in cancer patients undergoing CC or ICI.2022年04月, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 28(4) (4), 516 - 520, 英語, 国際誌研究論文（学術雑誌）
- In the randomized, phase 3 CheckMate 141 trial, nivolumab significantly improved overall survival (OS) versus investigator's choice (IC) of chemotherapy at primary analysis among 361 patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) post-platinum therapy. Nivolumab versus IC as first-line treatment also improved OS among patients with R/M SCCHN who progressed on platinum therapy for locally advanced disease in the adjuvant or primary setting at 1-year follow-up. In the present long-term follow-up analysis of patients receiving first-line treatment, OS benefit with nivolumab (n = 50) versus IC (n = 26) was maintained (median: 7.7 months versus 3.3 months; hazard ratio: 0.56; 95% confidence interval, 0.34-0.94) at 2 years. No new safety signals were identified. In summary, this long-term 2-year analysis of CheckMate 141 supports the use of nivolumab as a first-line treatment for patients with platinum-refractory R/M SCCHN.2022年03月, The oncologist, 27(2) (2), e194-e198, 英語, 国際誌研究論文（学術雑誌）
- BACKGROUND/AIM: Aldehyde dehydrogenase (ALDH) 1A1 is a well-known marker for cancer stem cells (CSCs), characterized by self-renewal capacity and multidrug resistance in breast cancer. We developed a near-infrared turn-on fluorescence probe for ALDH1A1, C5S-A, which is suitable for observing and analyzing viable cells. Here, we demonstrated the utility of C5S-A in CSC research using breast cancer cell lines. MATERIALS AND METHODS: To evaluate concordance between C5S-A and conventional stem cell markers, breast cancer cells sorted for ALDEFLUOR-positive cells and for CD44+/CD24- cell populations were stained with C5S-A. Tumorigenicity of C5S-A-positive cells was examined by mammosphere formation assay and subcutaneous transplantation to immunodeficient mice. Additionally, to determine how long fluorescence from a single staining remained observable, we cultured breast cancer cells for 5 days after C5S-A staining. We then evaluated whether C5S-A-positive cells possessed resistance to cytotoxic drugs by chronological imaging. RESULTS: C5S-A staining showed good concordance with conventional breast CSC markers, and good utility for research into CSC characteristics in breast cancer cell lines, including tumorigenesis. Additionally, C5S-A was observable for more than 3 days with a single staining. Using this property, we then confirmed that C5S-A-positive cells possessed resistance to cytotoxic drugs, which is one of the characteristics of CSCs. CONCLUSION: We showed that C5S-A is suitable for CSC research using breast cancer cell lines, and confirmed its utility in observing cells over time.2022年03月, Anticancer research, 42(3) (3), 1199 - 1205, 英語, 国際誌研究論文（学術雑誌）
- PURPOSE: The aim of this study was to explore what methods should be used to determine the minimal important difference (MID) and minimal important change (MIC) in scores for the European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module, the EORTC QLQ-HN43. METHODS: In an international multi-centre study, patients with head and neck cancer completed the EORTC QLQ-HN43 before the onset of treatment (t1), three months after baseline (t2), and six months after baseline (t3). The methods explored for determining the MID were: (1) group comparisons based on performance status; (2) 0.5 and 0.3 standard deviation and standard error of the mean. The methods examined for the MIC were patients' subjective change ratings and receiver-operating characteristics (ROC) curves, predictive modelling, standard deviation, and standard error of the mean. The EORTC QLQ-HN43 Swallowing scale was used to investigate these methods. RESULTS: From 28 hospitals in 18 countries, 503 patients participated. Correlations with the performance status were |r|< 0.4 in 17 out of 19 scales; hence, performance status was regarded as an unsuitable anchor. The ROC approach yielded an implausible MIC and was also discarded. The remaining approaches worked well and delivered MID values ranging from 10 to 14; the MIC for deterioration ranged from 8 to 16 and the MIC for improvement from - 3 to - 14. CONCLUSIONS: For determining MIDs of the remaining scales of the EORTC QLQ-HN43, we will omit comparisons of groups based on the Karnofsky Performance Score. Other external anchors are needed instead. Distribution-based methods worked well and will be applied as a starting strategy for analyses. For the calculation of MICs, subjective change ratings, predictive modelling, and standard-deviation based approaches are suitable methods whereas ROC analyses seem to be inappropriate.2022年03月, Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 31(3) (3), 841 - 853, 英語, パスワードが無い, 国際誌[査読有り]研究論文（学術雑誌）
- Salivary gland malignancies are rare neoplasms that have a broad histological spectrum and a variety of biologic behaviors. Salivary gland malignancies are known as chemo-resistant tumors, which render optimal treatment challenging. This review summarizes the role of systemic therapy for salivary gland malignancies. To date, the advantage of adding concurrent chemotherapy has remained undefined for both postoperative and inoperable locally advanced salivary gland malignancy patients undergoing radiotherapy. For recurrent/metastatic disease, local and/or systemic treatment options should be discussed in a multidisciplinary setting with consideration to both patient needs and tumor factors. For symptomatic patients or those who may compromise organ function, palliative systemic therapy can be a reasonable option based on the results of phase II studies. Platinum combination regimens as first-line therapy have been widely accepted. Personalized therapies have become established options, particularly for androgen receptor-positive, HER2-positive and NTRK fusion-positive salivary gland malignancies (i.e. androgen receptor and HER2 in salivary duct carcinoma and NTRK3 in secretory carcinoma). For patients with adenoid cystic carcinoma, multi-targeted tyrosine kinase inhibitors have also been developed. Anti-PD1 checkpoint inhibitors have shown limited activity to date. Investigation of active systemic treatments for salivary gland malignancy remains a significant unmet need. Future directions might include a more comprehensive genomic screening approach (usually next-generation sequencing-based) and combination strategies using immune checkpoint inhibitors. These are rare malignancies that require ongoing effort in the conduct of high-quality clinical trials.2022年02月, Japanese journal of clinical oncology, 52(4) (4), 293 - 302, 英語, パスワードが無い, 国際誌[査読有り][招待有り]研究論文（学術雑誌）
- (公社)日本医学放射線学会, 2022年02月, Japanese Journal of Radiology, 40(Suppl.) (Suppl.), 36 - 36, 日本語cT3N0M0声門癌に対する根治的放射線治療の成績
- We investigated the efficacy of BNT162b2 mRNA COVID-19 vaccine in patients with B-cell malignancies treated with anti-CD20 antibody. Although T-cell-mediated immune responses were detected even in patients receiving R-CHOP treatment, the S1 antibody titer following BNT162b2 vaccination remained only marginally increased for more than 3 years after the final dose of anti-CD20 antibody. We found no relationship between the percent of B-cells and S1 antibody titer. The duration of this suppression was much longer than we anticipated. Further protection and treatment strategies against COVID-19 for these patients are warranted.2022年01月, International journal of hematology, 115(1) (1), 7 - 10, 英語, 国内誌研究論文（学術雑誌）
- Purpose: To investigate the oncological outcomes of orbital malignant tumors invading the skull base. Methods: A retrospective analysis was conducted on 16 patients with orbital malignant tumors invading the skull base. Eleven patients were treated with skull base surgery, four patients were treated with particle therapies, and one patient was treated with chemoradiotherapy (CRT) as initial treatment. Results: The most frequent histological type was adenoid cystic carcinoma in seven patients, followed by squamous cell carcinoma in two patients. Local recurrence occurred in two of the six surgically treated patients who did not receive postoperative radiotherapy (RT) or CRT. One of them was successfully salvaged by RT, and the other died of disease. With a median follow-up of 24 months, the 2-year overall, local control, and disease-free survival rates of all patients were 82.5%, 87.5%, and 59%, respectively. Conclusions: Patients with positive surgical margins were at risk of local recurrence. Postoperative RT should be considered for all surgically treated patients.Level of Evidence: 4.2021年12月, Laryngoscope investigative otolaryngology, 6(6) (6), 1347 - 1352, 英語, 国際誌研究論文（学術雑誌）
- OBJECTIVE: The blowing time ratio, which is the ratio of the blowing time when the nostrils are open and closed, is significantly correlated with velopharyngeal pressure, not only during speech but also during swallowing. This study aimed to further evaluate the usefulness of the blowing time ratio as a screening tool to evaluate the swallowing pressure of patients treated for oral and oropharyngeal cancers using high-resolution manometery (HRM). METHODS: Ten patients treated for oral or oropharyngeal cancer were recruited for this study. Swallowing pressures at the velopharynx, oropharynx, and upper esophageal sphincter (UES) were measured using HRM. Their correlations with the blowing time ratio were analyzed. RESULTS: The blowing time ratio was significantly correlated with the swallowing pressures of the oropharynx (CC = 0.815, p = 0.004) and the velopharynx (CC = 0.657, p = 0.039), but not of the UES. CONCLUSIONS: The present results further support our previous finding that the blowing time ratio is a useful screening tool to evaluate velopharyngeal and oropharyngeal swallowing pressures in patients treated for oral and oropharyngeal cancer.2021年11月, Auris, nasus, larynx, 49(3) (3), 477 - 483, 英語, 国際誌研究論文（学術雑誌）
- BACKGROUND: This study aimed to reveal the influence of the invasion site of external auditory canal (EAC) cancer by analyzing the outcome of patients with advanced tumor. METHODS: A total of 111 patients with T4 EAC cancer were enrolled in this study. Of these patients, 79 underwent chemoradiotherapy and 32 underwent surgery under curative intent. Univariate and multivariate analyses and the Kaplan-Meier method were used to focus on the tumor invasion sites and overall survival of the patients. RESULTS: The 3-year overall survival rate of all patients was 55.0%. In multivariate analysis, the only significant invasion site for overall survival was the facial nerve, with the dura mater being the next most influential site. When Kaplan-Meier survival curve was calculated, facial nerve and dura mater were the significant factors resulting in poor patient outcomes. CONCLUSION: The facial nerve and dura mater are crucial sites of EAC cancer for patient outcomes.2021年10月, Head & neck, 43(10) (10), 3097 - 3105, 英語, 国際誌研究論文（学術雑誌）
- The clinical utility of systemic therapy and genomic profiling in non-squamous-cell head and neck cancer (NSCHNC) has not been fully elucidated. This phase II trial evaluated the efficacy and safety of docetaxel and cisplatin combination in the first-line setting. Eligibility criteria were recurrent and/or metastatic NSCHNC; progressive disease within the last 6 months; no prior systemic therapy; and ECOG performance status of 0-1. Patients received docetaxel (75 mg/m2 on day 1) and cisplatin (75 mg/m2 on day 1), repeated every 21 days for 6 cycles. The primary endpoint was confirmed objective response rate (ORR). The secondary endpoints included progression-free survival (PFS), overall survival (OS), and adverse events. Next-generation sequencing (NGS) was performed using the Ion AmpliSeq Cancer Hotspot Panel v2. Twenty-three patients were enrolled from November 2012 to October 2016, of whom 8 were male. Median age was 57 years. Ninety-six percent of cases were metastatic. Among 22 evaluable patients, confirmed ORR was 45% (95% confidential interval 24-68%). With a median follow-up period of 18.8 months, median PFS and OS were 6.7 and 20.1 months, respectively. Grade 3/4 adverse events included febrile neutropenia (39%) and anemia (22%). No treatment-related deaths were observed. NGS analysis revealed potential treatment targets, including ERBB2, KIT, and ALK. The docetaxel and cisplatin combination regimen can be considered a new treatment option in recurrent and/or metastatic NSCHNC, although primary prophylaxis for febrile neutropenia should be considered. Diverse genomic alterations may lead novel treatment options.This trial was registered with the UMIN Clinical Trials Registry as UMIN000008333 on [September 1st, 2012].2021年09月, Medical oncology (Northwood, London, England), 38(11) (11), 128 - 128, 英語, パスワードが無い, 国際誌[査読有り]研究論文（学術雑誌）
- (有)科学評論社, 2021年09月, 腫瘍内科, 28(3) (3), 291 - 295, 日本語
- BACKGROUND: The incidence of cancer-associated venous thromboembolism (CA-VTE) in Japan has not been fully investigated. METHODS AND RESULTS: Clinicopathological information from patients with solid malignancies who first visited our department between November 2011 and March 2018 were retrospectively reviewed from medical records. The primary outcome was incidence of CA-VTE, defined as deep-vein thrombosis (DVT) and/or pulmonary embolism (PE). On median follow-up of 187 days, 91 of 2735 patients (3.3%) developed CA-VTE during their clinical course, giving an incidence rate of 40.7 per 1000 person-years. Of the 91 patients, 75 (82%) were diagnosed with DVT alone, 6 (7%) with PE alone, and 10 (11%) with both DVT and PE. CA-VTE was most frequent in non-small cell lung cancer (10.8%), followed by cancer of unknown origin (5.8%). Forty-four patients (48%) had one or more symptoms at the initial diagnosis of VTE. Five patients (6%) had a normal D-dimer level (≤ 1.0 µg/mL); of these, 2 were asymptomatic. CONCLUSIONS: In this retrospective study, the incidence of CA-VTE in Japanese patients with cancer was equivalent to that in Western populations. Approximately half of CA-VTE patients were asymptomatic and 6% had normal D-dimer levels, indicating the need for closer attention to occult CA-VTE.2021年09月, International journal of hematology, 114(3) (3), 319 - 324, 英語, 国内誌研究論文（学術雑誌）
- 2021年09月, Advances in therapy, 38(9) (9), 4989 - 4993, 英語, 国際誌
- PURPOSE: Chemoradiotherapy with docetaxel (DOC), cisplatin (CDDP), and 5-FU (TPF-CRT) for locally advanced external auditory canal cancer (EACC) has favorable oncological and functional outcomes. To establish TPF-CRT as a standard of care for advanced EACC, we conducted this study to determine the maximum tolerated (MTD) and recommended dose (RD) of DOC in TPF-CRT for locally advanced EACC. METHODS: To determine the recommended (RD) and maximum tolerated dose (MTD) of DOC in TPF-CRT for EACC, a phase I trial was conducted using the standard "3 + 3" design for maximum dose finding. DOC was administered twice every 4 weeks, CDDP at 70 mg/m2 and 5-FU at 700 mg/m2; patients were also receiving radiotherapy (66 Gy). Eight patients with T3 or T4 EACC were prospectively enrolled. RESULTS: Two patients treated with DOC, 50 mg/m2, and one out of six patients treated with DOC, 40 mg/m2, had dose-limiting toxicities. Prolonged febrile neutropenia was observed in three patients. Grade 3 non-hematological toxicities were observed in only three patients. At study completion, six patients survived, five of whom were disease free. CONCLUSION: The RD and MTD of DOC in TPF-CRT for locally advanced EACC are 40 mg/m2 when doses of CDDP and 5-FU are 70 mg/m2 and 700 mg/m2, respectively.2021年07月, European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 279(6) (6), 2805 - 2810, 英語, 国際誌研究論文（学術雑誌）
- 2021年07月, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(20) (20), 2317 - 2318, 英語, 国際誌
- Treatment with anti-programmed cell death-1 (PD-1) antibodies improves the anti-cancer immune response and can provide a meaningful clinical benefit to cancer patients. However, this treatment can result in specific autoimmune toxicities, termed immune-related adverse events (irAEs). Although irAEs are well recognized, the development of infectious diseases due to this treatment is not often observed. Some recent reports have indicated that patients who receive anti-PD-1 antibodies are at a higher risk for tuberculosis than others. However, reports on nontuberculous mycobacterial infection during anti-PD-1 antibody treatment are still rare. We herein report the first case of Mycobacterium mageritense infection during anti-PD-1 antibody treatment.2021年05月, Internal medicine (Tokyo, Japan), 60(21) (21), 3485 - 3488, 英語, 国内誌研究論文（学術雑誌）
- (一社)日本内分泌学会, 2021年04月, 日本内分泌学会雑誌, 97(1) (1), 224 - 224, 日本語高レニン、高アルドステロンを呈したDOC産生副腎皮質癌の一例
- Cambridge University Press (CUP), 2021年04月, The Journal of Laryngology & Otology, 135(4) (4), 297 - 303
Abstract Background The prognosis of patients with advanced squamous cell carcinoma of the external auditory canal and middle ear has been improved by advances in skull base surgery and multidrug chemoradiotherapy during the last two decades.Methods Ninety-five patients with squamous cell carcinoma of the external auditory canal and middle ear who were treated between 1998 and 2017 were enrolled. The number of patients with tumour stages T1, T2, T3 and T4 was 15, 22, 24 and 34, respectively. Oncological outcomes and prognostic factors were retrospectively investigated.Results Among patients with T4 disease, invasion of the brain (p = 0.024), carotid artery (p = 0.049) and/or jugular vein (p = 0.040) were significant predictors of poor prognosis. The five-year overall survival rate of patients with at least one of these factors (T4b) was significantly lower than that of patients without these factors (T4a) (25.5vs 65.5 per cent,p = 0.049).Conclusion It is proposed that stage T4 be subclassified into T4a and T4b according to the prognostic factors.研究論文（学術雑誌） - Capicua transcriptional repressor (CIC)-rearranged sarcoma is an Ewing-like sarcoma with an aggressive clinical course and poor prognosis. No standard treatment has been established. The present study describes a case of CIC-rearranged sarcoma with lung metastases developing in a 24-year-old woman as a therapy-associated malignancy following chemotherapy for anaplastic large cell lymphoma at nine years old. This was treated with palliative regimens used for Ewing sarcoma. The patient achieved disease control for one year. Of note, ifosfamide and etoposide (IE), which were used as a second line treatment lead to a partial response. The case described in the present study indicated that treatment with Ewing regimens is a reasonable option for patients with metastatic CIC-rearranged sarcoma, including those with a second malignant case.2021年04月, Molecular and clinical oncology, 14(4) (4), 68 - 68, 英語, 国際誌研究論文（学術雑誌）
- OBJECTIVES: This study aimed to evaluate the efficacy of chemoradiotherapy (CRT) for patients with advanced cancer of the external auditory canal (EAC) by analyzing the outcome of the patients. METHODS: This is a multi-institutional retrospective survey, and we reviewed the medical records of the subjects. A total of 181 patients with tumor (T)3 or T4 tumor in 17 institutions were enrolled. Further analysis was performed for 74 patients who underwent CRT under curative intent. RESULTS: Overall 5-year survival rates of the patients who underwent CRT (n = 74) were 54.6%. Those of the patients who underwent CRT with modified TPF (docetaxel, cisplatin [CDDP], and 5-fluorouracil) regimen (n = 50) and CRT with CDDP regimens (n = 24) were 64.4% and 36.7%, respectively. Significant differences were observed between these two groups. CONCLUSION: Given the tendency that head and neck surgeons prefer CRT for advanced larger cancer of the EAC, CRT for advanced EAC cancer using the modified TPF regimen showed good clinical outcomes. LEVEL OF EVIDENCE: 4 Laryngoscope, 131:E870-E874, 2021.2021年03月, The Laryngoscope, 131(3) (3), E870-E874, 英語, 国際誌研究論文（学術雑誌）
- In order to maximize the benefit of induction chemotherapy, practice based on a comprehensive interpretation of a large number of clinical trials, as in this review, is essential. The standard treatment for locally advanced squamous cell carcinoma of the head and neck is surgery or chemoradiation. However, induction chemotherapy followed by (chemo) radiotherapy may be used in some circumstances. Although many clinical trials of induction chemotherapy have been conducted, a rationale other than to preserve the larynx is still controversial. Selection of this modality should therefore be made with care. The current standard regimen for induction chemotherapy is docetaxel, cisplatin and 5-FU, but concerns remain about toxicity, cost and the duration of treatment. Regarding treatment after induction chemotherapy, it is also unclear whether radiation alone or chemoradiation is the better option. Furthermore, there is no answer as to what drugs should be used in combination with radiation therapy after induction chemotherapy. Several new induction chemotherapy treatment developments are currently underway, and future developments are expected. This review article summarizes the current position of induction chemotherapy for head and neck squamous cell carcinoma, based on the evidence produced to date, and discusses the future prospects for this treatment.2021年02月, Japanese journal of clinical oncology, 51(2) (2), 173 - 179, 英語, 国際誌研究論文（学術雑誌）
- Spartalizumab is a humanized IgG4/κ mAb directed against human programmed cell death-1 (PD-1). In this phase I study, we investigated safety, pharmacokinetics, preliminary antitumor activity, and toxicity of spartalizumab in patients with advanced malignancies. Patients (n = 18) with a range of tumor types received spartalizumab i.v. at doses of 1, 3, and 10 mg/kg every 2 weeks until disease progression, unacceptable toxicity, or discontinuation at the discretion of the investigator or patient. Most patients (61%) had received five or more prior lines of therapy. No dose-limiting toxicities were reported and, hence, the maximum tolerated dose was 10 mg/kg or more. Pharmacokinetics in Japanese patients aligned with those reported in a global dose-escalation study. The safety profile was consistent with other approved anti-PD-1 mAbs; the most common drug-related adverse events were maculopapular rash (22%), followed by malaise and increased blood alkaline phosphatase (11% each). Partial responses were reported in two patients (11%), one with transitional cell carcinoma and the other with hepatocellular carcinoma. In conclusion, this study confirmed the safety of spartalizumab given at a dose of up to 10 mg/kg every 2 weeks in Japanese patients with cancers.2021年02月, Cancer science, 112(2) (2), 725 - 733, 英語, 国際誌研究論文（学術雑誌）
- BACKGROUND: To promote precision oncology in clinical practice, the Japanese Society of Medical Oncology, the Japanese Society of Clinical Oncology, and the Japanese Cancer Association, jointly published "Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment" in 2017. Since new information on cancer genomic medicine has emerged since the 1st edition of the guidance was released, including reimbursement for NGS-based multiplex gene panel tests in 2019, the guidance revision was made. METHODS: A working group was organized with 33 researchers from cancer genomic medicine designated core hospitals and other academic institutions. For an impartial evaluation of the draft version, eight committee members from each society conducted an external evaluation. Public comments were also made on the draft. The finalized Japanese version was published on the websites of the three societies in March 2020. RESULTS: The revised edition consists of two parts: an explanation of the cancer genomic profiling test (General Discussion) and clinical questions (CQs) that are of concern in clinical practice. Particularly, patient selection should be based on the expectation that the patient's post-test general condition and organ function will be able to tolerate drug therapy, and the optimal timing of test should be considered in consideration of subsequent treatment plans, not limited to treatment lines. CONCLUSION: We expect that the revised version will be used by healthcare professionals and will also need to be continually reviewed in line with future developments in cancer genome medicine.2021年02月, International journal of clinical oncology, 26(2) (2), 233 - 283, 英語, 国内誌研究論文（学術雑誌）
- Regorafenib is an oral multi-kinase inhibitor which targets tumor angiogenesis, the tumor microenvironment and oncogenesis. Based on this mode of action, regorafenib has a broad spectrum of toxicities. However, at present, few reports have focused on autoimmune adverse events. We report a first case of regorafenib-induced exacerbation of chronic immune thrombocytopenic purpura in remission during treatment for the patients with heavily treated advanced colorectal cancer. This case report highlights the need for caution with regard to regorafenib treatment in patients with cancer with concomitant immune thrombocytopenic purpura.2021年02月, Molecular and clinical oncology, 14(2) (2), 30 - 30, 英語, 国際誌研究論文（学術雑誌）
- BACKGROUND/AIM: Biomarkers for immune-related adverse events (irAEs) induced by immune checkpoint inhibitors (ICIs) are required. We encountered a patient whose skin irAE fluctuated in parallel with serum soluble interleukin-2 receptor (sIL-2R). PATIENTS AND METHODS: We examined 15 patients with cancer who received ICIs. Serum sIL-2R levels before and during ICI treatment were measured. The sIL-2R levels of preserved serum samples from another five patients who developed grade 3 irAEs were measured. RESULTS: Twelve patients showed no significant changes in sIL-2R levels during ICI treatment. Baseline serum sIL-2R levels in three patients increased beyond the normal range before the second cycle. These three patients had grade ≥2 irAEs at the second cycle treatment visit, supporting our hypothesis. Furthermore, at diagnosis of irAEs, the sIL-2R levels of all preserved samples from patients with grade 3 irAEs were significantly elevated. CONCLUSION: Serum sIL-2R is a promising biomarker for the diagnosis of irAEs.2021年02月, Anticancer research, 41(2) (2), 1021 - 1026, 英語, 国際誌研究論文（学術雑誌）
- BACKGROUND: To evaluate factors associated with osteoradionecrosis of the jaw (ORNJ) in patients with head and neck squamous cell carcinoma (HNSCC), focusing on jaw-related dose-volume histogram (DVH) parameters. METHODS: We retrospectively reviewed the medical records of 616 patients with HNSCC treated with curative-intent or postoperative radiation therapy (RT) during 2008-2018. Patient-related (age, sex, history of smoking or alcohol use, diabetes mellitus, performance status, pre-RT dental evaluation, pre- or post-RT tooth extraction), tumor-related (primary tumor site, T-stage, nodal status), and treatment-related (pre-RT surgery, pre-RT mandible surgery, induction or concurrent chemotherapy, RT technique) variables and DVH parameters (relative volumes of the jaw exposed to doses of 10 Gy-70 Gy [V10-70]) were investigated and compared between patients with and without ORNJ. The Mann-Whitney U test was used to compare RT dose parameters. Univariate and multivariate Cox regression analyses were used to assess factors associated with ORNJ development. Kaplan-Meier analyses were performed for cumulative ORNJ incidence estimation. RESULTS: Forty-six patients (7.5%) developed ORNJ. The median follow-up duration was 40 (range 3-145) months. The median time to ORNJ development was 27 (range 2-127) months. DVH analysis revealed that V30-V70 values were significantly higher in patients with than in those without ORNJ. In univariate analyses, primary tumor site, pre-RT mandible surgery, post-RT tooth extraction, and V60 > 14% were identified as important factors. In multivariate analyses, V60 > 14% (p = 0.0065) and primary tumor site (p = 0.0059) remained significant. The 3-year cumulative ORNJ incidence rates were 2.5% and 8.6% in patients with V60 ≤ 14% and > 14%, respectively (p < 0.0001), and 9.3% and 1.4% in patients with oropharyngeal or oral cancer and other cancers, respectively (p < 0.0001). CONCLUSIONS: V60 > 14% and oropharyngeal or oral cancer were found to be independent risk factors for ORNJ. These findings might be useful to minimize ORNJ incidence in HNSCC treated with curative RT.2021年01月, Radiation oncology (London, England), 16(1) (1), 1 - 1, 英語, 国際誌研究論文（学術雑誌）
- CONTEXT: Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of immune cells of myeloid lineage. Recent reports have suggested that human MDSC are divided into three subsets: monocytic MDSC (M-MDSC), granulocytic MDSC (G-MDSC), and immature MDSC (I-MDSC). However, the characteristics of each human MDSC subset still remain unclear. MATERIALS AND METHODS: To evaluate the immunosuppressive effects and mechanisms, we first performed a T-cell suppression assay using cells obtained from healthy donor peripheral blood samples. The levels of immune inhibitory molecules in the culture supernatant of each MDSC subset were measured to reveal the T-cell suppressive mechanisms. Then, we compared these results with the results from cells obtained from cancer patient blood samples. Finally, we investigated the difference in the frequency of each MDSC subset between the healthy donors and the cancer patients. RESULTS: Although M-MDSC and G-MDSC suppressed T-cell activation, I-MDSC had no T-cell suppressive effect. We found that the culture supernatant of M-MDSC and G-MDSC contained high levels of interleukin-1 receptor antagonist (IL-1RA) and arginase, respectively, in both healthy donors and cancer patients. No inhibitory molecules were detected in the culture supernatant of I-MDSC. The population of functional MDSC (M-MDSC and G-MDSC) in the total MDSC was significantly increased in cancer patients compared with that in healthy donors. CONCLUSIONS: Although M-MDSC and G-MDSC, which released IL-1RA and arginase, respectively, suppressed T-cell activation, I-MDSC did not have an immunosuppressive effect. The population of functional MDSC was increased in cancer patients compared with that in healthy donors.2021年, Journal of cancer research and therapeutics, 17(4) (4), 1093 - 1100, 英語, 国際誌研究論文（学術雑誌）
- CONTEXT: There is an increasing demand for appropriate preclinical mice models for evaluating the efficacy of cancer immunotherapies. AIMS: Therefore, we established a humanized patient-derived xenograft (PDX) model using microsatellite instability-high (MSI-H) colorectal cancer (CRC) tissues and patient-derived peripheral blood mononuclear cells (PBMCs). SUBJECTS AND METHODS: The CRC tissues of patients scheduled for surgery were tested for MSI status, and CRC tumors were transplanted into NOD/LtSz-scid/IL-2Rg-/-(NSG) mice to establish MSI-H PDX models. PDX tumors were compared to the original patient tumors in terms of histological and genetic characteristics. To humanize the immune system of MSI-H PDX models, patient PBMCs were injected through the tail vein. RESULTS: PDX models were established from two patients with MSI-H CRC; one patient had a germline mutation in MLH1 (c.1990-2A > G), and the other patient had MLH1 promoter hypermethylation. PDX with the germline mutation was histologically similar to the patient tumor, and retained the genetic characteristics, including MSI-H, deficient mismatch repair (dMMR), and MLH1 mutation. In contrast, the histological features of the other PDX from a tumor with MLH1 promoter hypermethylation were clearly different from those of the original tumor, and MLH1 promoter hypermethylation and MSI-H/dMMR were lost in the PDX. When T cells from the same patient with MLH1 mutation were injected into the PDX through the tail vein, they were detected in the PDX tumor. CONCLUSIONS: The MSI-H tumor with an MMR mutation is suitable for MSI-H PDX model generation. The PBMC humanized MSI-H PDX has the potential to be used as an efficient model for cancer immunotherapy research.2021年, Journal of cancer research and therapeutics, 17(6) (6), 1358 - 1369, 英語, 国際誌研究論文（学術雑誌）
- Background: We previously reported that a high tumor burden is a prognostic factor based on an analysis of 26 patients with radioactive iodine-refractory differentiated thyroid cancer (RR-DTC) who were treated with lenvatinib. However, the optimal tumor burden for starting lenvatinib still remains to be defined. The aim of this retrospective study was to further explore in the same patient cohort the optimal timing for the start of lenvatinib by focusing on the pre- and post-treatment tumor burden. Methods: The 26 patients were treated with lenvatinib from 2012 to 2017. We explored the optimal timing for the start of lenvatinib by comparing the characteristics of long-term responders who were defined as patients with progression-free survival ≥ 30 months and non-long-term responders. Results: Long-term responders had a smaller post-treatment tumor burden at maximum shrinkage than non-long-term responders. Further, post-treatment tumor burden had a strong linear correlation with baseline tumor burden. We created an estimation formula for baseline tumor burden related to prognosis, using these regression lines. Patients with a sum of diameters of target lesions < 60 mm or maximum tumor diameter < 34 mm at baseline were estimated to have significantly better survival outcomes. Conclusions: We found a strong linear correlation between pre- and post-treatment tumor burden. Our results suggested a cut-off value for baseline tumor burden for long-term prognosis among patients treated with lenvatinib.2021年, Frontiers in oncology, 11, 638123 - 638123, 英語, パスワードが無い, 国際誌[査読有り]研究論文（学術雑誌）
- PURPOSE: We conducted a phase 1 study to determine the maximum tolerated dose and the recommended dose of gemcitabine/nab-paclitaxel/S-1 combination chemotherapy in patients with unresectable pancreatic cancer. METHODS: We enrolled patients aged 20 years or older with unresectable pancreatic cancer and who had not been treated with chemotherapy or radiation therapy. Gemcitabine and nab-paclitaxel were administered on days 1 and 8, and S-1 was administered orally twice daily for 2 weeks, repeated every 3 weeks. The starting dose was level 0 [gemcitabine 700 mg/m2, nab-paclitaxel 90 mg/m2, S-1 60/80/100 mg/day (< 1.25 m2/1.25-1.50 m2/ > 1.5 m2)]. Dose-limiting toxicities were determined during the first course, and a classical 3 + 3 dose finding design was planned. RESULTS: From March 2018 to October 2019, 20 patients were enrolled. At dose level 0, three of six patients experienced dose-limiting toxicities; one grade 3 skin rash on day 8, and two grade 3 or 4 neutropenia on day 8. At dose level-1 (gemcitabine 600 mg/m2, nab-paclitaxel 90 mg/m2, and S-1 50/70/80 mg/day), two of twelve patients experienced dose-limiting toxicities, all of which were grade 3 neutropenia on day 8. The most frequently observed toxicity during eight courses was neutropenia. Other treatment-related adverse events were mild. Eleven out of 19 (58%) patients achieved partial response. CONCLUSION: We defined the maximum tolerated dose and the recommended dose for combination therapy with gemcitabine/nab-paclitaxel/S-1 as dose level-1. Considering the observed response rate, further studies are warranted in order to determine the efficacy of this regimen (UMIN-CTR 000030007).2021年01月, Cancer chemotherapy and pharmacology, 87(1) (1), 65 - 71, 英語, 国際誌研究論文（学術雑誌）
- Intimal sarcoma of the pulmonary artery (PAIS) is a rare disease with a poor prognosis. Pazopanib, which has been indicated in metastatic non-adipocytic soft-tissue sarcomas and is expected to be active in PAIS, is a multi-kinase inhibitor that targets the tyrosine kinase activity of vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and stem cell factor receptor. The present study reports findings related to two cases of PAIS with PDGF and VEGF expression following treatment with pazopanib. A case with a moderate to strong expression of PDGFR-α and -β presented a long-term stable disease when treated with pazopanib (progression-free survival, 5.8 months). In a second case with a weak expression of PDGFR-α and -β, the disease progressed rapidly on pazopanib (progression-free survival, 1.1 months). VEGFR-2 was not expressed in the tumors of both cases. The level of PDGFR expression in the tumor tissue may therefore be predictive of pazopanib efficacy.2021年01月, Molecular and clinical oncology, 14(1) (1), 6 - 6, 英語, 国際誌研究論文（学術雑誌）
- PURPOSE: Surgical complications such as hypoparathyroidism (HPT) or vocal cord palsy are seldom assessed when the quality of life (QOL) in thyroid cancer patients is investigated. The aim of this study was to measure the QOL difference in thyroid cancer survivors with and without HPT. METHODS: Participants for this analysis were enrolled in 13 countries from a study that pilot-tested a thyroid cancer-specific QOL instrument. They were included if they had been diagnosed with thyroid cancer at least 9 months previously. QOL was measured using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core (EORTC QLQ-C30) and some items on HPT symptoms (eg, tingling in fingers or toes). HPT status and other clinical data were extracted from the patients' medical charts. Comparisons of QOL domains between patients with and without HPT were performed using Mann-Whitney U test. The occurrence of HPT-related symptoms was compared using chi-square tests. Multiple ordinal regression analysis was performed to evaluate factors that might affect QOL. RESULTS: Eighty-nine patients participated in this study, 17 of whom were considered to have HPT. Patients in the HPT group reported significantly reduced QOL in 9 of the 15 scales of the EORTC QLQ-C30 compared to patients without HPT. Regression analysis showed that HPT was independently negatively associated with various scales of the QLQ-C30. Both groups showed a high prevalence of typical HPT symptoms. CONCLUSION: Thyroid cancer patients with HPT report significantly impaired QOL compared to thyroid cancer survivors without HPT. The assessment of HPT should be considered when measuring QOL in thyroid cancer patients.2020年12月, The Journal of clinical endocrinology and metabolism, 105(12) (12), 英語, 国際誌, 国際共著している研究論文（学術雑誌）
- This report summarizes the presentations and discussion in the first Japan Clinical Oncology Group-European Organisation for Research and Treatment of Cancer Quality of Life/Patient-Reported Outcome workshop funded by the National Cancer Center Hospital that was held on Saturday, 1 September 2018 in Tokyo, Japan. The infrastructure and understanding regarding the Quality of Life/Patient-Reported Outcome assessment of cancer patients in Japan is still immature, in spite of the increased demand for oncological Patient-Reported Outcome research felt not only by researchers but also by patients or other stakeholders of cancer drug development. The workshop aimed to share each perspective, common issues to be considered and future perspectives regarding the strong alliance between the European Organisation for Research and Treatment of Cancer Quality of Life Group and the Japan Clinical Oncology Group for Quality of Life/Patient-Reported Outcome research as well as explore the possibility of conducting collaborative research. European Organisation for Research and Treatment of Cancer is a leading international cancer clinical trials organization, and its Quality of Life Group is a global leader in the implementation of Quality of Life research in cancer patients. The three invited speakers from the European Organisation for Research and Treatment of Cancer Quality of Life Group presented their perspective, latest methodology and ongoing projects. The three speakers from the Japan Clinical Oncology Group presented their current status, experience and some issues regarding data management or interpretation of the Patient-Reported Outcome data. The two patient advocates also shared their expectations in terms of advances in cancer research based on the Patient-Reported Outcome assessment. As the next steps after this workshop, the Japan Clinical Oncology Group and European Organisation for Research and Treatment of Cancer have decided to cooperate more closely to facilitate Patient-Reported Outcome research in both the groups, and the Japan Clinical Oncology Group has approved the establishment of a new committee for Quality of Life/Patient-Reported Outcome research in Japan.2020年10月, Japanese journal of clinical oncology, 50(11) (11), 1333 - 1341, 英語, パスワードが無い, 国際誌, 国際共著している[査読有り]研究論文（学術雑誌）
- (一社)日本癌治療学会, 2020年10月, 日本癌治療学会学術集会抄録集, 58回, O1 - 1, 英語局所進行頭頸部癌術後補助化学放射線療法の第II/III相試験(JCOG1008)
- BACKGROUND: The present study evaluated the 2-year survival of the Asian population in the CheckMate 141 trial. METHODS: The CheckMate 141 trial included patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). In the present study, 34 Asian patients (nivolumab group: 23 patients; investigator's choice of therapy [IC] group: 11 patients) were analyzed. RESULTS: The median overall survival (OS) was 12.1 and 6.2 months for the nivolumab and IC groups, respectively. The estimated 2-year OS rates were 22.7% and 0% for the nivolumab and IC groups, respectively. In the nivolumab group, the patients with any treatment-related adverse events (TRAEs), including skin-related disorders, showed better OS than the patients without any TRAEs. CONCLUSIONS: Nivolumab demonstrated prolonged OS benefits in the Asian population with platinum-refractory R/M SCCHN and a favorable safety profile. TRAEs, including skin-related disorders, may be favorable prognostic factors for nivolumab efficacy. CLINICAL TRIAL REGISTRATION: NCT02105636.2020年10月, Head & neck, 42(10) (10), 2852 - 2862, 英語, パスワードが無い, 国際誌, 国際共著している[査読有り]研究論文（学術雑誌）
- Squamous cell carcinoma of the head and neck is characterized by an immunosuppressive environment and evades immune responses through multiple resistance mechanisms. A breakthrough in cancer immunotherapy employing immune checkpoint inhibitors has evolved into a number of clinical trials with antibodies against programmed cell death 1 (PD-1), its ligand PD-L1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) for patients with squamous cell carcinoma of the head and neck. CheckMate141 and KEYNOTE-048 were practice-changing randomized phase 3 trials for patients with platinum-refractory and platinum-sensitive recurrent or metastatic squamous cell carcinoma of the head and neck, respectively. Furthermore, many combination therapies using anti-CTLA-4 inhibitors, tyrosine kinase inhibitors and immune accelerators are currently under investigation. Thus, the treatment strategy of recurrent or metastatic squamous cell carcinoma of the head and neck is becoming more heterogeneous and complicated in the new era of individualized medicine. Ongoing trials are investigating immunotherapeutic approaches in the curative setting for locoregionally advanced disease. This review article summarizes knowledge of the role of the immune system in the development and progression of squamous cell carcinoma of the head and neck, and provides a comprehensive overview on the development of immunotherapeutic approaches in both recurrent/metastatic and locoregionally advanced diseases.2020年09月, Japanese journal of clinical oncology, 50(10) (10), 1089 - 1096, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- INTRODUCTION: Lenvatinib is approved in Japan for treating patients with all histological subtypes of unresectable thyroid cancer, including differentiated thyroid cancer (DTC), medullary thyroid cancer (MTC), and anaplastic thyroid cancer (ATC). However, safety and effectiveness data are limited in Japanese patients. Therefore, this prospective, post-marketing observational study evaluated, in daily clinical practice, the safety and effectiveness of lenvatinib in Japanese patients with unresectable thyroid cancer. METHODS: All patients with unresectable thyroid cancer first treated with lenvatinib between May and November 2015 were registered. Patients were orally administered lenvatinib and followed up for 12 months. The endpoints included adverse drug reactions (ADRs), overall survival (OS), overall response rate (ORR), and time-to-treatment failure. Post hoc Cox multivariate analyses were performed to assess prognostic factors associated with the 12-month OS rate. RESULTS: Of 629 registered patients, 594 were included in the analysis. A total of 442 patients (74.4%) had DTC, 28 (4.7%) had MTC, and 124 (20.9%) had ATC. Hypertension, proteinuria, and palmar-plantar erythrodysesthesia syndrome were the most frequently reported ADRs across all histological subtypes. The median OS was 101.0 days in patients with ATC which was not reached in patients with DTC and patients with MTC, with 12-month OS rates of 15.6%, 75.7%, and 83.0%, respectively. The ORRs were 59.2%, 45.0%, and 43.8% among 368 patients with DTC, 20 with MTC, and 105 with ATC, respectively. Multivariate analyses revealed that Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size, the presence of tumor invasion, and body weight were baseline prognostic factors affecting OS in patients with DTC, while ECOG PS and the presence of liver metastasis were prognostic factors in patients with ATC. CONCLUSION: Lenvatinib demonstrated an acceptable safety profile for patients with thyroid cancer in a real-world setting in Japan. The safety profile and effectiveness findings for lenvatinib in this study were consistent with those from previous clinical trials, irrespective of histological subtype.2020年09月, Advances in therapy, 37(9) (9), 3850 - 3862, 英語, 国際誌研究論文（学術雑誌）
- (一社)日本循環器学会, 2020年07月, 日本循環器学会学術集会抄録集, 84回(4) (4), PE52 - 6, 英語, 国内誌研究論文（学術雑誌）
- (一社)日本頭頸部癌学会, 2020年07月, 頭頸部癌, 46(2) (2), 168 - 168, 日本語小児・若年の上咽頭癌3例の治療経験
- (一社)日本頭頸部癌学会, 2020年07月, 頭頸部癌, 46(2) (2), 174 - 174, 日本語頭頸部癌における免疫チェックポイント阻害薬後の救済化学療法についての後方視的検討
- (一社)日本頭頸部癌学会, 2020年07月, 頭頸部癌, 46(2) (2), 185 - 185, 日本語当院における頭頸部がんに対する高用量シスプラチン併用化学放射線療法による急性腎障害の後方視的検討
- BACKGROUND: Nivolumab improves overall survival (OS) in patients with platinum-refractory recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). In one study, however, Kaplan-Meier OS and progression-free survival (PFS) curves for the nivolumab and cytotoxic agent arms crossed at 3-6 months, suggesting that patients with initial resistance to immunotherapy might have better outcomes with cytotoxic treatment. Here, we explored the conditions and candidates which are predictive of nivolumab outcomes in R/M HNSCC. METHODS: We retrospectively reviewed the clinical records of 27 consecutive R/M HNSCC patients treated with nivolumab from 2014 to 2018. Tumor size was evaluated by RECIST ver.1.1. Tumor growth rate (Gr) was defined as 3log(D0/Dpre)/t, where D0 and Dpre are the sum of the diameters of the target lesions (SumTLs) at baseline and pre-baseline, and t is time, with 1t defined as 4 weeks. RESULTS: Twenty-five patients were enrolled. Survival was significantly worse in patients with disease progression within 3 months. Outcomes appeared poorer in patients with higher pre-treatment Gr and bigger SumTLs at baseline. We therefore explored the association between prognosis, Gr and SumTLs. Recursive partitioning analysis showed that the characteristics of patients with disease progression after 3 months were Gr < 0.76 and SumTLs < 31.0 mm. Further, Gr < 0.76 and SumTLs < 31.0 mm was associated with significantly longer PFS (p = 0.01) and OS (p < 0.01). CONCLUSIONS: These results suggest that Gr and SumTLs at baseline are significantly associated with OS and PFS in R/M HNSCC patients treated with nivolumab.Springer Science and Business Media LLC, 2020年07月, International Journal of Clinical Oncology, 25(7) (7), 1270 - 1277, 英語, パスワードが無い, 国内誌[査読有り]研究論文（学術雑誌）
- AME Publishing Company, 2020年06月, Therapeutic Radiology and Oncology, 4, 5 - 5, 英語, パスワードが無い[査読有り][招待有り]研究論文（学術雑誌）
- (一社)日本内科学会, 2020年02月, 日本内科学会雑誌, 109(Suppl.) (Suppl.), 230 - 230, 日本語HER2陽性再発・転移唾液腺癌患者に対するトラスツズマブ・ドセタキセル併用療法の第II相試験
- (一社)日本内科学会, 2020年02月, 日本内科学会雑誌, 109(Suppl.) (Suppl.), 186 - 186, 日本語がん免疫療法時代の再発・転移頭頸部扁平上皮癌における全身性炎症スコアの予後予測性
- (一社)日本内科学会, 2020年02月, 日本内科学会雑誌, 109(Suppl.) (Suppl.), 226 - 226, 日本語2735人を対象とした悪性腫瘍関連静脈血栓塞栓症の合併率に関する後ろ向きコホート研究 甲状腺癌に対するチロシンキナーゼ阻害薬と血栓の関係
- (一社)日本内科学会, 2020年02月, 日本内科学会雑誌, 109(Suppl.) (Suppl.), 259 - 259, 日本語当院における頭頸部がんに対する3-weekly高用量シスプラチン併用化学放射線療法の臨床的忍容性の検討
- Background: Oral mucositis frequently occurs in cancer patients treated with chemotherapy and chemoradiotherapy (CRT). This study examined the safety and efficacy of ibuprofen gargle in healthy volunteers and patients with chemotherapy- and concomitant CRT-induced oral mucositis. Methods: We enrolled healthy volunteers and patients with chemotherapy- and CRT-induced oral mucositis. In cohort I, single and multiple doses of ibuprofen gargle (0.6% or 1.0%) were administered to healthy volunteers on day 1 and days 4-10. In cohort II, multiple doses of ibuprofen gargle (0.6%) were administered to patients with complicated grade 2-3 oral mucositis based on the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. The primary endpoint of cohort I was the treatment-related adverse events (TRAEs) as defined by CTCAE version 4.0. The primary endpoint of cohort II was the change in the visual analogue scale (VAS) pain score from before to 15 min after gargle use on day 3. The incidence and severity of TRAEs were assessed based on the CTCAE version 4.0 and a subjective rating scale completed by healthy volunteers and patients. Results: In cohort I, 9 of 10 healthy volunteers were evaluable for safety. All 9 healthy volunteers reported the TRAE of oral irritation with single or multiple use of the gargle. In cohort II, 10 patients were enrolled and evaluable for safety and 7 of 10 patients were evaluable for efficacy. The mean change in the VAS pain score from before to 15 min after using the gargle on day 3 was - 1.28 (95% confidence interval: - 2.06, - 0.51), and all patients experienced some degree of pain relief (range: - 0.2 to - 2.5). All 10 patients reported the TRAE of oral irritation. No other TRAEs of ibuprofen gargle were observed in the healthy volunteers and patients. Conclusion: Despite oral irritation, the ibuprofen gargle appeared to be safe and effective for the pain related to chemo- or CRT-induced oral mucositis. However, ibuprofen-related oral irritation warrants further formulation improvement. Trial registration: This study was registered with the University Hospital Medical Information Network Clinical Trials Registry (UMIN000014433).2020年, Journal of pharmaceutical health care and sciences, 6, 12 - 12, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- OBJECTIVES: To explore the risk factors of laryngo-esophageal dysfunction-free survival and nutritional support dependence over 12 months in patients with unresectable locally advanced head and neck carcinomas who received chemoradiotherapy in a phase II trial of JCOG0706 (UMIN000001272). METHODS: Forty-five patients received radiation therapy for a total of 70 Gy/35fr concurrently with S-1 and cisplatin. Risk factors of laryngo-esophageal dysfunction-free survival and nutritional support dependence over 12 months were analyzed using Cox regression models and logistic regression models, respectively, with consideration to patient laboratory data just before chemoradiotherapy. Radiation fields were reviewed to analyze the relationship between the extent of the irradiated field and functional outcome. RESULTS: With a median follow-up period of 3.5 years, 3-year laryngo-esophageal dysfunction-free survival was 48.9%. For laryngo-esophageal dysfunction-free survival, hazards ratio of 2.35 in patients with nutritional support at registration (vs. without nutritional support; 95% confidence interval 0.96-5.76). For nutritional support dependence over 12 months, odds ratio was 6.77 in patients with hemoglobin less than the median of 13.4 g/dl (vs. higher than or equal to the median; 95% confidence interval 1.24-36.85) and was 6.00 in patients with albumin less than the median of 3.9 g/dl (vs. higher than or equal to the median; 95% confidence interval 1.11-32.54). Primary sites in disease-free patients with nutritional support dependence over 12 months were the oropharynx (N = 2) or hypopharynx (N = 1), and all pharyngeal constrictor muscles were included in irradiated fields with a curative dose. CONCLUSIONS: This supplementary analysis showed that pretreatment severe dysphagia requiring nutritional support, anemia and hypoalbuminemia might have a negative prognostic impact on long-term functional outcomes after curative chemoradiotherapy in head and neck cancer.2019年12月, Japanese journal of clinical oncology, 49(11) (11), 1009 - 1015, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- {ClinMed} International Library, 2019年09月, International Journal of Oncology Research, 2(2) (2)研究論文（学術雑誌）
- (有)科学評論社, 2019年09月, 腫瘍内科, 24(3) (3), 232 - 236, 日本語
- OBJECTIVES: Many patients with squamous cell carcinoma of the head and neck (SCCHN) are ≥65 years old; comorbidities and other age-related factors may affect their ability to tolerate traditional chemotherapy. Nivolumab is the only immunotherapy to significantly improve overall survival (OS) versus investigator's choice (IC) of single-agent chemotherapy at primary analysis in a phase 3 trial (CheckMate 141) in patients with recurrent/metastatic SCCHN post-platinum therapy. In this post hoc analysis, we report efficacy and safety by age. PATIENTS AND METHODS: Eligible patients were randomized 2:1 to nivolumab 3 mg/kg every 2 weeks (n = 240) or IC (methotrexate, docetaxel, or cetuximab n = 121). The primary endpoint of the trial was OS. For this analysis, outcomes were analyzed by age < 65 and ≥65 years. The data cut-off date was September 2017 (minimum follow-up 24.2 months). RESULTS: At baseline, 68 patients (28.3%) receiving nivolumab and 45 patients (37.2%) receiving IC were ≥65 years. Baseline characteristics were generally similar across age groups. OS and tumor response benefits with nivolumab versus IC were maintained regardless of age. The 30-month OS rates of 11.2% (<65 years) and 13.0% (≥65 years) with nivolumab were more than tripled versus corresponding IC rates of 1.4% and 3.3%, respectively. The nivolumab arm had a lower rate of treatment-related adverse events versus IC regardless of age, consistent with the overall patient population. CONCLUSION: In CheckMate 141, nivolumab resulted in a higher survival versus IC in patients <65 and ≥65 years, with a manageable safety profile in both age groups. ClinicalTrials.gov: NCT02105636.2019年09月, Oral oncology, 96, 7 - 14, 英語, 国際誌, 国際共著している[査読有り]研究論文（学術雑誌）
- BACKGROUND: Multitarget kinase inhibitors (m-TKI), including lenvatinib, are now available as treatment options for radioiodine-refractory differentiated thyroid cancer (RR-DTC). However, the optimal timing of treatment initiation with m-TKI in these patients remains to be defined. METHODS: We retrospectively reviewed the clinical records of 30 consecutive patients with RR-DTC. The relationship between clinical characteristics was evaluated, including tumor growth parameters at pretreatment/post-treatment and efficacy of lenvatinib. RESULTS: A total of 26 patients with RR-DTC treated with lenvatinib were evaluable for response and eligible for analysis. From the results of multivariate analysis, baseline tumor size and tumor-related symptoms were independent negative prognostic factors for overall survival (OS) and progression-free survival (PFS). Pretreatment tumor growth parameters were not prognostic for either PFS or OS. CONCLUSIONS: Patients with RR-DTC with a high tumor burden and tumor-related symptoms had significantly worse prognosis. Greater tumor reduction after starting lenvatinib may lead to better prognosis, irrespective of pretreatment high tumor growth rate.2019年09月, Head & neck, 41(9) (9), 3023 - 3032, 英語, パスワードが無い, 国際誌[査読有り]研究論文（学術雑誌）
- (株)じほう, 2019年07月, 薬事, 61(10) (10), 1710 - 1714, 日本語【逸脱症例から学ぶ がん薬物療法 標準治療の実践!】(第1章)がん薬物治療 頭頸部がん[査読有り]
- LESSONS LEARNED: The results of the APPEARANCE trial indicate that adapalene does not prevent acne-like rash over placebo when added to topical moisturizer and oral minocycline but instead may have a detrimental effect. Therefore, adapalene is not recommended as prophylaxis against acne-like rash induced by anti-epidermal growth factor receptor therapies.Given that acne-like rash was completely controlled with placebo in approximately half of patients, predictive measures to identify patients needing intensive prophylaxis are required. BACKGROUND: Anti-epidermal growth factor receptor (EGFR) therapies are frequently associated with acne-like rash. To evaluate the prophylactic efficacy of adapalene, a topical retinoid used as first-line therapy for acne vulgaris, we conducted a randomized, placebo-controlled, evaluator-blinded, left-right comparative trial. METHODS: Patients with non-small cell lung, colorectal, or head and neck cancer scheduled to receive anti-EGFR therapies were randomly assigned to once-daily adapalene application on one side of the face, with placebo on the other side. All patients had topical moisturizer coapplied to both sides of the face, and received oral minocycline. The primary endpoint was the difference in total facial lesion count of acne-like rash at 4 weeks. Secondary endpoints included complete control rate (CCR) of acne-like rash (≤5 facial lesions) and global skin assessment (Investigator's Global Assessment [IGA] scale, grade 0-4) at 4 weeks. Two blinded dermatologists independently evaluated the endpoints from photographs. RESULTS: A total of 36 patients were enrolled, of whom 26 were evaluable. Adapalene treatment was associated with a greater lesion count than placebo at 4 weeks, although the difference was not statistically significant (mean, 12.6 vs. 9.8, p = .12). All four patients with a difference >10 in lesion count between face sides had a greater count on the adapalene-treated side. No significant differences were observed in CCR of acne-like rash (54% vs. 50%) or IGA scale (mean grade, 1.9 vs. 1.7) between the adapalene and placebo sides. CONCLUSION: Adapalene is not recommended as prophylaxis against acne-like rash induced by anti-EGFR therapies.2019年07月, The oncologist, 24(7) (7), 885-e413, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- A number of major modifications were made to the classification of head and neck carcinomas in the eighth edition of the American Joint Committee on Cancer, Cancer Staging Manual and Union for International Cancer Control TNM classification of Malignant Tumors. These modifications were aimed at improving the prognosis prediction accuracy of the system. In this article, we review the new edition of the TNM classification system. Among the several changes in the new system, a separate algorithm for p16-positive oropharyngeal carcinoma was included, as were new chapters on 'Head and Neck Skin Carcinoma' and 'Unknown Primary Carcinoma-Cervical Nodes.' Changes to Tumor (T) classification were made by introducing the depth of invasion of oral carcinoma, whereas changes to Node (N) classification were made by adding extra-nodal extension. It is believed that these changes will help improve the accuracy of the system in the prediction of prognosis. However, it is necessary to verify their validity through further clinical research.Oxford University Press (OUP), 2019年07月, Japanese journal of clinical oncology, 49(7) (7), 589 - 595, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- Importance: Locoregionally advanced head and neck squamous cell cancer (HNSCC) is treated curatively; however, risk of recurrence remains high among some patients. The ERBB family blocker afatinib has shown efficacy in recurrent or metastatic HNSCC. Objective: To assess whether afatinib therapy after definitive chemoradiotherapy (CRT) improves disease-free survival (DFS) in patients with HNSCC. Design, Setting, and Participants: This multicenter, phase 3, double-blind randomized clinical trial (LUX-Head & Neck 2) studied 617 patients from November 2, 2011, to July 4, 2016. Patients who had complete response after CRT, comprising radiotherapy with cisplatin or carboplatin, with or without resection of residual disease, for locoregionally advanced high- or intermediate-risk HNSCC of the oral cavity, hypopharynx, larynx, or oropharynx were included in the study. Data analysis was of the intention-to-treat population. Interventions: Patients were randomized (2:1) to treatment with afatinib (40 mg/d) or placebo, stratified by nodal status (N0-2a or N2b-3) and Eastern Cooperative Oncology Group performance status (0 or 1). Treatment continued for 18 months or until disease recurrence, unacceptable adverse events, or patient withdrawal. Main Outcomes and Measures: The primary end point was DFS, defined as time from the date of randomization to the date of tumor recurrence or secondary primary tumor or death from any cause. Secondary end points were DFS at 2 years, overall survival (defined as time from the date of randomization to death), and health-related quality of life. Results: A total of 617 patients were studied (mean [SD] age, 58 [8.4] years; 528 male [85.6%]). Recruitment was stopped after a preplanned interim futility analysis on July 4, 2016, on recommendation from an independent data monitoring committee. Treatment was discontinued. Median DFS was 43.4 months (95% CI, 37.4 months to not estimable) in the afatinib group and not estimable (95% CI, 40.1 months to not estimable) in the placebo group (hazard ratio, 1.13; 95% CI, 0.81-1.57; stratified log-rank test P = .48). The most common grade 3 and 4 drug-related adverse effects were acneiform rash (61 [14.8%] of 411 patients in the afatinib group vs 1 [0.5%] of 206 patients in the placebo group), stomatitis (55 [13.4%] in the afatinib group vs 1 [0.5%] in the placebo group), and diarrhea (32 [7.8%] in the afatinib group vs 1 [0.5%] in the placebo group). Conclusions and Relevance: This study's findings indicate that treatment with afatinib after CRT did not improve DFS and was associated with more adverse events than placebo in patients with primary, unresected, clinically high- to intermediate-risk HNSCC. The use of adjuvant afatinib after CRT is not recommended. Trial Registration: ClinicalTrials.gov identifier: NCT01345669.2019年06月, JAMA oncology, 5(8) (8), 1170 - 1180, 英語, 国際誌, 国際共著している[査読有り]研究論文（学術雑誌）
- (株)医学書院, 2019年06月, 耳鼻咽喉科・頭頸部外科, 91(7) (7), 572 - 578, 日本語
- BACKGROUND: We validated the new European Organisation for Research and Treatment of Cancer Quality of Life Head and Neck Module (EORTC QLQ-HN43). METHODS: We enrolled 812 patients with head and neck cancer from 18 countries. Group 1 completed the questionnaire before therapy, and 3 and 6 months later. In group 2 (survivors), we determined test-retest reliability using intraclass correlation coefficients (ICC). Internal consistency was assessed using Cronbach's Alpha, the scale structure with confirmatory factor analysis, and discriminant validity with known-group comparisons. RESULTS: Cronbach's alpha was >0.70 in 10 of the 12 multi-item scales. All standardized factor loadings exceeded 0.40. The ICC was >0.70 in all but two scales. Differences in scale scores between known-groups were >10 points in 17 of the 19 scales. Sensitivity to change was found to be sufficient in 18 scales. CONCLUSIONS: Evidence supports the reliability and validity of the EORTC QLQ-HN43 as a measure of quality of life.2019年06月, Head & neck, 41(6) (6), 1725 - 1737, 英語, 国際誌, 国際共著している[査読有り]研究論文（学術雑誌）
- OBJECTIVES: To evaluate the impact of retropharyngeal lymph node (RPLN) dissection in the surgical treatment of hypopharyngeal cancer. METHODS: Between 2007 and 2016, 98 previously untreated patients with pathological diagnosed hypopharyngeal squamous cell carcinoma underwent total pharyngolaryngectomy and bilateral neck dissection at Kobe University Hospital. Bilateral dissection of RPLN was simultaneously performed in all patients. Pharynx was reconstructed with free jejunal transfer in 94 patients and primarily closed in 4 patients. Postoperative chemoradiotherapy was performed in patients with high risk factors including metastasis to RPLN, multiple lymph node metastasis, extranodal invasion, and/or positive/close surgical margins. RESULTS: The median follow-up period was 25 months ranging from 1 to 105 months. RPLN adenopathy was preoperatively identified in 9 patients in FDG-positron emission tomography. All of them had pathologically diagnosed RPLN metastases, which had been controlled in all patients during the observation periods. Among the other 89 patients, 7 patients had RPLN metastasis. The 2-year overall survival rates of the patients with and without RPLN metastasis were 65.7% and 69.8% (P = .61), respectively. CONCLUSIONS: In the present study, patients with RPLN metastasis showed equally favorable oncological outcome compared with patients without RPLN metastasis. At least, ipsilateral RPLN dissection should be considered in the surgical treatment of advanced hypopharyngeal cancer and multiple neck lymph node metastasis regardless of primary subsite.2019年06月, Head & neck, 41(6) (6), 1738 - 1744, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- Wiley, 2019年05月, Cancer Science, 110(6) (6), 1987 - 1994[査読有り]研究論文（学術雑誌）
- (株)メディカルレビュー社, 2019年05月, がん免疫療法, 3(1) (1), 12 - 19, 日本語
- (一社)日本頭頸部癌学会, 2019年05月, 頭頸部癌, 45(2) (2), 131 - 131, 日本語再発・転移性頭頸部扁平上皮癌に対するニボルマブ第III相試験(CheckMate141)のアジア人2年フォローアップ
- (一社)日本頭頸部癌学会, 2019年05月, 頭頸部癌, 45(2) (2), 218 - 218, 日本語免疫関連有害事象に対する支援体制の構築と運用[査読有り]
- The standard local treatment for early-stage tongue cancer with no clinical lymph node metastases is partial glossectomy. The frequency of occult lymph node metastasis is ~20-30%. Thus, whether prophylactic neck dissection with glossectomy or glossectomy alone should be performed has been a controversial issue since the 1980s. Both treatments have advantages and disadvantages; however, especially in cases involving prophylactic neck dissection, surgical invasion and complications including the cosmetic disadvantage caused by neck skin incision, accessory nerve paralysis or facial nerve (mandibular marginal branch) paralysis, stiffness of the shoulder or neck and a feeling of neck tightness have been considered issues that could be solved by providing less-invasive treatment to the 70-80% of patients without occult lymph node metastasis. A more accurate preoperative diagnosis and strict follow-up are required to provide minimally invasive treatment while ensuring the therapeutic effect. It is also necessary to narrow down the target based on the risk-benefit balance. The depth of invasion should be considered in cases involving oral cavity malignancies. This was also taken into account in recent revisions of eighth edition of the TNM Classification of Malignant Tumors and it is an important factor for N0 neck management. This review article summarizes previous and recent reports on neck management, focusing on the risk-benefit and future perspectives of the diagnosis and treatment of early-stage oral tongue cancer. This effort is an attempt to establish treatment from the patient's point of view, with the patient's quality of life taken into account.2019年04月, Japanese journal of clinical oncology, 49(4) (4), 297 - 305, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- AIM: To investigate the safety and efficacy of lenvatinib in advanced thyroid cancer. PATIENTS/METHODS: In this Phase II study, 51 Japanese patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC), medullary thyroid cancer (MTC) or anaplastic thyroid cancer (ATC) received once-daily lenvatinib 24 mg. The primary end point was safety. RESULTS: All patients experienced ≥1 adverse event (AE); only one patient experienced an AE leading to discontinuation. The most common any-grade AEs were hypertension, decreased appetite, palmar-plantar erythrodysesthesia, fatigue and proteinuria. Response rates for RR-DTC: 68%; MTC: 22%; ATC: 24%. Median progression-free survival for RR-DTC: 25.8 months; MTC: 9.2 months; ATC: 7.4 months. CONCLUSION: Lenvatinib demonstrated a manageable safety profile, proven antitumor activity in RR-DTC and promising efficacy in MTC and ATC. CLINICAL TRIAL REGISTRATION: clinicaltrials.gov NCT01728623.2019年03月, Future oncology (London, England), 15(7) (7), 717 - 726, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- (一社)日本内科学会, 2019年02月, 日本内科学会雑誌, 108(Suppl.) (Suppl.), 284 - 284, 日本語甲状腺癌に対するレンバチニブ治療中の観血的処置の安全性・予後への影響に関する遡及的検討[査読有り]
- Tumor microenvironment plays a key role for tumor development and progression. Although adipose tissue is a predominant component of stroma in mammary tissues and secretes various cytokines, chemokines and growth factors, roles of adipocytes in breast cancers remain to be elucidated. In this study, we found that adipsin, an adipokine secreted from mammary adipose tissues, enhanced proliferation and cancer stem cell (CSC)-like properties of human breast cancer patient-derived xenograft (PDX) cells. Adipsin was predominantly expressed in both adipose tissues of the surgical specimens of breast cancer patients and adipose-derived stem cells (ADSCs) isolated from them, and its expression level was significantly higher in obese patients. ADSCs significantly enhanced the sphere-forming ability of breast cancer PDX cells derived from both estrogen receptor-positive and -negative breast cancer PDX cells. Suppression of adipsin-mediated signaling by a specific inhibitor or adipsin knockdown in ADSCs significantly decreased the sphere-forming ability and the expression of CSC markers in co-cultured breast cancer PDX cells. Growth of breast cancer PDX tumors was significantly enhanced by co-transplantation with ADSCs in vivo, and it was weakened when co-transplanted with the adipsin knocked-down ADSCs. These results suggest that adipsin is an important adipokine secreted from mammary adipose tissue that functions as a component of tumor microenvironment and a CSC niche in breast cancers.2019年02月, Oncogene, 38(6) (6), 767 - 779, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- 2019年, Otolaryngology - Head and Neck Surgery (Japan), 91(7) (7)研究論文（学術雑誌）
- (一社)日本がん看護学会, 2019年01月, 日本がん看護学会誌, 33(Suppl.) (Suppl.), 214 - 214, 日本語生活支援における効果的な多職種連携 経口抗がん薬服用患者への介入[査読有り]
- Objectives: To evaluate the clinical impact of cachexia, defined by the combination of albumin and C-reactive protein levels, in patients with unresectable locally advanced head and neck squamous cell carcinomas who received chemoradiotherapy in a phase II trial of JCOG0706. Methods: Forty-five patients received radiation for a total of 70 Gy/35fr concurrently with S-1 and cisplatin. The present analysis was conducted in 44 patients with available data. The association between treatment efficacy and cachexia was investigated. Pretreatment cachexia was defined as a serum albumin level of less than 3.5 mg/dl and C-reactive protein level of more than 0.5 mg/dl. Results: Among the 44 patients, 5 patients had cachexia. On comparison with the cachexic and non-cachexic patients, the percentage of clinical complete remission (20% vs 72%), time to treatment failure at 3 years, (20% vs 53%) and proportion of treatment completion (20% vs 79%) were statistically worse in the cachexic patients, while overall survival, progression-free survival and local progression-free survival at 3 years tended to be worse in cachexic patients. Conclusions: This supplementary analysis from a prospective study suggests that a pretreatment status of cancer cachexia is a prognostic factor for treatment outcomes and compliance in patients with locally advanced head and neck squamous cell carcinomas treated with chemoradiotherapy, and a candidate stratification factor in future prospective trials in this population.2019年01月, Japanese journal of clinical oncology, 49(1) (1), 37 - 41, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- Background: Induction chemotherapy (IC) is a treatment option for locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). However, treatment with docetaxel, cisplatin, and 5-FU (TPF) followed by cisplatin and radiotherapy is controversial because of toxicity concerns. The aim of this phase II study was to assess the feasibility of docetaxel, cisplatin, and cetuximab (TPEx) followed by cetuximab and concurrent radiotherapy for LA SCCHN. Patients and Methods: We enrolled patients with histological evidence of squamous cell carcinoma of the oropharynx, hypopharynx, or larynx without distant metastases. IC comprised cisplatin (75 mg/m2) and docetaxel (75 mg/m2) on day 1, repeated every 3 weeks for up to three courses. Cetuximab was initiated at 400 mg/m2, followed by 250 mg/m2 doses weekly until the end of radiotherapy. Radiotherapy (70 Gy/35 fr/7 w) was initiated after the last docetaxel administration. The primary endpoint was the rate of treatment completion. Results: We enrolled 54 patients (median age, 58 years) between August 2013 and October 2015. Our patients were 49 males and 5 females with hypopharyngeal (n = 28), oropharyngeal (n = 19), or laryngeal (n = 7) cancers, and 48 of them had stage IV disease. The overall response rate was 72.2% with a median follow-up of 36.1 months and a 3-year overall survival of 90.7%. The treatment completion rate was 76%; 50 patients (93%) received ≥2 courses of IC, and 41 (76%) completed radiotherapy. The frequencies of grade ≥3 febrile neutropenia or allergy/infusion reactions were 39% and 11%, respectively. There was one treatment-related death. Conclusions: IC with TPEx followed by cetuximab with concurrent radiotherapy showed acceptable compliance for the treatment of LA SCCHN. However, high frequency of febrile neutropenia remains a challenge and further improvement in the management of TPEx is necessary. Trial Registration: UMIN000009928.2019年, Frontiers in oncology, 9, 6 - 6, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- In locally advanced squamous cell carcinomas of the head and neck (LA-SCCHN), concurrent chemoradiotherapy is an integral part of multimodality management both in the adjuvant and in the definitive settings. Although de-intensification strategies have been propelled to the forefront of clinical research in human papillomavirus (HPV) positive oropharyngeal cancer, three cycles of 100 mg/m2 cisplatin given every 3 weeks concurrently with conventionally fractionated external beam radiotherapy represent a cost-effective and globally accessible treatment option for the majority of LA-SCCHN cases. Based on four large randomized trials, this regimen has become the non-surgical standard of care for cisplatin-eligible patients. Nevertheless, the outcomes in terms of efficacy, toxicity, and compliance have been rather disappointing. Therefore, there is an unmet need to find a better alternative. With limited support from randomized trials, weekly low-dose cisplatin regimens have replaced the standard high-dose schedule at some institutions. Four prospective trials exploring radiotherapy with and without weekly low-dose cisplatin have been published. Two of them were conducted in the 1980s, one of which had a negative outcome, the third study provided insufficient information on toxicity, and the fourth trial had to be prematurely terminated due to poor accrual. Moreover, the findings of two phase III trials comparing the two concurrent cisplatin regimens favored the high-dose protocol. We performed a composite meta-analysis of 59 prospective trials enrolling a total of 5,582 patients. The primary endpoint was overall survival. Reflecting different radiotherapy fractionation schemes and treatment intents, three meta-analyses were carried out, one for postoperative conventional chemoradiotherapy, one for definitive conventional chemoradiotherapy, and one for definitive altered fractionation chemoradiotherapy. In the former two settings, both high- and low-dose regimens yielded similar survival outcomes, thus, the primary objective was not met. When given concurrently with altered fractionation radiotherapy, patients treated with high-dose cisplatin had significantly longer overall survival than those who received low-dose cisplatin. In this article we provide a synthetic view of the results, discuss the issue of cumulative dose, compare two vs. three cycles of high-dose cisplatin, and present our three-step recommendations for use of the current standard of care, high-dose cisplatin, in clinical practice.2019年, Frontiers in oncology, 9, 86 - 86, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- (一社)日本頭頸部癌学会, 2018年12月, 頭頸部癌, 44(4号) (4号), 336 - 341, 日本語頭頸部がんに対する免疫チェックポイント阻害薬[招待有り]研究論文（学術雑誌）
- (一社)日本口腔腫瘍学会, 2018年12月, 日本口腔腫瘍学会誌, 30(4号) (4号), 144 - 150, 日本語口腔癌に対する免疫チェックポイント阻害剤投与の実際と腫瘍内科医との連携 頭頸部がんに対する免疫チェックポイント阻害薬と頭頸部がん診療連携プログラム[招待有り]研究論文（学術雑誌）
- For stage I/II tongue cancer patients, it is controversial whether prophylactic neck dissection should be performed with partial glossectomy. Based on the evidence of the primary tumor's depth of invasion as a predictive factor of occult lymph node metastases and a prognostic factor of disease-free survival, randomized phase III trial was initiated in November 2017 to evaluate the omission value for prophylactic neck dissection for stage I/II tongue cancer with 3-10 mm of depth of invasion. In 5 years, 440 patients will be accrued from 28 institutions. The primary end point of the study is the overall survival, whereas the secondary end points are relapse-free survival, local relapse-free survival, proportion of unresectable relapse and of cervical lymph node relapse, post-operative function (paralysis of the accessory and facial nerves and subjective symptoms) and adverse events. This trial has been registered with the UMIN Clinical Trials Registry (registration number: UMIN000030098; http://www.umin.ac.jp/ctr/index.htm).2018年12月, Japanese journal of clinical oncology, 48(12) (12), 1105 - 1108, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- Sorafenib and lenvatinib showed efficacy for patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC) in pivotal phase 3 clinical trials. Although the efficacy of lenvatinib in patients who received previous treatment with multi-target kinase inhibitors (m-TKIs), including sorafenib, was reported, the efficacy of sorafenib in patients who previously received lenvatinib remains unknown. A 75-year-old woman diagnosed as RAI-refractory poorly differentiated carcinoma with multiple lung metastases and started treatment with lenvatinib. She continued to receive lenvatinib but with repeated dose interruptions and reductions due to continuous proteinuria. Because of severe and persistent proteinuria as well as newly developed renal impairment, lenvatinib was suspended after two years of treatment. After the 7-month suspension, her proteinuria and renal impairment were partially improved, but her lung metastases progressed. Because she was unable to tolerate previous treatment with lenvatinib, sorafenib was started. At 7 months of treatment with sorafenib, her lung metastases shrank and she could continue sorafenib without exacerbation of proteinuria or renal impairment. This case may suggest that sorafenib does not exacerbate the proteinuria or renal impairment induced by lenvatinib, and may be an effective treatment option for RAI-refractory DTC patients who are unable to tolerate lenvatinib.2018年12月, Auris, nasus, larynx, 45(6) (6), 1249 - 1252, 英語, パスワードが無い, 国際誌[査読有り]研究論文（学術雑誌）
- BACKGROUND: Concomitant chemoradiotherapy (CCRT) produces severe mucositis and swallowing dysfunction, often resulting in malnutrition. Intensive nutrition support (INS) in addition to percutaneous endoscopic gastrostomy (PEG) is reported to decrease adverse effects during CCRT. PATIENTS AND METHODS: Fifty-eight patients with oropharyngeal cancer treated by CDDP-based CCRT were retrospectively analyzed. Twenty-nine patients treated with INS in addition to PEG were classified as INS group, and other 29 patients treated with PEG but without INS were classified as control group. RESULTS: INS in addition to PEG significantly increased calorie intake in the second half of CCRT and reduced adverse events including mucositis (p = 0.0019), leukopenia (p = 0.04), and renal function (p = 0.006). Moreover, 21 out of 29 patients had successfully administration of 200 mg/m2 or more of CDDP, while only 10 out of 29 patients had enough amount of CDDP in control group. CONCLUSIONS: These results suggest that INS in addition to prophylactic PEG not only decreases adverse effects but also may potentially improve oncological outcome of the patients with oropharyngeal cancer treated by CCRT.2018年12月, International journal of clinical oncology, 23(6) (6), 1023 - 1028, 英語, 国内誌[査読有り]研究論文（学術雑誌）
- A 69-year-old woman who had been diagnosed with unresectable papillary thyroid cancer was referred to our hospital. We initially treated her with sorafenib, but she subsequently developed erythema multiforme, which was suspected to be a drug rush due to sorafenib; therefore, sorafenib was discontinued. At the time of discontinuation, immature blast cells were detected in her peripheral blood. Approximately two weeks later, her skin rash improved substantially, but the proportion of blasts in the peripheral blood increased. We performed a bone marrow examination, and she was diagnosed with FLT3-ITD-positive acute myeloid leukemia. FLT3-ITD expression is found in 20-25% of AML and is a known independent poor prognostic factor. To overcome the poor prognosis associated with FLT3-ITD, molecular drugs targeting FLT3-ITD are attracting much attention. Sorafenib, a multi-kinase inhibitor, also has an effect on FLT3-ITD. Although primary disease flares after tyrosine kinase inhibitor discontinuation have been reported, this is the first report to describe discontinuation of sorafenib treatment as a potential trigger of FLT3-ITD-positive acute myeloid leukemia in papillary thyroid cancer.2018年12月, J Oncol Pharm Pract, 25(8) (8), 2010 - 2015, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- 2018年11月, Case Rep Oncol, 11(3) (3), 735 - 741, 英語, パスワードが無い[査読有り]研究論文（学術雑誌）
- (有)科学評論社, 2018年10月, 腫瘍内科, 22(4号) (4号), 399 - 403, 日本語【頭頸部がん・甲状腺がん・希少がん】 甲状腺がん BRAF遺伝子変異陽性甲状腺未分化がんに対するdabrafenib trametinib併用療法[招待有り]
- (一社)日本血液学会-東京事務局, 2018年09月, 臨床血液, 59(9) (9), 1641 - 1641, 英語sorafenib投薬を中断することで顕在化したFLT3-ITD陽性急性骨髄性白血病の一例(Discontinuation of sorafenib can lead to the emergence of FLT3-ITD-positive acute myeloid leukemia)
- 2018年09月, Ther Radiol Oncol, 2(39) (39), 英語, パスワードが無い[査読有り][招待有り]研究論文（学術雑誌）
- Nivolumab significantly improved overall survival (OS) vs investigator's choice (IC) of chemotherapy at the primary analysis of randomized, open-label, phase 3 CheckMate 141 in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). Here, we report that OS benefit with nivolumab was maintained at a minimum follow-up of 11.4 months. Further, OS benefit with nivolumab vs IC was also noted among patients who received first-line treatment for R/M SCCHN after progressing on platinum therapy for locally advanced disease in the adjuvant or primary (i.e., with radiation) setting.2018年09月, The oncologist, 23(9) (9), 1079 - 1082, 英語, 国際誌, 国際共著している[査読有り]研究論文（学術雑誌）
- (株)医学書院, 2018年09月, 耳鼻咽喉科・頭頸部外科, 90(10号) (10号), 855 - 860, 日本語【どこが変わった頭頸部癌診療ガイドライン】 がん薬物療法
- (株)東京医学社, 2018年08月, JOHNS, 34(8号) (8号), 983 - 985, 日本語【ちょっと気になる頭頸部癌化学療法】 術後再発高リスク患者に対する治療の現状とエビデンス[招待有り]研究論文（学術雑誌）
- BACKGROUND: Hypertension (HTN) is an established class effect of vascular endothelial growth factor receptor (VEGFR) inhibition. In the phase 3 Study of (E7080) Lenvatinib in Differentiated Cancer of the Thyroid (SELECT) trial, HTN was the most frequent adverse event of lenvatinib, an inhibitor of VEGFR1, VEGFR2, VEGFR3, fibroblast growth factor receptor 1 (FGFR1), FGFR2, FGFR3, FGFR4, platelet-derived growth factor receptor α (PDGFRα), ret proto-oncogene (RET), and stem cell factor receptor (KIT). This exploratory analysis examined treatment-emergent hypertension (TE-HTN) and its relation with lenvatinib efficacy and safety in SELECT. METHODS: In the multicenter, double-blind SELECT trial, 392 patients with progressive radioiodine-refractory differentiated thyroid cancer (RR-DTC) were randomized 2:1 to lenvatinib (24 mg/d on a 28-day cycle) or placebo. Survival endpoints were assessed with Kaplan-Meier estimates and log-rank tests. The influence of TE-HTN on progression-free survival (PFS) and overall survival (OS) was analyzed with univariate and multivariate Cox proportional hazards models. RESULTS: Overall, 73% of lenvatinib-treated patients and 15% of placebo-treated patients experienced TE-HTN. The median PFS for lenvatinib-treated patients with (n = 190) and without TE-HTN (n = 71) was 18.8 and 12.9 months, respectively (hazard ratio [HR], 0.59; 95% confidence interval [CI], 0.39-0.88; P = .0085). For lenvatinib-treated patients, the objective response rate was 69% with TE-HTN and 56% without TE-HTN (odds ratio, 1.72; 95% CI, 0.98-3.01). The median change in tumor size for patients with and without TE-HTN was -45% and -40%, respectively (P = .2). The median OS was not reached for patients with TE-HTN; for those without TE-HTN, it was 21.7 months (HR, 0.43; 95% CI, 0.27-0.69; P = .0003). CONCLUSIONS: Although HTN is a clinically significant adverse event that warrants monitoring and management, TE-HTN was significantly correlated with improved outcomes in patients with RR-DTC, indicating that HTN may be predictive for lenvatinib efficacy in this population. Cancer 2018;124:2365-72. © 2018 American Cancer Society.2018年06月, Cancer, 124(11) (11), 2365 - 2372, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- OBJECTIVES: We report 2-year results from CheckMate 141 to establish the long-term efficacy and safety profile of nivolumab and outcomes by tumor PD-L1 expression in patients with recurrent or metastatic (R/M),platinum-refractory squamous cell carcinoma of the head and neck (SCCHN). METHODS: Patients with R/M SCCHN with tumor progression/recurrence within 6 months of platinum therapy were randomized 2:1 to nivolumab 3 mg/kg every 2 weeks or investigator's choice (IC). Primary endpoint: overall survival (OS). Data cutoff: September 2017. RESULTS: With 24.2 months' minimum follow-up, nivolumab (n = 240) continued to improve OS vs IC (n = 121), hazard ratio (HR) = 0.68 (95% CI 0.54-0.86). Nivolumab nearly tripled the estimated 24-month OS rate (16.9%) vs IC (6.0%), and demonstrated OS benefit across patients with tumor PD-L1 expression ≥1% (HR [95% CI] = 0.55 [0.39-0.78]) and < 1% (HR [95% CI] = 0.73 [0.49-1.09]), and regardless of tumor HPV status. Estimated OS rates at 18, 24, and 30 months with nivolumab were consistent irrespective of PD-L1 expression (<1%/≥1%). In the nivolumab arm, there were no observed differences in baseline characteristics or safety profile between long-term survivors and the overall population. Grade 3-4 treatment-related adverse event rates were 15.3% and 36.9% for nivolumab and IC, respectively. CONCLUSION: Nivolumab significantly improved OS at the primary analysis and demonstrated prolonged OS benefit vs IC and maintenance of a manageable and consistent safety profile with 2-year follow-up. OS benefit was observed with nivolumab irrespective of PD-L1 expression and HPV status. (Clinicaltrials.gov: NCT02105636).2018年06月, Oral oncology, 81, 45 - 51, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- BACKGROUND AND OBJECTIVES: To explore whether lymphocytes in sentinel lymph nodes (SLNs) are highly exposed to tumor neoantigens and thus express high level of programmed death 1 (PD-1), we examined PD-1 expression in SLNs and non-sentinel regional lymph nodes (non-SLNs) in breast cancer. METHODS: We performed PD-1 immunohistochemistry in two cohorts: 40 metastasis-negative SLNs including 10 patients for each subtype (luminal A-like, luminal B-like, HER2, and triple negative breast cancer [TNBC]); and 25 pairs of metastasis-positive SLNs and non-SLNs (10 luminal A-like, 10 luminal B-like, and 5 TNBC). RESULTS: Among 40 metastasis-negative SLNs, 34 and 6 samples were PD-1 intensity grade 1 (low) and 2 (high), respectively. PD-1 intensity correlated with PD-1-positive lymphocyte numbers (P = 0.005); TNBC had the highest PD-1 lymphocyte numbers among all subtypes. The median PD-1-positive lymphocyte number was higher in SLNs than non-SLNs. In most cases, more lymphocytes in SLNs expressed PD-1 than those in non-SLNs (P < 0.0001). CONCLUSIONS: TNBC had the greatest PD-1 expression among all subtypes, and metastasis-positive SLNs had more PD-1-positive lymphocytes than downstream non-SLNs. These data suggested that lymphocytes in SLNs are activated following exposure to tumor neoantigens and thus tumor specific, and could be utilized as a biomarker platform.2018年05月, Journal of surgical oncology, 117(6) (6), 1131 - 1136, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- 3D Culture Represents Apoptosis Induced by Trastuzumab Better than 2D Monolayer Culture.BACKGROUND: Our hypothesis was that three-dimensional (3D) culture better represents differential in vivo responses to trastuzumab between PIK3CA-wild-type (wt) and mutant (mt) cell lines than does two-dimensional (2D) culture. MATERIALS AND METHODS: Apoptosis and cell signaling proteins were evaluated in response to trastuzumab with and without BKM120, a pan-phosphatidylinositol 3-kinase (PI3K) inhibitor, using western blot analysis of four breast cancer cell lines with human epidermal growth factor receptor 2 (HER2) amplification. RESULTS: Increased expression of cleaved poly (ADP-ribose) polymerase (PARP) was observed only in 3D-cultured PIK3CA-wt lines in response to trastuzumab, but not in 2D-cultured PIK3CA-wt or PIK3CA-mt lines. Decrease in the ratio of phosphorylated (p-)AKT to AKT in response to trastuzumab was more profound in PIK3CA-wt cells than in PIK3CA-mt cells in 3D culture, while the difference between PIK3CA genotypes was less apparent in 2D culture. Treatment with BKM120 and trastuzumab resulted in a stronger increase in cleaved PARP than either treatment alone. CONCLUSION: 3D Culture appears to better represent trastuzumab-induced apoptosis and resistance to trastuzumab associated with PIK3CA mutation.2018年05月, Anticancer research, 38(5) (5), 2831 - 2839, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- Modified TALK Score for Japanese Patients with Laryngeal and Hypopharyngeal Cancers to Predict the Possibility of Laryngeal Preservation by Concurrent Chemoradiotherapy.OBJECTIVE: TALK score has been developed as an index for predicting the possibility of larynx preservation and prognosis of the patients with advanced laryngeal and hypopharyngeal cancers treated by concurrent chemoradiotherapy (CCRT). In this study, we validated the original TALK score in our clinical setting and modified the score for Japanese population. METHODS: The subjects were 21 patients with laryngeal cancer and 50 patients with hypopharyngeal cancer who underwent CCRT at Kobe University Hospital between April 2007 and August 2012. Data regarding T stage, serum albumin level just before treatment, maximum alcohol use, Karnofsky Performance Status (KPS), 3-year overall survival rate and 3-year larynx-preservation rate were collected from medical records. In the revised TALK score (JTALK), the following scoring criteria were modified to adjust Japanese population: T stage of the primary tumor (≥T3), serum albumin level (<3.5 g/dl), maximum alcohol use (≥one 350-ml can of beer/day or an equivalent amount), and KPS (<80%). RESULTS: The original TALK score was not significantly associated with the larynx preservation rates or survival rates for laryngeal cancer or hypopharyngeal cancer. Instead, JTALK score was significantly associated with the 3-year larynx preservation rates and 3-year survival rates of the patients with hypopharyngeal and laryngeal cancer. CONCLUSION: These results indicate that JTALK score could be a useful index for predicting the possibility of larynx preservation and prognosis of Japanese patients with advanced laryngeal and hypopharyngeal cancer treated by CCRT.2018年04月, The Kobe journal of medical sciences, 63(4) (4), E113-E122 - E122, 英語, 国内誌[査読有り]研究論文（学術雑誌）
- Background: The development of skin rashes is the most common adverse event observed in cancer patients treated with epidermal growth factor receptor-tyrosine kinase inhibitors such as erlotinib. However, the pharmacological evidence has not been fully revealed. Results: Erlotinib distribution in the rashes was more heterogeneous than that in the normal skin, and the rashes contained statistically higher concentrations of erlotinib than adjacent normal skin in the superficial skin layer (229 ± 192 vs. 120 ± 103 ions/mm2; P = 0.009 in paired t-test). LC-MS/MS confirmed that the concentration of erlotinib in the skin rashes was higher than that in normal skin in the superficial skin layer (1946 ± 1258 vs. 1174 ± 662 ng/cm3; P = 0.028 in paired t-test). The results of MALDI-MSI and LC-MS/MS were well correlated (coefficient of correlation 0.879, P < 0.0001). Conclusions: Focal distribution of erlotinib in the skin tissue was visualized using non-labeled MALDI-MSI. Erlotinib concentration in the superficial layer of the skin rashes was higher than that in the adjacent normal skin. Methods: We examined patients with advanced pancreatic cancer who developed skin rashes after treatment with erlotinib and gemcitabine. We biopsied both the rash and adjacent normal skin tissues, and visualized and compared the distribution of erlotinib within the skin using matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI). The tissue concentration of erlotinib was also measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) with laser microdissection.2018年04月, Oncotarget, 9(26) (26), 18540 - 18547, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- (一社)日本内科学会, 2018年02月, 日本内科学会雑誌, 107(Suppl.) (Suppl.), 189 - 189, 日本語次世代シークエンサーを用いた唾液腺導管癌・腺癌NOSの新規治療標的遺伝子の同定[査読有り]
- (一社)日本内科学会, 2018年02月, 日本内科学会雑誌, 107(Suppl.) (Suppl.), 189 - 189, 日本語がんクリニカルシークエンスと遺伝性腫瘍の関係[査読有り]
- BACKGROUND: The standard of care for first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) is combination treatment with platinum, 5-FU and cetuximab (PFE). However, this regimen requires hospitalization to ensure proper hydration and continuous infusion of 5-FU, and causes severe nausea and anorexia. We evaluated the efficacy and safety of paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with R/M SCCHN. PATIENTS AND METHODS: Eligibility criteria included recurrent and/or metastatic, histologically proven SCC of the oropharynx, oral cavity, hypopharynx or larynx; PS 0-1; adequate organ function; no suitable local therapy for R/M SCCHN; and no prior systemic chemotherapy for R/M SCCHN. Chemotherapy consisted of paclitaxel 100 mg/m2 on days 1, 8; carboplatin area under the blood concentration-time curve 2.5 on days 1, 8, repeated every 3 weeks for up to 6 cycles; and cetuximab at an initial dose of 400 mg/m2, followed by 250 mg/m2 weekly until disease progression or unacceptable toxicities. Primary end point was overall response rate. Secondary end points were safety, treatment completion rate, progression-free survival, overall survival, and clinical benefit rate. Planned sample size was 45 patients. RESULTS: Forty-seven subjects were accrued from July 2013 to October 2014. Of 45 evaluable, 40 were male; median age was 63 years; Eastern Cooperative Oncology Group Performance Status was 0/1 in 23/22 cases; site was the hypopharynx/oropharynx/oral cavity/larynx in 17/11/10/7 cases; and 36/9 cases were smokers/nonsmokers, respectively. Overall response rate, the primary end point, was 40%. Median overall survival was 14.7 months and progression-free survival was 5.2 months. Grade 3/4 adverse events included neutropenia (68%), skin reaction (15%), fatigue (9%) and febrile neutropenia (9%). A potentially treatment-related death occurred in one patient with intestinal pneumonia. CONCLUSIONS: The PCE regimen shows promising activity with acceptable toxicity in the outpatient clinic. Further studies are needed to compare PCE with PFE in this population. REGISTERED CLINICAL TRIAL NUMBER: UMIN000010507.2018年02月, Ann Oncol, 29(4) (4), 1004 - 1009, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- 2018年, Otolaryngology - Head and Neck Surgery (Japan), 90(10) (10)研究論文（学術雑誌）
- OBJECTIVES: Altered fractionation radiotherapy and concomitant chemoradiotherapy represent commonly used intensification strategies in the management of locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). This meta-analysis compares compliance, safety, and efficacy between two single-agent cisplatin schedules given concurrently with altered fractionation radiotherapy. METHODS: We systematically searched for prospective trials of patients with LA-SCCHN who received post-operative or definitive altered fractionation concurrent chemoradiotherapy. High-dose cisplatin once every three to four weeks (100 mg/m2, 2 doses) was compared with a weekly low-dose protocol (≤50 mg/m2, ≥4 doses). The primary outcome was overall survival. The secondary endpoints comprised treatment adherence, acute and late toxicities, and objective response rate. RESULTS: Twelve studies with 1373 patients treated with definitive chemoradiotherapy were included. Compared to the weekly low-dose cisplatin regimen, the three- to four-weekly high-dose cisplatin regimen improved overall survival (p=.0185), was more compliant with respect to receiving all planned cycles of cisplatin (71% versus 95%, p=.0353), and demonstrated less complications in terms of severe (grade 3-4) acute mucositis and/or stomatitis (75% versus 40%, p=.0202) and constipation (8% versus 1%, p=.0066), toxic deaths (4%, versus 1%, p=.0168), 30-day mortality (8% versus 3%, p=.0154), and severe late subcutaneous fibrosis (21% versus 2%, p<.0001). Overall and complete response rates were similar between both chemotherapy schedules. CONCLUSION: In chemoradiotherapy incorporating altered fractionation, two cycles of high-dose cisplatin with a three to four week interval are superior to weekly low-dose schedules. Further studies should identify those who might derive the greatest benefit from this intensified approach.2018年01月, Oral oncology, 76, 52 - 60, 英語, 国際誌, 国際共著している[査読有り]研究論文（学術雑誌）
- (株)日本臨床社, 2017年12月, 日本臨床, 75(増刊9 がん転移学(下)) (増刊9 がん転移学(下)), 159 - 163, 日本語
- 2017年12月, PLOS ONE, 12(12) (12), e0187992, 英語[査読有り]研究論文（学術雑誌）
- (一社)日本癌治療学会, 2017年10月, 日本癌治療学会学術集会抄録集, 55回, P108 - 3, 日本語根治切除不能な頭頸部扁平上皮癌における悪液質と予後の検討 JCOG0706副次的解析
- (一社)日本癌治療学会, 2017年10月, 日本癌治療学会学術集会抄録集, 55回, P108 - 3, 日本語根治切除不能な頭頸部扁平上皮癌における悪液質と予後の検討 JCOG0706副次的解析
- STUDY DESIGN: A prospective cohort study of performance status (PS) and activities of daily living (ADL) in patients with spinal metastasis. OBJECTIVE: To identify the effect of spinal surgery on PS and ADL in patients with spinal metastasis. SUMMARY OF BACKGROUND DATA: Spinal metastasis causes severe neurological deficits, resulting in drastic loss of patients' PS and ADL. However, the effect of spine surgery on PS and ADL is not well known. MATERIALS AND METHODS: Seventy patients with spinal metastasis were enrolled in this study. Forty-six patients desired and underwent spine surgery ("surgery" group) and 24 patients did not desire surgery ("nonsurgery" group). Both groups received optimal treatments, including radiation, chemotherapy, and palliative care services. Evaluation was performed at 1, 3, and 6 months after study enrollment using the Eastern Cooperative Oncology Group PS, the Barthel index (BI) for ADL, and Frankel classification for neurological status. RESULTS: There was no significant difference in baseline PS, the BI, or Frankel classification between the groups. The surgery group showed significant improvement in PS, maintaining grade 2 or less throughout the duration of the study, as well as in ADL, exceeding 70 points of the BI, compared with the nonsurgery group (P<0.05). Significantly improved neurological condition was also observed in the surgery group over the following 6 months. More than 95% of patients who underwent surgery improved their PS, the BI, and neurological status. Furthermore, >80% of these patients maintained improvement in PS, the BI, and neurological status for at least 6 months. In contrast, PS, the BI, and neurological status of patients in the "nonsurgery" group deteriorated throughout the study period. CONCLUSIONS: Spine surgery improves PS, ADL, and neurological status in patients with spinal metastasis for a minimum 6 months. This indicates that these patients can acquire an independent daily life.2017年10月, Clinical spine surgery, 30(8) (8), E1026-E1032, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- 2017年10月, ORAL ONCOLOGY, 73, 138 - 146, 英語, パスワードが無い, 国際共著している[査読有り]研究論文（学術雑誌）
- AlphaMed Press, 2017年09月, Oncologist, 22(9) (9), 1056 - 1066, 英語, 国際共著している[査読有り]研究論文（学術雑誌）
- 2017年09月, THYROID, 27(9) (9), 1135 - 1141, 英語, パスワードが無い, 国際共著している[査読有り]研究論文（学術雑誌）
- 2017年08月, LANCET ONCOLOGY, 18(8) (8), 1104 - 1115, 英語, 国際共著している[査読有り]研究論文（学術雑誌）
- 2017年08月, AURIS NASUS LARYNX, 44(4) (4), 375 - 380, 英語[査読有り]研究論文（学術雑誌）
- Japanese Journal of Cancer and Chemotherapy Publishers Inc., 2017年07月, Japanese Journal of Cancer and Chemotherapy, 44(7) (7), 575 - 578, 日本語Non-surgical treatment strategy for locally advanced laryngeal and hypopharyngeal cancer[査読有り]研究論文（学術雑誌）
- 2017年06月, INTERNATIONAL ORTHOPAEDICS, 41(6) (6), 1265 - 1271, 英語[査読有り]研究論文（学術雑誌）
- 2017年05月, 頭頸部癌, 43(2号) (2号), 205, 日本語当院における嗅神経芽細胞腫症例の検討[査読有り]
- (一社)日本頭頸部癌学会, 2017年05月, 頭頸部癌, 43(2号) (2号), 144 - 144, 日本語個別化治療を目指した頭頸部癌診療ガイドライン 頭頸部がんに対する放射線治療の個別化 治療効果予測からの検討[査読有り][招待有り]
- (一社)日本頭頸部癌学会, 2017年05月, 頭頸部癌, 43(2号) (2号), 177 - 177, 日本語局所進行頭頸部扁平上皮癌における導入化学療法TPFの安全性と有効性の検討[査読有り]
- 2017年04月, Endocrine-related cancer, 24(4) (4), 197 - 207, 英語, 国際誌, 国際共著している[査読有り]研究論文（学術雑誌）
- 日本気管食道科学会, 2017年04月, 日本気管食道科学会会報, 68(2号) (2号), 202 - 203, 日本語高齢社会の癌薬物療法 高齢頭頸部癌患者に対する癌薬物療法[査読有り][招待有り]研究論文（学術雑誌）
- 2017年04月, EUROPEAN JOURNAL OF CANCER, 75, 213 - 221, 英語, 国際共著している[査読有り]研究論文（学術雑誌）
- 2017年04月, 日本内分泌・甲状腺外科学会雑誌, 34(Suppl.1) (Suppl.1), S45, 日本語転移・再発甲状腺がんに対する薬物療法[招待有り]
- (公社)日本整形外科学会, 2017年03月, 日本整形外科学会雑誌, 91(3) (3), S1058 - S1058, 日本語[招待有り]
- This study evaluated the prognostic significance of the maximum standardized uptake value of the primary site (pSUVmax) in 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) scans of patients with oropharyngeal or hypopharyngeal cancer who were treated using definitive radiotherapy. The study included 86 patients who were primarily treated with radiotherapy for oropharyngeal or hypopharyngeal cancer. Sixty-nine patients underwent concurrent chemotherapy. The associations between pre-treatment pSUVmax and treatment outcomes were evaluated. The most appropriate pSUVmax cut-off value for predicting disease-free survival (DFS) and local control (LC) was selected using receiver operating characteristic (ROC) curves. The median follow-up time for surviving patients was 60 months, while the median survival time in the entire patient cohort was 55 months. A pSUVmax cut-off value of 9.0 showed the best discriminative performance. Five-year OS and DFS rates were 65.9% and 60.0%, respectively. In univariate analyses, pSUVmax (p = 0.009), T-stage (p = 0.001), N-stage (p = 0.039), and clinical stage (p = 0.017) were identified as significant prognostic predictors for DFS. The multivariate analysis did not identify any statistically significant factors, but the association between pSUVmax and DFS was borderline significant (p = 0.055). Interestingly, pSUVmax was predictive of local controllability in T1-T2 disease (p = 0.024), but there was no significant association for T3-T4 disease (p = 0.735). In this study, pSUVmax was predictive of DFS and LC in patients with oropharyngeal or hypopharyngeal cancer that was treated with definitive radiotherapy. pSUVmax was strongly associated with LC in T1-T2 disease.2017年02月, Nagoya journal of medical science, 79(1) (1), 27 - 36, 英語, 国内誌[査読有り]
- 2017年02月, 日本臨床, 75(増刊2 頭頸部癌学) (増刊2 頭頸部癌学), 451 - 456, 日本語【頭頸部癌学-診断と治療の最新研究動向-】 頭頸部癌の治療 放射線治療・薬物治療 口腔・咽頭・喉頭癌 局所進行頭頸部癌に対する薬物療法 術後治療[査読有り][招待有り]研究論文（学術雑誌）
- (公社)日本医学放射線学会, 2017年02月, Japanese Journal of Radiology, 35(Suppl.) (Suppl.), 46 - 46, 日本語当院におけるT3N0M0喉頭癌の放射線治療成績[査読有り]
- John Libbey Eurotext, 2017年, European Journal of Dermatology, 27(2) (2), 177 - 178, 英語[査読有り]研究論文（学術雑誌）
- BACKGROUND: Lenvatinib has been approved by regulatory agencies in Japan, the United States, and the European Union for treatment of radioiodine-refractory differentiated thyroid cancer (RR-DTC). Thyroid cancer, however, is a clinically diverse disease that includes anaplastic thyroid cancer (ATC), the subtype associated with the highest lethality. Effective therapy for ATC is an unmet need. PATIENTS AND METHODS: This phase 2, single-arm, open-label study in patients with thyroid cancer, including ATC, RR-DTC, and medullary thyroid cancer was conducted from 3 September 2012 to 9 July 2015. Patients received lenvatinib 24 mg daily until disease progression or development of unacceptable toxicity. The primary endpoint was safety, and the secondary endpoint was efficacy, as assessed by progression-free survival (PFS), overall survival (OS), and objective response rate. RESULTS: At data cutoff, 17 patients with ATC were enrolled. All experienced ≥1 treatment-emergent adverse event (TEAE). The most frequent TEAEs were decreased appetite (82%), hypertension (82%), fatigue (59%), nausea (59%), and proteinuria (59%). Of note, only one patient required lenvatinib withdrawal because of a TEAE, and this TEAE was considered unrelated to lenvatinib. The median PFS was 7.4 months [95% confidence interval (CI): 1.7-12.9], the median OS was 10.6 months (95% CI: 3.8-19.8), and the objective response rate was 24%. CONCLUSION: In this study, lenvatinib demonstrated manageable toxicities with dose adjustments and clinical activity in patients with ATC. This clinical activity of lenvatinib warrants further investigation in ATC. CLINICALTRIALSGOV: NCT01728623.2017年, Frontiers in oncology, 7, 25 - 25, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- The development of orally active, multitargeted kinase inhibitors (MKIs) represents a significant advance in the treatment of progressive, metastatic thyroid cancer. Lenvatinib, an MKI targeting vascular endothelial growth factor receptor, fibroblast growth factor receptor, platelet-derived growth factor receptor, c-Kit, and RET, has shown efficacy in stabilizing previously progressive disease, with emerging evidence of a possible benefit in terms of overall survival. However, lenvatinib is associated with a side-effect profile similar to those of other MKIs that might affect the outcome of therapy. The aim of this review is to summarize the clinical efficacy and safety of MKIs in the treatment of advanced thyroid cancer in pivotal phase III trials. Common adverse events that may occur during lenvatinib therapy and their management are discussed, including conditions in which its administration should be temporarily withdrawn and resumed pending resolution of adverse events. We focus on data from a subanalysis of Japanese patients in the SELECT trial and in a post-marketing study in Japan. We suggest that lenvatinib is a valuable treatment option for advanced differentiated thyroid cancer. Monitoring and careful management of adverse events including supportive care are required to ensure continuation of therapy.2017年, Cancers of the head & neck, 2(7) (7), 7 - 7, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- (一社)日本頭頸部癌学会, 2016年12月, 頭頸部癌, 42(4号) (4号), 432 - 437, 日本語[査読有り]研究論文（学術雑誌）
- OBJECTIVE: Radiation-induced mucositis (RIM) in chemoradiotherapy (CRT) for head and neck cancer (HNC) causes severe pain and worsens CRT compliance, QOL and outcome. Following retrospective reports, we conducted a randomized trial of the safety and efficacy of gabapentin for RIM-associated pain during CRT. METHODS: HNC patients (pts) receiving CRT were randomized to standard pain control (SPC) with acetaminophen and opioids, or SPC plus gabapentin (SPC+G). Gabapentin was maintained at 900mg/day for 4 weeks after CRT. Primary endpoint was maximum visual analogue scale (VAS) score during CRT, and secondary endpoints were total opioid dose, changes in QOL (EORTC QLQ-C30 and QLQ-HN 35) from baseline to 4 weeks after CRT, and adverse events. RESULTS: Twenty-two eligible Stage III or IV pts were randomly assigned to SPC or SPC+G (n=11 each). Twelve were treated in a locally advanced setting and 10 in a postoperative setting. Median maximum VAS scores, median total dose of opioids at maximum VAS and total dose of opioids at 4 weeks after CRT tended to be higher in the SPC+G arm (47 in SPC vs. 74 in SPC+G, p=0.517; 215mg vs. 745.3mg, p=0.880; and 1260mg vs. 1537.5mg, p=0.9438, respectively), without significance. QOL analysis showed significantly worse scores in the SPC+G arm for weight gain (p=0.005). Adverse events related to gabapentin were manageable. CONCLUSIONS: This pilot study is the first prospective randomized trial of gabapentin for RIM-related pain. Gabapentin had no apparent beneficial effect. Further research into agents for RIM-related pain is warranted.2016年12月, Auris, nasus, larynx, 43(6) (6), 677 - 84, 英語, パスワードが無い, 国際誌[査読有り]研究論文（学術雑誌）
- 2016年12月, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 96(5) (5), 976 - 984, 英語[査読有り]研究論文（学術雑誌）
- 2016年11月, Thyroid : official journal of the American Thyroid Association, 26(11) (11), 1605 - 1613, 英語, 国際誌, 国際共著している[査読有り]研究論文（学術雑誌）
- 2016年11月, NEW ENGLAND JOURNAL OF MEDICINE, 375(19) (19), 1856 - 1867, 英語, 国際共著している[査読有り]研究論文（学術雑誌）
- (一社)日本癌治療学会, 2016年10月, 日本癌治療学会学術集会抄録集, 54回, MS29 - 1, 英語頭頸・口腔 頭頸部がんに対する治療戦略 再発性または転移性(R/M)頭頸部扁平上皮癌(HNSCC)に対するnivolumab療法と検査者選択療法の比較(Nivolumab vs investigator's choice for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (HNSCC))
- (一社)日本癌治療学会, 2016年10月, 日本癌治療学会学術集会抄録集, 54回, WS80 - 1, 日本語頭頸・口腔 頭頸部がんに対する治療戦略 再発・転移頭頸部癌に対するPaclitaxel+Carboplatin+Cetuximab療法の第II相試験
- 2016年07月, ANNALS OF ONCOLOGY, 27, 英語Phase 2 Trial of Bi-weekly Cetuximab for Recurrent or Metastatic Colorectal Cancer (BIC-K Trial)[査読有り]
- 2016年07月, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 78(1) (1), 91 - 99, 英語[査読有り]研究論文（学術雑誌）
- 2016年06月, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 77(6) (6), 1165 - 1170, 英語[査読有り]研究論文（学術雑誌）
- 2016年05月, 頭頸部癌, 42(2号) (2号), 181, 日本語同時併用化学放射線療法を施行した進行期喉頭癌、下咽頭癌症例におけるTalk Scoreの検討研究論文（その他学術会議資料等）
- 2016年05月, 頭頸部癌, 42(2号) (2号), 181, 日本語当科で放射線治療を施行した下咽頭癌T1・T2症例の検討研究論文（その他学術会議資料等）
- (一社)日本頭頸部癌学会, 2016年05月, 頭頸部癌, 42(2号) (2号), 207 - 207, 日本語舌癌術後再発症例に対する放射線治療成績[査読有り]研究論文（その他学術会議資料等）
- 2016年05月, 頭頸部癌, 42(2号) (2号), 211, 日本語セツキシマブ追加の有無による、再発性/転移性頭頸部癌の第一選択治療の比較(First-line Treatment of Recurrent/Metastatic Head and Neck Cancer with or without Cetuximab)(英語)研究論文（その他学術会議資料等）
- Springer Verlag, 2016年04月, European Radiology, 26(4) (4), 1018 - 1030, 英語[査読有り]研究論文（学術雑誌）
- BACKGROUND: The purpose of this study was to analyze outcomes for the treatment of locally advanced temporal bone cancer by means of concomitant chemoradiotherapy (CCRT) with a combination of cisplatin (CDDP), 5-fluorouracil (5-FU), and docetaxel (TPF). METHODS: Between 2006 and 2011, 34 patients with squamous cell carcinoma of the temporal bone were treated at Kobe University Hospital. Medical records were retrospectively reviewed to obtain information concerning patient characteristics, extent of disease, treatment, adverse events, and oncologic results. RESULTS: Ten patients were treated with CCRT using TPF regimen. The 5-year overall survival rate and disease-free survival rate were both 60%. Of special interest is that even for patients with unresectable T4 disease, the 5-year overall survival rate was 56%. CONCLUSION: The results of our study indicate that CCRT with TPF for locally advanced temporal bone cancer is an effective and promising regimen. © 2015 Wiley Periodicals, Inc. Head Neck 38: E949-E953, 2016.2016年04月, Head & neck, 38 Suppl 1, E949-53, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- 2016年02月, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 77(2) (2), 281 - 288, 英語[査読有り]研究論文（学術雑誌）
- 2016年, Otolaryngology - Head and Neck Surgery (Japan), 88(2) (2)研究論文（学術雑誌）
- Japan Society for Head and Neck Cancer, 2016年, Japanese Journal of Head and Neck Cancer, 42(4) (4), 432 - 437, 日本語[査読有り]研究論文（学術雑誌）
- Japan Society for Head and Neck Cancer, 2016年, Japanese Journal of Head and Neck Cancer, 42(1) (1), 51 - 56, 日本語[査読有り]研究論文（学術雑誌）
- Oxford University Press, 2016年, Japanese Journal of Clinical Oncology, 46(5) (5), 448 - 452, 英語[査読有り]研究論文（学術雑誌）
- 2015年12月, CANCER SCIENCE, 106(12) (12), 1714 - 1721, 英語, パスワードが無い, 国際共著している[査読有り]研究論文（学術雑誌）
- John Wiley and Sons Inc., 2015年09月, Head & neck, 37(9) (9), 1358 - 67, 英語, 国際誌, 国際共著している[査読有り]研究論文（学術雑誌）
- We report a mediastinal germ cell tumor (GCT) that exhibited a discrepancy between the time course of serum human chorionic gonadotropin (hCG) levels and clinical consequences. An otherwise healthy man, aged 34 years, was diagnosed with a nonseminomatous GCT, most likely embryonal carcinoma (EC), based on a mediastinal tumor biopsy. Standard chemotherapy resulted in an optimal decrease in serum hCG levels. However, multiple lesions in the liver continued to enlarge, which led to his death. Autopsy revealed few viable tumor cells in the liver, with the great majority of the tumor cells appearing to have undergone necrosis, suggesting that they responded to the chemotherapy. The residual tumor cells in the mediastinum and the liver were similar to syncytiotrophoblast cells, suggesting a choriocarcinoma (CC). On immunohistochemical analysis, the mediastinal tumor cells in the diagnostic biopsy specimen expressed both CD30 and hCG, whereas residual mediastinal and hepatic tumor cells in the autopsy specimen after chemotherapy also expressed hCG, but not CD30. These findings suggested that the patient suffered from a primary mixed GCT consisting of an EC and a CC. Both pre- and postchemotherapy tumors strongly expressed matrix metalloproteinase-2, supporting the aggressive and invasive features of the tumor phenotype. We speculate that the extremely invasive tumor destroyed normal liver structure, whereas chemotherapy and central necrosis reduced the number of viable cells themselves, causing a discordant decrease in serum hCG levels.S. Karger AG, 2015年08月, Case Rep Oncol, 8(2) (2), 323 - 31, 英語[査読有り]研究論文（学術雑誌）
- Japanese Journal of Cancer and Chemotherapy Publishers Inc., 2015年07月, Japanese Journal of Cancer and Chemotherapy, 42(7) (7), 806 - 809, 日本語III. Molecular targeting treatment for thyroid cancer[査読有り]研究論文（学術雑誌）
- Blackwell Publishing Ltd, 2015年06月, Cancer Science, 106(6) (6), 726 - 733, 英語[査読有り]研究論文（学術雑誌）
- Lancet Publishing Group, 2015年05月, The Lancet. Oncology, 16(5) (5), 583 - 594, 英語研究論文（学術雑誌）
- (一社)日本頭頸部癌学会, 2015年05月, 頭頸部癌, 41(2) (2), 98 - 98, 英語甲状腺がん 2015年の甲状腺がんの治療 甲状腺がんに対する分子標的療法(Thyroid Cancer: Treatment of Thyroid Cancer 2015 Molecular Targeted Treatment for Thyroid Cancer)
- (一社)日本頭頸部癌学会, 2015年05月, 頭頸部癌, 41(2) (2), 136 - 136, 英語プラチナ薬剤抵抗性の頭頸部がんに関する炎症スコアの予後的な意義(Prognostic Value of the Inflammation Scores for Platinum Refractory Head and Neck Cancer)
- 2015年04月, ONCOLOGY REPORTS, 33(4) (4), 1837 - 1843, 英語[査読有り]研究論文（学術雑誌）
- (一社)日本内科学会, 2015年02月, 日本内科学会雑誌, 104(臨増) (臨増), 282 - 282, 日本語再発・転移粘膜悪性黒色腫に対するダカルバジン単剤療法の後方視的検討
- 2015年02月, Nihon rinsho. Japanese journal of clinical medicine[Concurrent chemoradiotherapy with cisplatin for locally advanced squamous cell carcinoma of head and neck].研究論文（学術雑誌）
- 2015年02月, NEW ENGLAND JOURNAL OF MEDICINE, 372(7) (7), 621 - 630, 英語, 国際共著している[査読有り]研究論文（学術雑誌）
- Japan Society for Head and Neck Cancer, 2015年01月, Japanese Journal of Head and Neck Cancer, 40(4) (4), 490 - 496, 日本語[査読有り]研究論文（学術雑誌）
- Japan Society for Head and Neck Cancer, 2015年01月, Japanese Journal of Head and Neck Cancer, 40(4) (4), 406 - 411, 日本語[査読有り]研究論文（学術雑誌）
- 2015年, Nihon rinsho. Japanese journal of clinical medicine, 73研究論文（学術雑誌）
- Lancet Publishing Group, 2015年, The Lancet. Oncology, 16(5) (5), 583 - 594, 英語研究論文（学術雑誌）
- 2015年01月, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 45(1) (1), 2 - 6, 英語, パスワードが無い[査読有り]研究論文（学術雑誌）
- 2014年12月, 頭頸部癌, 40(4号) (4号), 406 - 411, 日本語頭頸部進行がんに対する治療戦略 進行期(Stage III/IV)喉頭癌・下咽頭癌の治療戦略[査読有り]研究論文（学術雑誌）
- 2014年12月, 頭頸部癌, 40(4号) (4号), 490 - 496, 日本語当院における再発・転移頭頸部がんに対するドセタキセル・シスプラチン併用(DC)療法の遡及的解析[査読有り]研究論文（学術雑誌）
- Public Library of Science ({PLoS}), 2014年11月, PLoS ONE, 9(11) (11), e113259, 英語[査読有り]研究論文（学術雑誌）
- Japan Society for Head and Neck Cancer, 2014年10月, Japanese Journal of Head and Neck Cancer, 40(3) (3), 294 - 296, 日本語[査読有り]研究論文（学術雑誌）
- 2014年10月, 頭頸部癌, 40(3号) (3号), 294 - 296, 日本語頭頸部がん治療医の養成の現状と今後の方向について 腫瘍内科医の立場から[査読有り][招待有り]研究論文（学術雑誌）
- Elsevier BV, 2014年09月, Annals of Oncology, 25, iv343 - iv343研究論文（学術雑誌）
- 日本内分泌外科学会・日本甲状腺外科学会, 2014年09月, 日本内分泌・甲状腺外科学会雑誌, 31(Suppl.2) (Suppl.2), S217 - S217, 日本語進行甲状腺癌の治療戦略 進行性甲状腺癌(放射性ヨウ素治療抵抗性の分化癌、髄様癌、未分化癌)に対するレンバチニブの第2相試験
- 2014年09月, 核医学, 51(3号) (3号), 265, 日本語治療前FDG-PETによる喉頭癌の再発予測
- 2014年09月, 日本内分泌・甲状腺外科学会雑誌, 31(Suppl.2) (Suppl.2), S192, 日本語甲状腺がんに対する分子標的薬の適正使用と副作用管理について
- 2014年08月, PLOS ONE, 9(8) (8), e104215, 英語[査読有り]研究論文（学術雑誌）
- 2014年07月, ANTICANCER RESEARCH, 34(7) (7), 3337 - 3345, 英語TYRO3 as a Potential Therapeutic Target in Breast Cancer[査読有り]研究論文（学術雑誌）
- 2014年05月, PLOS ONE, 9(5) (5), e96999, 英語[査読有り]研究論文（学術雑誌）
- 2014年05月, 頭頸部癌, 40(2号) (2号), 186, 日本語免疫組織化学染色による唾液腺導管癌15例の検討
- 2014年05月, 頭頸部癌, 40(2号) (2号), 148, 日本語頭頸部進行がんに対する治療戦略 進行期喉頭癌・下咽頭癌に対する治療戦略
- (一社)日本頭頸部癌学会, 2014年05月, 頭頸部癌, 40(2号) (2号), 265 - 265, 日本語頭頸部癌に対するセツキシマブ併用放射線治療の初期経験
- 2014年05月, 頭頸部癌, 40(2号) (2号), 136, 日本語頭頸部がん治療医の養成の現状と今後の方向について_腫瘍内科医の立場から
- (一社)日本頭頸部癌学会, 2014年05月, 頭頸部癌, 40(2号) (2号), 238 - 238, 日本語中咽頭癌に対する化学放射線療法におけるPEG留置患者の栄養投与量と有害事象
- (一社)日本頭頸部癌学会, 2014年05月, 頭頸部癌, 40(2号) (2号), 155 - 155, 日本語T3N0-1声門癌に対する喉頭温存を目的とした根治的化学放射線治療の検討
- 2014年02月, 日本内科学会雑誌, 103(Suppl.) (Suppl.), 253, 日本語当院における唾液腺導管癌15例の臨床病理学的検討
- Springer-Verlag Tokyo, 2014年, Clinical Journal of Gastroenterology, 7(3) (3), 255 - 259, 英語[査読有り]研究論文（学術雑誌）
- 2014年01月, GASTRIC CANCER, 17(1) (1), 161 - 172, 英語[査読有り]研究論文（学術雑誌）
- Oxford University Press, 2014年, Japanese Journal of Clinical Oncology, 44(8) (8), 770 - 774, 英語[査読有り]研究論文（学術雑誌）
- (一社)日本癌学会, 2013年10月, 日本癌学会総会記事, 72回, 484 - 484, 英語乳癌における新規治療標的としてのTyro3(Tyro3 as a potential therapeutic target in breast cancer)
- 2013年10月, Oncology Reports, 30(4) (4), 1802 - 1806, 英語[査読有り]研究論文（学術雑誌）
- 2013年10月, INVESTIGATIONAL NEW DRUGS, 31(5) (5), 1158 - 1168, 英語[査読有り]研究論文（学術雑誌）
- (一社)日本癌治療学会, 2013年09月, 日本癌治療学会誌, 48(3) (3), 2164 - 2164, 日本語進行喉頭癌に対する喉頭温存療法の後ろ向き多施設共同研究
- 2013年05月, 頭頸部癌, 39(2号) (2号), 233, 日本語当院における唾液腺導管癌15例の臨床病理学的特徴研究論文（その他学術会議資料等）
- 2013年05月, 頭頸部癌, 39(2号) (2号), 194, 日本語再発・転移頭頸部がんに対するドセタキセル・シスプラチン併用(DC)療法
- 2013年04月, 頭頸部癌, 39(1号) (1号), 72 - 76, 日本語頸部リンパ節転移を認めた原発不明悪性黒色腫の2例[査読有り]研究論文（学術雑誌）
- 2013年04月, INVESTIGATIONAL NEW DRUGS, 31(2) (2), 293 - 303, 英語[査読有り]研究論文（学術雑誌）
- 2013年04月, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 71(4) (4), 991 - 998, 英語[査読有り]研究論文（学術雑誌）
- 2013年03月, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 43(3) (3), 271 - 277, 英語[査読有り]研究論文（学術雑誌）
- (公社)日本医学放射線学会, 2013年02月, Japanese Journal of Radiology, 31(Suppl.I) (Suppl.I), 51 - 51, 日本語局所進行食道癌に対する化学放射線治療[査読有り]
- 2013年, Otolaryngology - Head and Neck Surgery (Japan), 85(7) (7)研究論文（学術雑誌）
- Japan Society for Head and Neck Cancer, 2013年, Japanese Journal of Head and Neck Cancer, 39(1) (1), 72 - 76, 日本語[査読有り]研究論文（学術雑誌）
- Cognizant Communication Corporation, 2013年, Oncology Research, 21(6) (6), 287 - 293, 英語[査読有り]研究論文（学術雑誌）
- 2012年11月, JOURNAL OF RADIATION RESEARCH, 53(6) (6), 892 - 899, 英語[査読有り]研究論文（学術雑誌）
- 2012年10月, INVESTIGATIONAL NEW DRUGS, 30(5) (5), 1950 - 1957, 英語研究論文（学術雑誌）
- 科学評論社, 2012年10月, 腫瘍内科, 10(4号) (4号), 372 - 377, 日本語嗄声を発症した横行結腸がん同時性肝転移術後の1例[査読有り][招待有り]研究論文（学術雑誌）
- 2012年10月, 頭頸部癌, 38(3号) (3号), 374 - 379, 日本語切除不能頭頸部癌に対するSequential therapyの安全性に関する後向き研究[査読有り]研究論文（学術雑誌）
- 2012年10月, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 42(10) (10), 927 - 933, 英語, パスワードが無い[査読有り]研究論文（学術雑誌）
- 2012年10月, 日本癌治療学会誌, 47(3号) (3号), 723, 日本語頭頸部がん治療の過去と未来 頭頸部がんの分子標的治療について
- 2012年08月, Investigational New Drugs, 30(4) (4), 1352 - 1360, 英語[査読有り]研究論文（学術雑誌）
- 2012年08月, 日本癌学会総会記事, (71回) (71回), 335, 日本語MCF-7乳癌細胞株におけるinsulin-like growth factor 1 receptor阻害薬に対する獲得耐性機構(Mechanisms of acquired resistance to insulin-like growth factor 1 receptor inhibitor in MCF-7 breast cancer cell line)(英語)研究論文（その他学術会議資料等）
- 2012年08月, INTERNATIONAL JOURNAL OF ONCOLOGY, 41(2) (2), 551 - 558, 英語[査読有り]研究論文（学術雑誌）
- 2012年06月, INVESTIGATIONAL NEW DRUGS, 30(3) (3), 1055 - 1064, 英語[査読有り]研究論文（学術雑誌）
- 2012年02月, 日本内科学会雑誌, 101(Suppl.) (Suppl.), 192, 日本語抗がん薬投与におけるeGFRの有用性の検討[査読有り]研究論文（その他学術会議資料等）
- Japan Society for Head and Neck Cancer, 2012年, Japanese Journal of Head and Neck Cancer, 38(4) (4), 399 - 402, 日本語[査読有り]研究論文（学術雑誌）
- 2012年, Japanese Journal of Head and Neck Cancer, 38(3) (3), 374 - 379, 日本語[査読有り]研究論文（学術雑誌）
- 2011年06月, INTERNATIONAL JOURNAL OF HEMATOLOGY, 93(6) (6), 765 - 770, 英語[査読有り]研究論文（学術雑誌）
- (一社)日本頭頸部癌学会, 2011年04月, 頭頸部癌, 37巻, 1号, pp. 62-66(1) (1), 62 - 66, 日本語[査読有り]研究論文（学術雑誌）
- 2011年, Japanese Journal of Head and Neck Cancer, 37(1) (1), 62 - 66, 日本語[査読有り]研究論文（学術雑誌）
- 2011年, Japanese Journal of Head and Neck Cancer, 37(3) (3), 362 - 365, 日本語[査読有り]研究論文（学術雑誌）
- 2011年01月, ANNALS OF ONCOLOGY, 22(1) (1), 175 - 180, 英語[査読有り]研究論文（学術雑誌）
- (一社)日本頭頸部癌学会, 2010年05月, 頭頸部癌, 36(2) (2), 211 - 211, 日本語下咽頭癌に対する術後放射線治療の遡及的検討[査読有り]
- (一社)日本頭頸部癌学会, 2010年05月, 頭頸部癌, 36(2) (2), 179 - 179, 日本語原発不明癌頸部リンパ節転移に対する治療経験
- (一社)日本頭頸部癌学会, 2010年05月, 頭頸部癌, 36(2) (2), 206 - 206, 日本語局所進行頭頸部扁平上皮癌術後再発High-Risk群に対するHigh-dose CDDP+RTの実施可能性試験
- (一社)日本内科学会, 2010年02月, 日本内科学会雑誌, 99(Suppl.) (Suppl.), 162 - 162, 日本語結腸直腸がんに対するmFOLFOX6/FOLFIRI±Bevacizumab療法における甲状腺機能の評価
- 2010年, Toukeibu Gan, 36(3) (3), 278 - 281, 英語[査読有り]研究論文（学術雑誌）
- 2010年, Rare Tumors, 2(3) (3), 151 - 153, 英語[査読有り]研究論文（学術雑誌）
- 2009年10月, 頭頸部癌, 35巻, 3号, pp. 287-292, 日本語中咽頭癌同時併用化学放射線療法における経皮内視鏡的胃瘻造設術の有用性[査読有り]研究論文（学術雑誌）
- 2009年07月, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 39(7) (7), 460 - 463, 英語研究論文（学術雑誌）
- (一社)日本消化器内視鏡学会, 2009年06月, Gastroenterological Endoscopy, 51巻, 6号, pp. 1423-1430(6) (6), 1423 - 1430, 日本語[査読有り]研究論文（学術雑誌）
- (一社)日本頭頸部癌学会, 2009年05月, 頭頸部癌, 35(2) (2), 173 - 173, 日本語頭頸部がん治療における多職種医療普及のためのサテライト講演会 その成果と課題
- 2009年04月, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 39(4) (4), 225 - 230, 英語, パスワードが無い[査読有り]研究論文（学術雑誌）
- 2009年, Gastroenterological Endoscopy, 51(6) (6), 1423 - 1430, 英語[査読有り]研究論文（学術雑誌）
- 2009年, Toukeibu Gan, 35(3) (3), 287 - 292, 英語[査読有り]研究論文（学術雑誌）
- (一社)日本癌治療学会, 2008年10月, 日本癌治療学会誌, 43(2) (2), 283 - 283, 日本語頭頸部癌における集学的治療 当院における切除不能局所進行頭頸部扁平上皮癌に対する5-FUとCisplatinを同時併用した化学放射線療法の治療成績
- (一社)日本頭頸部癌学会, 2008年05月, 頭頸部癌, 34(2) (2), 92 - 92, 日本語化学放射線療法の多角的治療戦略 頭頸部扁平上皮癌に対するInduction chemotherapy
- (一社)日本頭頸部癌学会, 2008年05月, 頭頸部癌, 34(2) (2), 93 - 93, 日本語化学放射線療法の多角的治療戦略 手術後の化学放射線療法 Adjuvant chemoradiotherapyの適応と位置づけ
- (一社)日本頭頸部癌学会, 2008年05月, 頭頸部癌, 34(2) (2), 115 - 115, 日本語喉頭がん(T2,T3)治療法の選択 切除・再建か放射線・化学療法か 喉頭がんT2,T3に対する治療 手術治療の立場から
- (一社)日本頭頸部癌学会, 2008年05月, 頭頸部癌, 34(2) (2), 151 - 151, 日本語切除不能中下咽頭喉頭扁平上皮癌に対するプラチナ同時併用化学放射線療法の検討
- (一社)日本頭頸部癌学会, 2008年05月, 頭頸部癌, 34(2) (2), 170 - 170, 日本語当院における転移・再発頭頸部扁平上皮癌に対するシスプラチン+5FU(PF)療法の治療成績
- 2008年04月, GASTROINTESTINAL ENDOSCOPY, 67(5) (5), AB187 - AB187, 英語[査読有り]
- 2008年02月, CANCER, 112(4) (4), 885 - 891, 英語, パスワードが無い[査読有り]研究論文（学術雑誌）
- 2007年04月, GASTROINTESTINAL ENDOSCOPY, 65(5) (5), AB170 - AB170, 英語[査読有り]
- 2007年, Alimentary Pharmacology and Therapeutics, 25(9) (9)研究論文（学術雑誌）
- (株)メジカルビュー社, 2006年11月, Mebio Oncology, 3(4) (4), 50 - 57, 日本語
- (一社)日本癌治療学会, 2006年09月, 日本癌治療学会誌, 41(2) (2), 522 - 522, 日本語FOLFOX投与中に間質性肺炎を発症した大腸癌2例の検討
- 2005年04月, Journal of gastroenterology研究論文（学術雑誌）
- 2005年, Journal of gastroenterology研究論文（学術雑誌）
- 2005年, Journal of gastroenterology, 40(4) (4)研究論文（学術雑誌）
- 2024年, 日本血栓止血学会誌, 35(2) (2)進行・再発・転移の固形腫瘍における血栓塞栓症と出血リスク:PROVE-emboli試験post-hoc解析
- (一社)日本遺伝カウンセリング学会, 2023年06月, 日本遺伝カウンセリング学会誌, 44(2) (2), 139 - 139, 日本語
- 2023年, 日本内科学会雑誌, 112がん関連静脈血栓塞栓症に対するアピキサバン療法の出血リスク予測:多施設共同第2相臨床試験副次的解析
- 2023年, 日本血栓止血学会誌, 34(2) (2)進行・再発・転移の未治療固形がん患者における静脈血栓塞栓症の前向き観察研究の統合解析
- 2023年, 日本腫瘍循環器学会学術集会抄録集(Web), 6th小児がん経験者の移行期医療の現状およびがん治療歴と心機能に関する解析
- 2023年, 日本腫瘍循環器学会学術集会抄録集(Web), 6thがん治療前の悪性腫瘍関連下肢静脈血栓塞栓症のリスク因子に関する検討:PROVE-emboli study
- (有)科学評論社, 2022年12月, 腫瘍内科, 30(6) (6), 671 - 676, 日本語【肺がん・頭頸部がん】頭頸部がんに対する化学放射線療法
- (株)文光堂, 2022年10月, Medical Practice, 39(10) (10), 1457 - 1461, 日本語
- (有)科学評論社, 2022年09月, 耳鼻咽喉科, 2(3) (3), 372 - 376, 日本語がんゲノム医療時代と生物学的製剤・分子標的治療薬
- (株)東京医学社, 2021年12月, JOHNS, 37(12) (12), 1551 - 1553, 日本語
- (有)科学評論社, 2021年11月, 腫瘍内科, 28(5) (5), 519 - 525, 日本語
- (有)科学評論社, 2021年09月, 腫瘍内科, 28(3) (3), 291 - 295, 日本語【10年後の乳がん診療】乳がん薬物療法におけるQOL評価
- 耳鼻咽喉科臨床学会, 2021年06月, 耳鼻咽喉科臨床 補冊, (補冊157) (補冊157), 50 - 50, 日本語臨床試験と倫理 倫理的な臨床試験とは?
- (一社)日本頭頸部癌学会, 2021年05月, 頭頸部癌, 47(2) (2), 208 - 208, 日本語再発・転移頭頸部扁平上皮癌に対するニボルマブ療法治療の予後予測における好酸球数変化の有用性
- (一社)日本頭頸部癌学会, 2021年05月, 頭頸部癌, 47(2) (2), 239 - 239, 日本語T3N0M0声門癌に対する根治的放射線治療の成績
- (一社)日本内分泌学会, 2021年04月, 日本内分泌学会雑誌, 97(1) (1), 224 - 224, 日本語
- (有)科学評論社, 2021年03月, 腫瘍内科, 27(3) (3), 326 - 331, 日本語
- 医歯薬出版(株), 2021年02月, 医学のあゆみ, 276(8) (8), 765 - 769, 日本語
- (一社)日本内分泌外科学会, 2020年11月, 日本内分泌外科学会雑誌, 37(Suppl.2) (Suppl.2), S250 - S250, 日本語Risk Benefit Balanceを考慮した分子標的薬の使用法
- (一社)日本内分泌外科学会, 2020年11月, 日本内分泌外科学会雑誌, 37(Suppl.2) (Suppl.2), S297 - S297, 日本語がんゲノム医療時代における甲状腺がんに対するがん薬物療法
- (一社)日本内分泌学会, 2020年10月, 日本内分泌学会雑誌, 96(2) (2), 564 - 564, 日本語
- (一社)日本甲状腺学会, 2020年10月, 日本甲状腺学会雑誌, 11(2) (2), 68 - 76, 日本語
- (株)日本臨床社, 2020年09月, 日本臨床, 78(増刊4 内分泌腺腫瘍) (増刊4 内分泌腺腫瘍), 423 - 428, 日本語
- (一社)日本内分泌学会, 2020年08月, 日本内分泌学会雑誌, 96(1) (1), 307 - 307, 日本語
- 2020年04月, CANCER SCIENCE, 111(4) (4), 1437 - 1437, 英語その他
- 2020年, Quintessence口腔がんに対する免疫チェックポイント阻害薬の最新情報と適正使用
- 2020年, 日本血液学会学術集会抄録(Web), 82nd日本人悪性腫瘍関連静脈血栓塞栓症に対するapixaban療法の第II相臨床試験
- (一社)日本癌治療学会, 2019年10月, 日本癌治療学会学術集会抄録集, 57回, O17 - 5, 英語患者満足度を評価するQOL尺度(EORTC IN-PATSAT9)の日本語版翻訳のパイロットスタディ
- 2019年07月, CANCER RESEARCH, 79(13) (13), 英語研究発表ペーパー・要旨（国際会議）
- (一社)日本頭頸部癌学会, 2019年05月13日, 頭頸部癌, 45(2) (2), 143 - 143, 日本語再発又は遠隔転移を有する頭頸部がんの患者を対象としたニボルマブの安全性及び有効性の検討
- (一社)日本頭頸部癌学会, 2019年05月, 頭頸部癌, 45(2) (2), 132 - 132, 日本語再発転移頭頸部扁平上皮癌 ニボルマブ投与例におけるmodified Glasgow Prognostic Scoreの予後予測性
- (一社)日本頭頸部癌学会, 2019年05月, 頭頸部癌, 45(2) (2), 149 - 149, 日本語下咽頭癌外側咽頭後リンパ節転移症例の検討
- (一社)日本頭頸部癌学会, 2019年05月, 頭頸部癌, 45(2) (2), 162 - 162, 日本語再発転移鼻副鼻腔原発粘膜悪性黒色腫に対するニボルマブの後方視的検討
- (一社)日本頭頸部癌学会, 2019年05月, 頭頸部癌, 45(2) (2), 168 - 168, 日本語頭頸部扁平上皮癌術後の再発高リスク症例に対する放射線療法の治療成績の検討
- (一社)日本頭頸部癌学会, 2019年05月, 頭頸部癌, 45(2) (2), 169 - 169, 日本語中咽頭癌に対する化学放射線療法による摂食・嚥下に関するQOLの変化
- (一社)日本頭頸部癌学会, 2019年05月, 頭頸部癌, 45(2) (2), 201 - 201, 日本語T4下咽頭癌に対する根治的(化学)放射線療法の後方視的検討
- (一社)日本頭頸部癌学会, 2019年05月, 頭頸部癌, 45(2) (2), 132 - 132, 日本語再発転移頭頸部扁平上皮癌 ニボルマブ投与例におけるmodified Glasgow Prognostic Scoreの予後予測性
- (一社)日本頭頸部癌学会, 2019年05月, 頭頸部癌, 45(2) (2), 149 - 149, 日本語下咽頭癌外側咽頭後リンパ節転移症例の検討
- (一社)日本頭頸部癌学会, 2019年05月, 頭頸部癌, 45(2) (2), 162 - 162, 日本語再発転移鼻副鼻腔原発粘膜悪性黒色腫に対するニボルマブの後方視的検討
- (一社)日本頭頸部癌学会, 2019年05月, 頭頸部癌, 45(2) (2), 168 - 168, 日本語頭頸部扁平上皮癌術後の再発高リスク症例に対する放射線療法の治療成績の検討
- (一社)日本頭頸部癌学会, 2019年05月, 頭頸部癌, 45(2) (2), 169 - 169, 日本語中咽頭癌に対する化学放射線療法による摂食・嚥下に関するQOLの変化
- (一社)日本頭頸部癌学会, 2019年05月, 頭頸部癌, 45(2) (2), 201 - 201, 日本語T4下咽頭癌に対する根治的(化学)放射線療法の後方視的検討
- 2019年, 日本がん看護学会誌(Web), 33生活支援における効果的な多職種連携~経口抗がん薬服用患者への介入~
- 2019年, 月刊薬事, 61(10) (10)がん薬物治療 1 頭頸部がん
- 2019年, 日本消化器癌発生学会総会プログラム・抄録集, 30th当院における高頻度マイクロサテライト不安定性大腸癌のスクリーニング方法の検討
- 2019年, 日本家族性腫瘍学会学術集会プログラム・抄録集, 25th本邦における高頻度マイクロサテライト不安定性大腸癌のスクリーニング方法の検討
- (一社)日本がん看護学会, 2019年01月, 日本がん看護学会誌, 33(Suppl.) (Suppl.), 173 - 173, 日本語EGFR阻害薬に伴うざ瘡様皮疹へのアダパレンゲル予防投与のプラセボ対照左右ランダム化比較試験
- 日本内分泌外科学会・日本甲状腺外科学会, 2018年10月, 日本内分泌・甲状腺外科学会雑誌, 35(Suppl.2) (Suppl.2), S319 - S319, 日本語甲状腺がんに対するレンバチニブ治療中の観血的処置の安全性に関する遡及的検討
- (一社)日本耳鼻咽喉科学会, 2018年07月, 日本耳鼻咽喉科学会会報, 121(7号) (7号), 941 - 943, 日本語頭頸部がんにおける免疫チェックポイント阻害薬の適正使用[招待有り]記事・総説・解説・論説等（学術雑誌）
- (一社)日本耳鼻咽喉科学会, 2018年06月, 日本耳鼻咽喉科学会会報, 121(6号) (6号), 826 - 828, 日本語頭頸部がんにおける免疫チェックポイント阻害薬の適応と実際[招待有り]記事・総説・解説・論説等（学術雑誌）
- (一社)日本頭頸部癌学会, 2018年05月09日, 頭頸部癌, 44(2) (2), 126 - 126, 日本語再発・転移の頭頸部非扁平上皮癌に対するドセタキセル+シスプラチン併用療法の第II相臨床試録
- (一社)日本頭頸部癌学会, 2018年05月, 頭頸部癌, 44(2) (2), 176 - 176, 日本語甲状腺癌気道浸潤例に対する放射線外照射の有効性の検討
- 2018年04月, 耳鼻咽喉科・頭頸部外科, 90(5号) (5号), 282 - 283, 日本語【患者・家族への説明ガイド-正しく伝え,納得を引き出し,判断を促すために】腫瘍のこと (Question 90)最近の抗癌剤はとても高額だそうですが,医療費はいくらくらいですか?[招待有り]記事・総説・解説・論説等（学術雑誌）
- 2018年, 日本臨床腫瘍学会学術集会(CD-ROM), 16thPazopanibにより長期病勢安定が得られた肺動脈原発血管内膜肉腫の一例
- 2018年, 日本臨床腫瘍学会学術集会(CD-ROM), 16th, ROMBUNNO.O1‐8‐3, 日本語局所進行頭頸部扁平上皮癌に対するTPE導入化学療法とセツキシマブ併用放射線療法の第II相試験(ECRIPS study)
- 2018年01月, がん分子標的治療, 15(4号) (4号), 379 - 382, 日本語【各臓器がんに対する免疫チェックポイント阻害薬】 各臓器がんに対する免疫チェックポイント阻害薬の現状について 頭頸部がん[招待有り]記事・総説・解説・論説等（商業誌、新聞、ウェブメディア）
- 2017年11月, ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 13, 144 - 144, 英語Nivolumab Versus Investigator'S Choice (IC) for Platinum-Refractory Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN; CHECKMATE 141): Outcomes in First-Line R/M Patients and Updated Safety and Efficacy研究発表ペーパー・要旨（国際会議）
- 2017年10月, ANNALS OF ONCOLOGY, 28, 英語Remarkable response to cetuximab-containing chemotherapy for tongue cancer refractory to immune checkpoint inhibitors研究発表ペーパー・要旨（国際会議）
- 2017年10月, 医学のあゆみ, 263(1号) (1号), 81 - 86, 日本語【がん免疫療法の躍進】がん免疫療法の臨床 がん種別治療 頭頸部がんのがん免疫療法[招待有り]記事・総説・解説・論説等（商業誌、新聞、ウェブメディア）
- 2017年09月, JOHNS, 33(9号) (9号), 1267 - 1270, 日本語【頭頸部悪性腫瘍の疑問に答える】 治療中の対応 抗がん薬減量の目安について教えてください記事・総説・解説・論説等（商業誌、新聞、ウェブメディア）
- (株)全日本病院出版会, 2017年09月, 整形外科最小侵襲手術ジャーナル, (84) (84), 79 - 83, 日本語【転移性脊椎腫瘍に対する最小侵襲脊椎安定術(MISt)】転移性脊椎腫瘍に対する出張型骨転移Cancer Boardの取り組み[査読有り]記事・総説・解説・論説等（学術雑誌）
- 2017年09月, がん免疫療法, 1(2号) (2号), 135 - 137, 日本語Cancer-Immunological Topics 免疫チェックポイント阻害薬 頭頸部がん[招待有り]記事・総説・解説・論説等（商業誌、新聞、ウェブメディア）
- 2017年07月, 癌と化学療法, 44(7号) (7号), 575 - 578, 日本語Head and Neck Tumor 頭頸部腫瘍 局所進行喉頭・下咽頭癌における喉頭温存 局所進行喉頭・下咽頭癌における機能温存戦略 非外科的治療のエビデンス[招待有り]記事・総説・解説・論説等（商業誌、新聞、ウェブメディア）
- 科学評論社, 2017年06月, 腫瘍内科 = Clinical oncology, 19(6) (6), 721 - 725, 日本語HPV関連頭頸部がんと免疫チェックポイント阻害薬 (免疫チェックポイント阻害薬の新しいバイオマーカー)
- 2017年06月, 頭頸部癌Frontier, 5(1号) (1号), 34 - 39, 日本語【中咽頭癌の新しい治療戦略/頭頸部癌に対する治療完遂のコツとチーム医療の実際/再発転移性頭頸部扁平上皮癌の最新治療戦略】 再発転移性頭頸部扁平上皮癌の最新治療戦略 生存延長最大化のための適正使用 プラチナ製剤抵抗性頭頸部扁平上皮癌に対する免疫チェックポイント阻害薬記事・総説・解説・論説等（商業誌、新聞、ウェブメディア）
- 2017年05月, JOURNAL OF CLINICAL ONCOLOGY, 35, 英語研究発表ペーパー・要旨（国際会議）
- 2017年05月, 頭頸部癌, 43(2号) (2号), 135, 日本語頭頸部癌治療にIMRTが与えた影響 腫瘍内科医からみた頭頸部がん臨床試験におけるIMRTの重要性と課題[招待有り]記事・総説・解説・論説等（その他）
- 科学評論社, 2017年01月, 腫瘍内科, 19(1号) (1号), 81 - 86, 日本語【免疫チェックポイント阻害薬の新しい展開】 頭頸部がんに対する免疫チェックポイント阻害薬記事・総説・解説・論説等（商業誌、新聞、ウェブメディア）
- 2017年01月, 頭頸部癌Frontier, 4(2号) (2号), 123 - 127, 日本語【症例から学ぶ頭頸部癌治療-化学療法/分子標的療法-】 症例から学ぶ分子標的療法 高齢頭頸部癌患者に対する抗EGFR抗体併用放射線療法 症例から考える[招待有り]記事・総説・解説・論説等（商業誌、新聞、ウェブメディア）
- (株)メディカルレビュー社, 2017年01月, 頭頸部癌Frontier, 4(2) (2), 128 - 131, 日本語TPF導入化学療法の副作用対策と完遂のためのポイントを教えてください[招待有り]記事・総説・解説・論説等（商業誌、新聞、ウェブメディア）
- 2016年11月, ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 12, 134 - 134, 英語PHASE 2 STUDY OF LENVATINIB IN PATIENTS WITH DIFFERENTIATED, MEDULLARY AND ANAPLASTIC THYROID CANCER: FINAL ANALYSIS RESULTS研究発表ペーパー・要旨（国際会議）
- (一社)日本癌治療学会, 2016年10月, 日本癌治療学会学術集会抄録集, 54回, MS20 - 4, 日本語食道 食道がんに対する治療戦略 頸部食道癌に対するCDDP/5-FU併用化学放射線療法の多施設共同臨床第II相試験
- (株)メディカルレビュー社, 2016年10月, Thyroid Cancer Explore, 2(2) (2), 105 - 114, 日本語
- 日本内分泌外科学会・日本甲状腺外科学会, 2016年09月, 日本内分泌・甲状腺外科学会雑誌, 33(Suppl.2) (Suppl.2), S211 - S211, 日本語再発甲状腺癌の治療 予後とQOLを考慮したレンバチニブの使用 いつから、そしてどう使うか
- 日本癌治療学会, 2016年09月, 日本癌治療学会誌 = The journal of Japan Society of Clinical Oncology, 51(2) (2), 339 - 344, 日本語頭頸部がんに対する免疫チェックポイント阻害薬の現状 (第54回 日本癌治療学会学術集会Educational Book) -- (教育シンポジウム がん免疫療法 : 特に免疫チェックポイント阻害剤)
- 2016年09月, Hospitalist, 4(3号) (3号), 547 - 557, 日本語【腫瘍】 初発時は限局期で手術し、その後再発したがんのマネジメント 胃がん 標準的な治療と押さえておきたい副作用[招待有り]記事・総説・解説・論説等（商業誌、新聞、ウェブメディア）
- 日本内分泌外科学会・日本甲状腺外科学会, 2016年09月, 日本内分泌・甲状腺外科学会雑誌, 33(3号) (3号), 140 - 144, 日本語
これまで放射性ヨウ素治療（RAI）に不応な転移・再発分化型甲状腺癌に対する薬物療法はドキソルビシンが治療選択肢の一つであったが，その有効性は不十分なものであった［１］。しかし，2014年にmulti-target kinase inhibitor（m-TKI）であるソラフェニブ（sorafenib：SOR）の有効性が証明され，新たな治療オプションとして日本でも使用できるようになった［２］。さらに，レンバチニブ（lenvatinib：LEN）も第Ⅲ相試験において明らかな有効性が示され［３,４］，RAI不応転移・再発分化型甲状腺癌の治療オプションがさらに充実することとなった。一方で，その使用にあたっては適応の慎重な判断と適切な管理が非常に重要な課題である。本稿では，このような分化型甲状腺癌（differentiated thyroid cancer，DTC）における分子標的薬の適正使用と今後の展望について解説する。
[招待有り]記事・総説・解説・論説等（学術雑誌） - 2016年07月, ANNALS OF ONCOLOGY, 27, 英語Current Status of Lenvatinib for Thyroid Cancer研究発表ペーパー・要旨（国際会議）
- 2016年07月, ANNALS OF ONCOLOGY, 27, 英語Pharmacokinetic study of S-1, an oral fluorouracil antitumor agent in Japanese patients with impaired renal function研究発表ペーパー・要旨（国際会議）
- 2016年07月, ANNALS OF ONCOLOGY, 27, 英語Relationship between Adverse Events and Efficacy of Lenvatinib for Thyroid Cancer研究発表ペーパー・要旨（国際会議）
- 2016年07月, ANNALS OF ONCOLOGY, 27, 英語Current status of immune check point inhibitors for solid malignancy研究発表ペーパー・要旨（国際会議）
- 2016年07月, CANCER RESEARCH, 76, 英語Nivolumab (nivo) vs investigator's choice (IC) for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): CheckMate-141研究発表ペーパー・要旨（国際会議）
- (株)全日本病院出版会, 2016年07月, ENTONI, (195号) (195号), 35 - 43, 日本語[招待有り]記事・総説・解説・論説等（商業誌、新聞、ウェブメディア）
- 科学評論社, 2016年06月, 腫瘍内科, 17(6号) (6号), 622 - 627, 日本語【頭頸部がん、肺がん】 甲状腺がんに対する分子標的治療の現状と展望[招待有り]記事・総説・解説・論説等（商業誌、新聞、ウェブメディア）
- 2016年05月, JOURNAL OF CLINICAL ONCOLOGY, 34(15) (15), 英語研究発表ペーパー・要旨（国際会議）
- 2016年05月, JOURNAL OF CLINICAL ONCOLOGY, 34(15) (15), 英語研究発表ペーパー・要旨（国際会議）
- ヴァン・メディカル, 2016年05月, 臨床腫瘍プラクティス, 12(2号) (2号), 175 - 180, 日本語がんの治療薬を知る 薬剤選択のための知識 レンバチニブ[招待有り]記事・総説・解説・論説等（商業誌、新聞、ウェブメディア）
- 2016年04月, 耳鼻咽喉科・頭頸部外科, 88(5号) (5号), 340 - 342, 日本語【耳鼻咽喉科処方マニュアル】 がん治療副作用・疼痛緩和 神経障害[招待有り]記事・総説・解説・論説等（商業誌、新聞、ウェブメディア）
- (株)医学書院, 2016年04月, 耳鼻咽喉科・頭頸部外科, 88(5号) (5号), 338 - 339, 日本語[招待有り]記事・総説・解説・論説等（商業誌、新聞、ウェブメディア）
- 2016年04月, がん分子標的治療, 14(1号) (1号), 36 - 40, 日本語【遺伝子解析に基づく新しい分子標的治療】 遺伝子解析に基づくがん治療 甲状腺がん[招待有り]記事・総説・解説・論説等（商業誌、新聞、ウェブメディア）
- 科学評論社, 2016年03月, 腫瘍内科, 17(3号) (3号), 271 - 275, 日本語【希少がんの治療戦略】 分化型甲状腺がんに対する新規抗がん剤と治療戦略[招待有り]記事・総説・解説・論説等（商業誌、新聞、ウェブメディア）
- 2016年02月, 耳鼻咽喉科・頭頸部外科, 88(2号) (2号), 140 - 146, 日本語【がん免疫療法のブレイクスルー-免疫チェックポイント阻害薬】 免疫チェックポイント阻害薬の副作用と管理法[招待有り]記事・総説・解説・論説等（学術雑誌）
- 2015年11月, Asia-Pacific Journal of Clinical Oncology, 11, 173 - 173, 英語EFFECT OF AGE AND LENVATINIB TREATMENT ON OVERALL SURVIVAL FOR PATIENTS WITH I-131- REFRACTORY DIFFERENTIATED THYROID CANCER IN SELECT研究発表ペーパー・要旨（国際会議）
- 2015年11月, ANNALS OF ONCOLOGY, 26, 14 - 14, 英語JCOG1008: Phase II/III Trial of postoperative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of head and neck研究発表ペーパー・要旨（国際会議）
- 2015年11月, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 93(3) (3), E341 - E342, 英語Radiation Therapy for T3/T4 Squamous Cell Carcinoma of Hypopharynx: A Retrospective Comparison Between Definitive Radiation Therapy and Surgery Followed by Postoperative Radiation Therapy研究発表ペーパー・要旨（国際会議）
- 2015年11月, ANNALS OF ONCOLOGY, 26, 53 - 53, 英語Current status and future perspectives of molecular targeting treatment for thyroid cancer研究発表ペーパー・要旨（国際会議）
- 科学評論社, 2015年11月, 腫瘍内科, 16(5号) (5号), 474 - 478, 日本語甲状腺がんに対する分子標的治療薬 適正使用と多職種連携を中心に[招待有り]記事・総説・解説・論説等（学術雑誌）
- 2015年11月, 耳鼻と臨床, 61(suppl.1) (suppl.1), S3 - S8, 日本語CRTとBRTの使い分け CRTとBRTの使い分け セツキシマブ-RTの現状と問題点(解説)[招待有り]記事・総説・解説・論説等（学術雑誌）
- 2015年10月, がん分子標的治療, 13(3号) (3号), 328 - 332, 日本語【分子標的治療を含む併用療法】 放射線治療と分子標的治療の併用療法[査読有り]記事・総説・解説・論説等（商業誌、新聞、ウェブメディア）
- 2015年08月, CANCER RESEARCH, 75, 英語研究発表ペーパー・要旨（国際会議）
- 科学評論社, 2015年08月, 腫瘍内科, 16(2号) (2号), 191 - 195, 日本語甲状腺がんに対するlenvatinib記事・総説・解説・論説等（学術雑誌）
- 2015年08月, クリニシアン, 62(8号) (8号), 829 - 836, 日本語【甲状腺癌】 レンビマ 甲状腺がんに対するレンバチニブ(レンビマ)の適正使用について記事・総説・解説・論説等（商業誌、新聞、ウェブメディア）
- メディカルレビュー社, 2015年08月, 頭頸部癌Frontier, 3(1号) (1号), 56 - 59, 日本語【機能温存を考慮した頭頸部癌治療-口腔癌(舌癌)・咽頭癌・喉頭癌を中心に-】 Evidence Based Medicine 各ガイドラインにおける機能温存の考え方 欧州臨床腫瘍学会ガイドライン[招待有り]記事・総説・解説・論説等（商業誌、新聞、ウェブメディア）
- 2015年07月, 癌と化学療法, 42(7号) (7号), 806 - 809, 日本語頭頸部腫瘍 甲状腺がんに対する分子標的治療薬[招待有り]記事・総説・解説・論説等（学術雑誌）
- 2015年05月, JOURNAL OF CLINICAL ONCOLOGY, 33(15) (15), 英語Effect of age and lenvatinib treatment on overall survival for patients with I-131-refractory differentiated thyroid cancer in SELECT研究発表ペーパー・要旨（国際会議）
- 2015年05月, JOURNAL OF CLINICAL ONCOLOGY, 33(15) (15), 英語Pharmacodynamic biomarkers of outcomes in the phase III study of lenvatinib in I-131-refractory differentiated thyroid cancer (SELECT).研究発表ペーパー・要旨（国際会議）
- (一社)日本頭頸部癌学会, 2015年05月, 頭頸部癌, 41(2) (2), 250 - 250, 日本語中咽頭癌に対する化学放射線療法におけるPEGの有用性
- (一社)日本頭頸部癌学会, 2015年05月, 頭頸部癌, 41(2) (2), 254 - 254, 日本語中・下咽頭後壁癌に対する放射線治療成績
- (一社)日本頭頸部癌学会, 2015年05月, 頭頸部癌, 41(2) (2), 254 - 254, 日本語食道癌同時合併中下咽頭癌に対する放射線治療の経験
- (一社)日本頭頸部癌学会, 2015年05月, 頭頸部癌, 41(2) (2), 262 - 262, 日本語原発不明癌頸部リンパ節転移に対する放射線治療の経験
- (一社)日本頭頸部癌学会, 2015年05月, 頭頸部癌, 41(2) (2), 266 - 266, 日本語N3頸部リンパ節転移症例に対する放射線治療の経験
- 2015年03月, 日本内分泌・甲状腺外科学会雑誌, 32(1号) (1号), 14 - 17, 日本語【甲状腺癌に対する分子標的薬治療の最前線】 甲状腺癌に対する分子標的薬の適正使用と副作用管理[招待有り]記事・総説・解説・論説等（学術雑誌）
- (公社)日本医学放射線学会, 2015年02月, Japanese Journal of Radiology, 33(Suppl.) (Suppl.), 76 - 76, 日本語頭頸部癌に対するセツキシマブ併用放射線治療の初期経験
- 2015年02月, 日本臨床, 73(増刊2 抗がん剤の副作用と支持療法) (増刊2 抗がん剤の副作用と支持療法), 559 - 561, 日本語【抗がん剤の副作用と支持療法-より適切な抗がん剤の安全使用をめざして-】 臓器別がん腫レジメンの副作用と対策 局所進行頭頸部扁平上皮癌 CDDP RT療法記事・総説・解説・論説等（学術雑誌）
- 2015年, 日本内科学会雑誌, 104再発・転移粘膜悪性黒色腫に対するダカルバジン単剤療法の後方視的検討
- 2015年01月, JOURNAL OF CLINICAL ONCOLOGY, 33(3) (3), 英語研究発表ペーパー・要旨（国際会議）
- 科学評論社, 2015年01月, 腫瘍内科, 15(1号) (1号), 14 - 20, 日本語【進化する頭頸部がん・食道がん・胃がんに対する個別化治療】 頭頸部がんの分子標的薬治療について記事・総説・解説・論説等（学術雑誌）
- 2014年12月, BLOOD, 124(21) (21), 英語Efficacy of the Two-Dose Influenza Vaccine in Cancer Patients Receiving Chemotherapy: A Prospective Study研究発表ペーパー・要旨（国際会議）
- 2014年10月, ANNALS OF ONCOLOGY, 25, 英語研究発表ペーパー・要旨（国際会議）
- 2014年10月, ANNALS OF ONCOLOGY, 25, 英語研究発表ペーパー・要旨（国際会議）
- 2014年10月, ANNALS OF ONCOLOGY, 25, 英語研究発表ペーパー・要旨（国際会議）
- 2014年08月, JOHNS, 30(8号) (8号), 977 - 980, 日本語【大きく変わりつつある頭頸部癌化学療法】 術後補助療法[招待有り]記事・総説・解説・論説等（学術雑誌）
- (株)メディカルレビュー社, 2014年07月, 頭頸部癌Frontier, 2(1号) (1号), 106 - 107, 日本語[招待有り]記事・総説・解説・論説等（商業誌、新聞、ウェブメディア）
- 2014年07月, 頭頸部癌Frontier, 2(1号) (1号), 70 - 73, 日本語【頭頸部癌に対する最新治療】 セツキシマブ療法 セツキシマブの副作用 薬剤性間質性肺炎とその対策[招待有り]記事・総説・解説・論説等（商業誌、新聞、ウェブメディア）
- 2014年06月, JOURNAL OF CLINICAL ONCOLOGY, 32(18) (18), 英語A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with I-131-refractory differentiated thyroid cancer (SELECT)研究発表ペーパー・要旨（国際会議）
- 2014年05月, JOURNAL OF CLINICAL ONCOLOGY, 32(15) (15), 英語Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients.研究発表ペーパー・要旨（国際会議）
- 2014年05月, JOURNAL OF CLINICAL ONCOLOGY, 32(15) (15), 英語A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with I-134-refractory differentiated thyroid cancer (SELECT)研究発表ペーパー・要旨（国際会議）
- 2014年02月, 日本臨床, 72(増刊2 最新がん薬物療法学) (増刊2 最新がん薬物療法学), 324 - 327, 日本語【最新がん薬物療法学-がん薬物療法の最新知見-】 臓器別がんの薬物療法 頭頸部がん[招待有り]記事・総説・解説・論説等（学術雑誌）
- 2013年11月, MOLECULAR CANCER THERAPEUTICS, 12(11) (11), 英語研究発表ペーパー・要旨（国際会議）
- 2013年10月, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 87(2) (2), S472 - S473, 英語Radiation-Induced Hypothyroidism in Squamous Cell Carcinoma of the Head and Neck: Comparison Between Concurrent Chemoradiation Therapy and Radiation Therapy Alone研究発表ペーパー・要旨（国際会議）
- メディカルレビュー社, 2013年09月, 頭頸部癌frontier, 1(2) (2), 199 - 201, 日本語Bulletin 第37回欧州臨床腫瘍学会(ESMO2012)における頭頸部癌の話題
- 2013年09月, EUROPEAN JOURNAL OF CANCER, 49, S753 - S753, 英語25-year experience with primary major salivary gland carcinoma at a single institution in Japan研究発表ペーパー・要旨（国際会議）
- (株)ヴァンメディカル, 2013年08月, 臨床腫瘍プラクティス, 9(3号) (3号), 252 - 253, 日本語【分子標的治療薬の選び方、使い方】 分子標的治療薬の選び方、使い方 パニツムマブ記事・総説・解説・論説等（学術雑誌）
- 2013年08月, 臨床腫瘍プラクティス, 9(3号) (3号), 249 - 251, 日本語【分子標的治療薬の選び方、使い方】 分子標的治療薬の選び方、使い方 セツキシマブ記事・総説・解説・論説等（学術雑誌）
- 2013年08月, コンセンサス癌治療, 12(3号) (3号), 128 - 131, 日本語【分子標的治療薬の使用手引き2013】 分子標的治療薬 抗EGFR抗体記事・総説・解説・論説等（学術雑誌）
- 2013年06月, 耳鼻咽喉科・頭頸部外科, 85(7号) (7号), 488 - 492, 日本語【分子標的薬時代の耳鼻咽喉科診療-処方するとき,服用患者を診るときのポイント】 頭頸部癌に対する分子標的薬治療 頭頸部癌に対する分子標的薬の将来展望 セツキシマブのほかには何があるのか記事・総説・解説・論説等（学術雑誌）
- 2013年05月, JOURNAL OF CLINICAL ONCOLOGY, 31(15) (15), 英語Phase I/II trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil (DCF) followed by concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.研究発表ペーパー・要旨（国際会議）
- (一社)日本頭頸部癌学会, 2013年05月, 頭頸部癌, 39(2号) (2号), 262 - 262, 日本語頭頸部扁平上皮癌に対する放射線治療後の甲状腺機能低下症に関する検討会議報告等
- (一社)日本頭頸部癌学会, 2013年05月, 頭頸部癌, 39(2号) (2号), 186 - 186, 日本語当院におけるT3喉頭癌の放射線治療の経験会議報告等
- (一社)日本頭頸部癌学会, 2013年05月, 頭頸部癌, 39(2号) (2号), 250 - 250, 日本語進行舌癌に対する術後放射線治療の経験会議報告等
- 2013年05月, 頭頸部癌Frontier, 1(1号) (1号), 33 - 35, 日本語【セツキシマブのすべて】 大腸癌など頭頸部癌以外の癌腫におけるセツキシマブの効果について記事・総説・解説・論説等（学術雑誌）
- (一社)日本頭頸部癌学会, 2013年05月, 頭頸部癌, 39(2号) (2号), 264 - 264, 日本語T1/2声門上癌に対する放射線治療成績の検討会議報告等
- 2013年, 日本臨床腫瘍学会学術集会(CD-ROM), 11thsunitinibを使用し腸管壊死をきたしたACTH産生神経内分泌腫瘍
- 2012年12月, 頭頸部癌, 38(4号) (4号), 399 - 402, 日本語分子標的薬の適正な使用について 分子標的薬の適正な使用のために 分子標的薬の特徴を理解する[査読有り][招待有り]記事・総説・解説・論説等（学術雑誌）
- 2012年11月, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 84(3) (3), S491 - S491, 英語Patterns of Local Recurrence and Metachronous Malignancy Following Radiation Therapy for Stage I or II Hypopharyngeal Carcinoma: Role of Close Observation and Multidisciplinary Approach研究発表ペーパー・要旨（国際会議）
- 2012年10月, ANNALS OF ONCOLOGY, 23, 91 - 91, 英語A PILOT RANDOMIZED TRIAL COMPARING STANDARD PAIN CONTROL WITH OR WITHOUT GABAPENTIN FOR THE TREATMENT OF PAIN RELATED TO RADIATION-INDUCED MUCOSITIS IN HEAD AND NECK CANCER研究発表ペーパー・要旨（国際会議）
- 2012年10月, ANNALS OF ONCOLOGY, 23, 161 - 161, 英語DACARBAZINE MONO-THERAPY FOR UNRESECTABLE NEUROENDOCRINE TUMOR: A RETROSPECTIVE ANALYSIS研究発表ペーパー・要旨（国際会議）
- 2012年07月, 日本耳鼻咽喉科学会会報, 115(7号) (7号), 671 - 675, 日本語頭頸部癌に対する分子標的治療[査読有り][招待有り]記事・総説・解説・論説等（学術雑誌）
- 2012年06月, 日本食道学会学術集会プログラム・抄録集66回, 283, 日本語当院における高齢者食道癌の内科的治療の成績と戦略について[査読有り]会議報告等
- 2012年05月20日, JOURNAL OF CLINICAL ONCOLOGY, 30(15) (15)Daily performance status-based target physical activity of early rehabilitation for hematologic malignancy patients after allogeneic hematopoietic stem cell transplantation.[査読有り]
- 2012年05月, JOURNAL OF CLINICAL ONCOLOGY, 30(15) (15), 英語Phase II trial of chemoradiotherapy concurrent with S-1 plus cisplatin in patients with unresectable, locally advanced squamous cell carcinoma of the head and neck (SCCHN): Results of the Japan Clinical Oncology Group study, JCOG 0706研究発表ペーパー・要旨（国際会議）
- (一社)日本頭頸部癌学会, 2012年05月, 頭頸部癌, 38(2) (2), 188 - 188, 日本語頭頸部癌患者における放射線性粘膜炎による疼痛に対するガバペンチンのパイロット・ランダム化比較試験
- (一社)日本頭頸部癌学会, 2012年05月, 頭頸部癌, 38(2) (2), 195 - 195, 日本語当院における中咽頭扁平上皮癌に対する放射線治療成績
- (一社)日本頭頸部癌学会, 2012年05月, 頭頸部癌, 38(2) (2), 226 - 226, 日本語頸部リンパ節転移を認めた原発不明悪性黒色腫の2例
- (一社)日本頭頸部癌学会, 2012年05月, 頭頸部癌, 38(2) (2), 231 - 231, 日本語多診療科共同で集学的治療を行った頭頸部原発骨軟部肉腫の2例
- ヴァン・メディカル, 2012年05月, 臨床腫瘍プラクティス, 8(2号) (2号), 105 - 110, 日本語【術前補助化学療法をめぐって】 術前補助化学療法の適応と実際 頭頸部がんに対する術前補助化学(放射線)療法 導入化学療法が適応となる症例と、期待される効果[招待有り]記事・総説・解説・論説等（学術雑誌）
- 2012年02月, 日本内科学会雑誌, 101(Suppl.) (Suppl.), 174, 日本語切除不能高分化神経内分泌腫瘍に対するダカルバジン療法[査読有り]会議報告等
- 2012年02月, 日本内科学会雑誌, 101(Suppl.) (Suppl.), 241, 日本語Extra-Pulmonary Neuroendocrine Carcinoma(EP-NEC)に対する救済化学療法としてのアムルビシン(AMR)の効果[査読有り]会議報告等
- 2012年, 日本造血細胞移植学会総会プログラム・抄録集, 34th造血幹細胞移植前の眼科受診の意義
- 2011年10月, 頭頸部癌, 37巻, 3号, pp. 362-365, 日本語頭頸部癌化学放射線療法の位置づけと今後 術後補助化学放射線療法の実臨床への浸透のために記事・総説・解説・論説等（学術雑誌）
- (NPO)日本食道学会, 2011年09月, 日本食道学会学術集会プログラム・抄録集, 65回, 323 - 323, 日本語局所進行切除不能食道癌(T4/M1LYM)に対する化学放射線療法の遡及的検討
- (一社)日本頭頸部癌学会, 2011年05月, 頭頸部癌, 37(2) (2), 249 - 249, 日本語当科における喉頭機能温存手術の検討
- (一社)日本頭頸部癌学会, 2011年05月, 頭頸部癌, 37(2) (2), 257 - 257, 日本語遊離空腸再建後の高リスク頭頸部癌に対する術後放射線治療の検討
- (一社)日本頭頸部癌学会, 2011年05月, 頭頸部癌, 37(2) (2), 258 - 258, 日本語切除不能頭頸部癌に対するSequential therapyの安全性に関する後向き研究
- (一社)日本頭頸部癌学会, 2011年05月, 頭頸部癌, 37(2) (2), 320 - 320, 日本語局所進行外耳道扁平上皮癌に対する3剤(TPF)併用化学放射線療法の経験
- 2011年04月, がん分子標的治療, 9巻, 2号, pp. 116-124, 日本語【抗EGFR抗体療法の展望】 頭頸部がん治療における抗EGFR抗体薬の位置づけ記事・総説・解説・論説等（学術雑誌）
- (公社)日本医学放射線学会, 2011年02月, 日本医学放射線学会学術集会抄録集, 70回, S353 - S353, 日本語局所進行外耳道扁平上皮癌に対する3剤(TPF)併用化学放射線療法の経験
- (公社)日本医学放射線学会, 2011年02月, 日本医学放射線学会学術集会抄録集, 70回, S354 - S354, 日本語原発不明癌頸部リンパ節転移に対する治療経験
- 2011年, 日本造血細胞移植学会総会プログラム・抄録集, 33rd急性GVHD予防薬ミコフェノール酸モフェチル(MMF)使用下における移植後G-CSF至適投与量の検討
- 2011年, 日本造血細胞移植学会総会プログラム・抄録集, 33rd臍帯血移植前にボリコナゾール水晶体内投与が有効であった真菌性眼内炎
- 2010年11月, ANNALS OF ONCOLOGY, 21, 34 - 34, 英語PHASE I TRIAL OF COMBINATION CHEMOTHERAPY WITH DOCETAXEL, CISPLATIN AND S-1 IN PATIENTS WITH HEAD AND NECK CANCER研究発表ペーパー・要旨（国際会議）
- 2010年10月, ANNALS OF ONCOLOGY, 21, 327 - 327, 英語OLFACTORY NEUROBLASTOMA: IMPACT OF INDUCTION CHEMOTHERAPY AND PROTON BEAM THERAPY研究発表ペーパー・要旨（国際会議）
- 2010年10月, 頭頸部癌, 36巻, 3号, pp. 278-281, 日本語本邦における頭頸部癌化学療法の展望 化学療法臨床研究の現状と対策記事・総説・解説・論説等（学術雑誌）
- 2010年07月, がん分子標的治療, 8巻, 3号, pp. 223-227, 日本語Cancer-Prevention and Early Detection 頭頸部がんとHPV(human papillomavirus)記事・総説・解説・論説等（学術雑誌）
- 2010年, 日本内科学会雑誌, 99結腸直腸がんに対するmFOLFOX6/FOLFIRI±Bevacizumab療法における甲状腺機能の評価
- 2009年12月, MOLECULAR CANCER THERAPEUTICS, 8(12) (12), 英語研究発表ペーパー・要旨（国際会議）
- 2009年12月, MOLECULAR CANCER THERAPEUTICS, 8(12) (12), 英語研究発表ペーパー・要旨（国際会議）
- 2009年09月, 耳鼻と臨床, 55 (044巻, Suppl.1, pp.(1) (1), S85 - S90, 日本語化学放射線療法(CCRT)と頸部制御 頭頸部癌に対する化学放射線療法後の頸部郭清に関する文献的考察 Planned Neck DissectionかSalvage Neck Dissectionか記事・総説・解説・論説等（学術雑誌）
- ヴァン・メディカル, 2009年02月, 臨床腫瘍プラクティス, 5巻, 1号, pp. 72-74(1) (1), 72 - 74, 日本語【食道がんの治療をどう行うか】 食道がんの化学放射線療法(50.4Gyか60Gyか) 50.4GyでOK記事・総説・解説・論説等（学術雑誌）
- 2008年04月, GASTROINTESTINAL ENDOSCOPY, 67(5) (5), AB190 - AB191, 英語Feasibility study of a new percutaneous endoscopic gastrostomy (PEG) procedure, the "Direct IDEAL PEG", in patients with advanced head and neck cancer or esophageal cancer研究発表ペーパー・要旨（国際会議）
- (有)科学評論社, 2007年12月, 腫瘍内科, 1巻, 6号, pp. 584-591(6) (6), 584 - 591, 日本語記事・総説・解説・論説等（学術雑誌）
- (一社)日本癌治療学会, 2007年09月, 日本癌治療学会誌, 42(2) (2), 282 - 282, 日本語再発消化管癌に対する治療 上部消化管 根治的化学放射線療法後遺残・再発食道癌に対するDocetaxelの治療成績
- (一社)日本癌治療学会, 2007年09月, 日本癌治療学会誌, 42(2) (2), 308 - 308, 日本語頭頸部癌に対する集学的治療 頭頸部腫瘍に対する化学放射線療法前の内視鏡的胃瘻造設術(PEG)の安全性と有用性
- (一社)日本消化器内視鏡学会, 2007年04月, Gastroenterological Endoscopy, 49(Suppl.1) (Suppl.1), 971 - 971, 日本語チアーパック入り半固形栄養剤と専用コネクターを用いた新しい胃瘻栄養管理の前向き検討
- (一社)日本消化器内視鏡学会, 2007年04月, Gastroenterological Endoscopy, 49(Suppl.1) (Suppl.1), 972 - 972, 日本語頭頸部癌に対する化学放射線療法前の予防的内視鏡的胃瘻造設術によって腹壁転移をきたした2例
- (有)科学評論社, 2007年04月, 消化器科, 44(4) (4), 375 - 380, 日本語【食道癌治療における放射線化学療法の位置づけと展望】 食道癌化学放射線療法の位置づけと今後の展望
- メジカルビュー社, 2006年, Mebio oncology, 3(1) (1), 106 - 108, 日本語What's going on 消化器癌 Phase 1 Pharmacokinetic Study of S-1 Plus Cisplatin in Patients With Advanced Gastric Carcinoma. Ajani JA, Faust J, Ikeda K, Yao JC, Anbe H, Carr KL, Houghton M, Urrea P. J Clin Oncol. 2005; 23: 6957-65. PMID: 16145066.--進行胃癌に対するS-1+CDDP併用療法の第1相薬物動態試験
- (一社)日本癌治療学会, 2005年09月, 日本癌治療学会誌, 40(2) (2), 318 - 318, 日本語当院における切除不能・再発大腸癌に対する全身化学療法の治療成績
- 2003年06月20日, 日本消化器内視鏡学会雑誌 = Gastroenterological endoscopy, 45(6) (6), 1031 - 1035, 日本語早期胃癌(IIC)様所見を呈し, 内視鏡的粘膜切除術(EMR)を行った胃前庭部の良性扁平上皮巣の1例
- 中外医学社, 2021年11月, 日本語, ISBN: 9784498022881頭頸部がん薬物療法ハンドブック
- 分担執筆, 内分泌がん, 南江堂, 2021年05月, 日本語, ISBN: 9784524227396新臨床腫瘍学 : がん薬物療法専門医のために
- 共編者(共編著者), 金原出版株式会社, 2018年10月, 日本語頭頸部がん薬物療法ガイダンス / 頭頸部がん薬物療法ガイダンス学術書
- その他, 南江堂, 2018年06月, 日本語新臨床腫瘍学 / 41 内分泌がん教科書・概説・概論
- 共編者(共編著者), 金原出版株式会社, 2017年12月, 日本語頭頸部癌診療ガイドライン2018年版 / 頭頸部癌診療ガイドライン2018年版学術書
- 中外医学社, 2017年08月, 日本語, ISBN: 9784498062696頭頸部がん薬物療法ハンドブック
- 共編者(共編著者), 金原出版株式会社, 2015年07月, 日本語頭頸部がん薬物療法ガイダンス / 頭頸部がん薬物療法ガイダンス学術書
- 中外医学社, 2014年05月, 日本語, ISBN: 9784498062689頭頸部がん化学療法ハンドブック = Handbook of head & neck cancer chemotherapy
- 共編者(共編著者), 中外医学社, 2014年05月, 日本語頭頸部がん化学療法ハンドブック教科書・概説・概論
- その他, 南江堂, 2012年12月, 日本語新臨床腫瘍学 / 血管新生に対する抗体薬教科書・概説・概論
- 共著, 日本看護協会出版会, 2011年02月, 日本語目で見て学ぶ放射線療法の有害反応 / 化学放射線療法に伴う有害反応教科書・概説・概論
- 共著, 日本看護協会出版会, 2011年02月, 日本語身で見て学ぶ放射線療法の有害反応 / 放射線療法と併用される化学療法の理解教科書・概説・概論
- 共著, 中外医学社, 2010年11月, 日本語EBM がん化学療法・分子標的治療法 / TPF療法後の化学放射線療法は標準治療とみなしうるか？学術書
- 共著, 中外医学社, 2010年05月, 日本語EBM 耳鼻咽喉科・頭頸部外科の治療 / 放射線治療におけるPEG（内視鏡的胃瘻造設術）のEBMとは学術書
- 共著, 中外医学社, 2010年05月, 日本語EBM 耳鼻咽喉科・頭頸部外科の治療 / 術後化学放射線療法のエビデンスとは学術書
- 共著, ヴァンメディカル, 2009年02月, 日本語臨床腫瘍プラクティス / 食道癌の化学放射線療法（50.4Gyか60Gyか）学術書
- 共著, 南江堂, 2009年, 日本語新臨床腫瘍学 / Bevacizumab教科書・概説・概論
- 共著, 株式会社メディカルレビュー社, 2008年11月, 日本語Cancer Treatment Navigator / 抗VEGF抗体学術書
- 共著, 篠原出版新社, 2008年10月, 日本語癌の基礎から臨床へ / 塩酸イリノテカンの薬物代謝動態におけるUGT1A1遺伝子多型の臨床的意義学術書
- 第47回日本頭頸部癌学会, 2023年06月, 日本語, 国内会議, 国際共著していないシスプラチン併用化学放射線療法の現状とこれから：術後シスプラチン併用化学放射線療法[招待有り]シンポジウム・ワークショップパネル（指名）
- ASCO2023, 2023年06月, 英語, 国際会議, 国際共著していないDarolutamide for patients with androgen receptor positive salivary gland cancers (DISCOVARY): The results of phase 2 study of darolutamide monotherapyポスター発表
- ASCO2023, 2023年06月, 英語, 国際会議, 国際共著していないA phase II trial of nivolumab for patients with platinum-refractory recurrent or metastatic salivary gland cancer.ポスター発表
- ASCO2023, 2023年06月, 英語, 国際会議, 国際共著していないA risk prediction model for cisplatin-induced acute kidney injury in head and neck cancer patients who receive chemoradiotherapy: A supplement analysis of a phase II/III trial of JCOG1008ポスター発表
- ASCO2023, 2023年06月, 英語, 国際会議, 国際共著していないImpact of acute kidney injury on overall survival in postoperative patients with head and neck cancer who received chemoradiotherapy with cisplatin: A supplementary analysis of a phase II/III trial of JCOG1008ポスター発表
- ASCO2023, 2023年06月, 英語A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibodyポスター発表
- JSMO2023, 2023年03月, 英語, 国際会議, 国際共著しているPhase IV study validating the European Organisation for Research and Treatment of Cancer Thyroid Cancer Module口頭発表（一般）
- JSMO2023, 2023年03月, 英語, 国際会議, 国際共著しているFeasibility of the online-based quality of life survey in patients with head and neck cancer. A multi-center, prospective study口頭発表（一般）
- ESMO Asia 2022, 2022年12月, 英語Multidisciplinary Tumor Board of Recurrent or Metastatic Nasopharyngeal Cancer Case presentation and overview of treatment strategy for RM-NPC[招待有り]シンポジウム・ワークショップパネル（指名）
- 5. 日本放射線腫瘍学会第35回学術大会, 2022年11月, 日本語最新臨床試験から考える局所進行頭頸部癌に対する化学放射線療法[招待有り]シンポジウム・ワークショップパネル（指名）
- ACKSS2022, 2022年11月, 英語Current Treatment Strategy and Future Perspective of Unresectable Anaplastic Thyroid Cancer in Japan[招待有り]シンポジウム・ワークショップパネル（指名）
- 第６５回日本甲状腺学会学術集会, 2022年11月, 日本語進行甲状腺がんに対する薬物療法の進歩と将来展望[招待有り]シンポジウム・ワークショップパネル（指名）
- 第６０回日本がん治療学会学術集会, 2022年10月, 日本語がんゲノム医療時代の甲状腺がんの薬物療法[招待有り]シンポジウム・ワークショップパネル（指名）
- WFNMB2022, 2022年09月, 英語Recent Updates of Molecular Targeted Treatment for Advanced Thyroid Cancer[招待有り]シンポジウム・ワークショップパネル（指名）
- 第46回日本頭頸部癌学会, 2022年06月, 日本語甲状腺がんにおけるがんゲノム医療[招待有り]シンポジウム・ワークショップパネル（指名）
- 第13回日本頭頸部癌学会教育セミナー, 2022年06月, 日本語進行甲状腺がんに対する薬物療法[招待有り]公開講演，セミナー，チュートリアル，講習，講義等
- 第123回日本耳鼻咽喉科・頭頸部外科学会総会・学術講演会, 2022年05月, 日本語頭頸部がんに対する薬物療法 update （免疫チェックポイント阻害薬）[招待有り]公開講演，セミナー，チュートリアル，講習，講義等
- ESMO Congress 2021, 2021年09月, 英語Nivolumab (N) + ipilimumab (I) vs EXTREME as first-line (1L) treatment (tx) for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Final results of CheckMate 651口頭発表（一般）
- American Society of Clinical Oncology 2020, 2020年05月, 英語Phase II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of head and neck (JCOG1008).口頭発表（一般）
- 第３７回日本口腔腫瘍学会, 2019年01月, 日本語, 日本口腔腫瘍学会, 長崎, 国内会議頭頸部がん診療連携プログラムについて[招待有り]シンポジウム・ワークショップパネル（指名）
- ASCO-SITC, 2019年01月, 英語, サンフランシスコ, 国際会議Relationship between tumor burden to growth rate and treatment outcomes of nivolumab for patients with head and neck squamous carcinoma.ポスター発表
- 第1回日本腫瘍循環器学会学術集会, 2018年11月, 日本語, 日本腫瘍循環器学会, 東京, 国内会議肺動脈原発内膜肉腫の3例ポスター発表
- 第1回日本腫瘍循環器学会学術集会, 2018年11月, 日本語, 日本腫瘍循環器学会, 東京, 国内会議悪性腫瘍関連静脈血栓寒栓症に対する包括的研究：J-CAV project in progress口頭発表（一般）
- 第31回日本放射線腫瘍学会学術大会, 2018年10月, 日本語, 日本放射線腫瘍学会, 京都, 国内会議頭頸部がんにおける免疫チェックポイント阻害薬と放射線治療[招待有り]シンポジウム・ワークショップパネル（指名）
- 日本甲状腺外科学会, 2018年10月, 日本語, 横浜, 国内会議甲状腺がんに対するレンバチニブ治療中の観血的処置の安全性に関する遡及的検討口頭発表（一般）
- ESMO2018, 2018年10月, 英語, 欧州臨床腫瘍学会, ミュンヘン, 国際会議Nutritional Support Dependence after Curative Chemoradiotherapy in Head and Neck Cancer: a Supplementary Analysis of a Phase II Trial (JCOG0706S1)ポスター発表
- 第80回日本血液学会学術集会, 2018年10月, 英語, 日本血液学会, 大阪, 国内会議Discontinuation of sorafenib can lead to the emergence of FLT3-ITD-positive actute myeloid leukemia.ポスター発表
- ESMO2018, 2018年10月, 英語, 欧州臨床腫瘍学会, ミュンヘン, 国際会議A randomized phase III study to evaluate the value of the omission of prophylactic neck dissection for stage I/II tongue cancer (RESPOND: JCOG1601)ポスター発表
- ESMO2018, 2018年10月, 英語, 欧州臨床腫瘍学会, ミュンヘン, 国際会議A Phase II Trial of Docetaxel plus Cisplatin in Recurrent and/or Metastatic Non-squamous Cell Carcinoma of Head and Neckポスター発表
- 第16回日本臨床腫瘍学会, 2018年07月, 日本語, 日本臨床腫瘍学会, 神戸, 国内会議頭頸部がんと甲状腺がんに対する薬物療法のUpdate[招待有り]口頭発表（招待・特別）
- 第16回日本臨床腫瘍学会, 2018年07月, 日本語, 日本臨床腫瘍学会, 神戸, 国内会議透析中の大腸癌患者におけるオキサリプラチンのPKおよび安全性の評価ポスター発表
- 第16回日本臨床腫瘍学会, 2018年07月, 日本語, 日本臨床腫瘍学会, 神戸, 国内会議神戸大学医学部附属病院腫瘍センターにおける免疫関連有害事象の患者教育と診療支援体制の構築ポスター発表
- 第16回日本臨床腫瘍学会, 2018年07月, 日本語, 日本臨床腫瘍学会, 神戸, 国内会議脂肪幹細胞によるアディプシンを介したヒト乳がん細胞の増殖促進口頭発表（一般）
- 第16回日本臨床腫瘍学会, 2018年07月, 日本語, 日本臨床腫瘍学会, 神戸, 国内会議局所進行頭頸部扁平上皮癌に対するTPE 導入化学療法とセツキシマブ併用放射線療法の第Ⅱ相試験口頭発表（一般）
- 第16回日本臨床腫瘍学会, 2018年07月, 日本語, 第16回日本臨床腫瘍学会, 神戸, 国内会議プラチナ抵抗性舌扁平上皮癌に対してニボルマブ投与後にStevens-Johson syndromeを発症した一例ポスター発表
- 第16回日本臨床腫瘍学会, 2018年07月, 日本語, 日本臨床腫瘍学会, 神戸, 国内会議Updates of chemotherapy for head and neck cancer and thyroid cancer[招待有り]口頭発表（招待・特別）
- 第16回日本臨床腫瘍学会, 2018年07月, 英語, 日本臨床腫瘍学会, 神戸, 国内会議Synchronous esophageal cancer and multiple myeloma: a report of two casesポスター発表
- 第16回日本臨床腫瘍学会, 2018年07月, 日本語, 日本臨床腫瘍学会, 神戸, 国内会議Pazopanibにより長期病勢安定が得られた肺動脈原発血管内膜肉腫の一例ポスター発表
- 第16回日本臨床腫瘍学会, 2018年07月, 日本語, 日本臨床腫瘍学会, 神戸, 国内会議Efficacy and Safety of Nivolumab for Previously Treated Non-squamous Cell Carcinoma of the Head and Neckポスター発表
- 第16回日本臨床腫瘍学会, 2018年07月, 日本語, 日本臨床腫瘍学会, 神戸, 国内会議Docetaxel plus Cisplatin in Recurrent and/or Metastatic Non-squamous Cell Carcinoma of Head and Neck: a Phase II Trial口頭発表（一般）
- 第16回日本臨床腫瘍学会, 2018年07月, 英語, 日本臨床腫瘍学会, 神戸, 国内会議Curent status of immune check point inhibitor for recurrent or metastatic head and neck cancer[招待有り]シンポジウム・ワークショップパネル（指名）
- 第16回日本臨床腫瘍学会, 2018年07月, 日本語, 日本臨床腫瘍学会, 神戸, 国内会議A Retrospective Analysis of Extra-pulmonary Small Cell Carcinoma Treated with Chemotherapy Concurrent with or without Radiotherapyポスター発表
- 第16回日本臨床腫瘍学会, 2018年07月, 英語, 日本臨床腫瘍学会, 神戸, 国内会議A Multicenter Phase ⅡＴrial of Docetaxel, Cisplatin and Cetuximab (TPE) Followed by Cetuximab with Concurrent Radiotherapy in Patients with Local Advanced Squamous Cell Carcinoma of the Head and Neck (ECRIPS study)口頭発表（一般）
- 第16回日本臨床腫瘍学会, 2018年07月, 日本語, 第16回日本臨床腫瘍学会, 神戸, 国内会議A Case of Stevens-Johnson Syndrome After Administration of Nivolumab for Platinum-refractory Tongue Cancerポスター発表
- 第16回日本臨床腫瘍学会, 2018年07月, 日本語, 日本臨床腫瘍学会, 神戸, 国内会議A case of intimal sarcoma of pulmonary artery with long-term disease stabilization by pazopanibポスター発表
- 第42回日本頭頸部癌学会, 2018年06月, 日本語, 日本頭頸部癌学会, 東京, 国内会議再発・転移の頭頸部非扁平上皮癌に対するドセタキセル+シスプラチン併用療法の第Ⅱ相臨床試験口頭発表（一般）
- 頭頸部癌学会, 2018年06月, 日本語, 東京, 国内会議再発・転移の頭頸部非扁平上皮癌に対するドセタキセル+シスプラチン併用療法の第II相臨床試録口頭発表（一般）
- 頭頸部癌学会, 2018年06月, 日本語, 東京, 国内会議甲状腺癌気道浸潤例に対する放射線外照射の有効性の検討口頭発表（一般）
- American Society of Clinical Oncology 2018 Annual Meeting, 2018年06月, 英語, American Society of Clinical Oncology, シカゴ, 国際会議Nivolumab (nivo) vs investigator’s choice (IC) in patients (pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Analysis of CheckMate 141 by age.ポスター発表
- American Society of Clinical Oncology Annual Meeting 2018, 2018年06月, 英語, Chicago, 国際会議Adapalene gel 0.1% vs. placebo as prophylaxis for anti-EGFR-induced acne-like rash: a randomized left-right comparative evaluation (APPEARANCE)ポスター発表
- 第115回内科学会総会, 2018年04月, 日本語, 日本内科学会, 京都, 国内会議がんクリニカルシークエンスと遺伝性腫瘍の関係ポスター発表
- AACR Annual Meeting 2018, 2018年04月, 英語, American Association for Cancer research, シカゴ, 国際会議A comparative analysis of pathological features and molecular genetics between salivary duct carcinoma and adenocarcinoma, not otherwise specified.ポスター発表
- 第51回制癌剤適応研究会, 2018年03月, 日本語, 制癌剤適応研究会, 下呂, 国内会議乳癌センチネルリンパ節におけるprogrammed death-1発現に関する検討口頭発表（一般）
- 第1回日本サルコーマ治療研究学会学術集会, 2018年02月, 日本語, 国内会議Pazopanibにより長期病勢安定が得られた肺動脈原発血管内膜肉腫の一例口頭発表（一般）
- The 2018 Multidisciplinary Head and Neck Cancers Symposium, 2018年02月, 英語, ASTRO, Arizona, USA, 国際会議Exploratory analysis of prognostic and predictive factors of lenvatinib for radioiodine-refractory differentiated thyroid cancerポスター発表
- 第36回日本口腔腫瘍学会総会学術大会, 2018年01月, 日本語, 日本口腔腫瘍学会, 新潟, 国内会議口腔癌に対する免疫チェックポイント阻害薬の適正使用と腫瘍内科医との診療連携[招待有り]シンポジウム・ワークショップパネル（指名）
- 第69回日本気管食道科学会総会, 2017年11月, 日本語, 日本気管食道科学会, 大阪, 国内会議頭頸部がんに対する分子標的薬及び免疫チェックポイント阻害薬の役割[招待有り]シンポジウム・ワークショップパネル（指名）
- 第31回日本耳鼻咽喉科学会専門医講習会, 2017年11月, 日本語, 日本耳鼻咽喉科学会, 神戸, 国内会議頭頸部がんにおける免疫チェックポイント阻害薬の適正使用公開講演，セミナー，チュートリアル，講習，講義等
- APTS2017, 2017年11月, 英語, Asia-Pcific Society of Thyroid Surgery, 沖縄, 国際会議Molecular targeted treatment for thyroid cancer[招待有り]シンポジウム・ワークショップパネル（指名）
- JSMO2017, 2017年07月, 日本語, Japanese Society of Medical Oncology, 神戸, 国際会議頭頸部がんのRare Cancer, 頭頸部悪性黒色腫[招待有り]シンポジウム・ワークショップパネル（指名）
- JSMO2017, 2017年07月, 英語, Japanese Society of Medical Oncology, 神戸, 国際会議Safety and efficacy of induction chemotherapy with TPF for locally advanced head and neck squamous cell carcinomaポスター発表
- 第15回日本臨床腫瘍学会学術集会, 2017年07月, 日本語, 日本臨床腫瘍学会, 神戸, 国内会議Remarkable response to cetuximab-containing chemotherapy for tongue cancer refractory to immune checkpoint inhibitorsポスター発表
- 第15回日本臨床腫瘍学会学術集会, 2017年07月, 日本語, 日本臨床腫瘍学会, 神戸, 国内会議Expression of programmed death-1 (PD-1) in sentinel lymph nodes of breast cancer口頭発表（一般）
- 第15回日本臨床腫瘍学会学術集会, 2017年07月, 日本語, 日本臨床腫瘍学会, 神戸, 国内会議Efficacy and feasibility of induction chemotherapy followed by chemoradiotherapy for locally advanced head and neck squamous cell carcinomaポスター発表
- 第15回日本臨床腫瘍学会学術集会, 2017年07月, 日本語, 日本臨床腫瘍学会, 神戸, 国内会議Dose Modification in Patients with Advanced Pancreatic Cancer Treated with Nab-paclitaxel/Gemcitabineポスター発表
- JSMO2017, 2017年07月, 英語, Japanese Society of Medical Oncology, 神戸, 国際会議Bone marrow involvement and extramedullary hematopoiesis in a case of malignant melanoma after introduction of nivolumabポスター発表
- 日本頭頸部癌学会主催第8回教育セミナー, 2017年06月, 日本語, 日本頭頸部癌学会, Kyoto, 国内会議頭頸部がんに対する免疫チェックポイント阻害薬公開講演，セミナー，チュートリアル，講習，講義等
- 第41回日本頭頸部癌学会, 2017年06月, 日本語, 京都, 国内会議当院における 嗅神経芽細胞腫の検討口頭発表（一般）
- 第41回日本頭頸部癌学会, 2017年06月, 日本語, 日本頭頸部癌学会, Kyoto, 国内会議腫瘍内科医からみた頭頸部がん臨床試験におけるIMRTの重要性と課題[招待有り]シンポジウム・ワークショップパネル（指名）
- American Society of Clinical Oncology Annual Meeting; June 2–6, 2017, 2017年06月, 英語, American Society of Clinical Oncology, Chicago, USA, 国際会議Nivolumab vs Investigator’s Choice for Platinum-Refractory Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (CheckMate 141): Outcomes in First-line R/M Patients and Updated Safety and Efficacyポスター発表
- 第41回日本頭頸部癌学会, 2017年06月, 日本語, 日本頭頸部癌学会, 京都, 国内会議Induction chemotherapy of TPF for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) - A retrospective safety analysis at our institution -口頭発表（一般）
- American Society of Clinical Oncology Annual Meeting; June 2–6, 2018, 2017年06月, 英語, American Society of Clinical Oncology, Chicago, USA, 国際会議A Multicenter Phase II Trial of Docetaxel, Cisplatin and Cetuximab (TPE) Followed by Cetuximab with Concurrent Radiotherapy in Patients with Local Advanced Squamous Cell Carcinoma of the Head and Neck (ECRIPS study)ポスター発表
- 日本内分泌外科学会2017, 2017年05月, 日本語, 日本内分泌外科学会, Kobe, 国内会議転移再発甲状腺がんに対する薬物療法[招待有り]シンポジウム・ワークショップパネル（指名）
- 第90回日本整形外科学会学術総会, 2017年05月, 日本語, 日本整形外科学会, 仙台, 国内会議骨転移診療の現状と各診療科の意識調査 整形外科医・腫瘍内科医・放射線治療医に対するアンケート口頭発表（一般）
- Annual Meeting of the American Association for Cancer Research 2017, 2017年04月, 英語, American Asociation for Cancer Research, Washington, DC, USA, 国際会議Quantitative mass spectrometry imaging of erlotinib in skin rashes of cancer patients receiving erlotinibポスター発表
- Annual Meeting of the American Association for Cancer Research 2017, 2017年04月, 英語, American Association for Cancer Research, Washington DC, USA, 国際会議3D culture may better represent trastuzumab resistance associated with PIK3CA mutation than 2D culture.ポスター発表
- 第50回制癌剤適応研究会, 2017年03月, 日本語, 制癌剤適応研究会, 徳島, 国内会議HER2陽性乳癌細胞株を用いたPIK3CA変異によるtrastuzumab耐性機構に関する2次元、3次元培養の比較シンポジウム・ワークショップパネル（公募）
- ESMO Asia 2016 Congress, 2016年12月, 英語, European Society of Medical Oncology, Singapore, Singapore, 国際会議Patient-reported outcomes (PROs) in recurrent or metastatic(R/M) squamous cell carcinoma of the head and neck (SCCHN)treated with nivolumab (Nivo) or Investigator’s Choice (IC):CheckMate 142口頭発表（一般）
- ESMO Asia 2016 Congress, 2016年12月, 英語, European Society of Medical Oncology, Singapore, Singapore, 国際会議Efficacy and safety of nivolumab for recurrent ormetastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in Asia: CheckMate 141 subgroup analysis口頭発表（一般）
- 日本放射線腫瘍学会第29回学術大会, 2016年11月, 日本語, 日本放射線腫瘍学会, 京都, 国内会議Outcomes after radiation therapy for recurrent carcinoma of the oral tongue口頭発表（一般）
- ESMO 2016, 2016年10月, 英語, European Society of Medical Oncology, Copenhagen, Denmark, 国際会議Patient-reported outcomes (PROs) in recurrent or metastatic(R/M) squamous cell carcinoma of the head and neck (SCCHN)treated with nivolumab (Nivo) or Investigator’s Choice (IC):CheckMate 141口頭発表（一般）
- 第213回内科学会近畿地方会, 2016年09月, 日本語, 日本内科学会近畿支部, 大阪, 国内会議FDG-PET/CTにて腹膜にびまん性の集積を認め、がん性腹膜炎との鑑別を要した腹膜結核の1例口頭発表（一般）
- 第14回日本臨床腫瘍学会学術集会, 2016年07月, 日本語, 日本臨床腫瘍学会, 神戸, 国内会議本邦における脊椎転移患者の治療にかかる院内連携の現状の検討 -骨転移キャンサーボードが与える影響について-口頭発表（一般）
- 第14回臨床腫瘍学会学術集会, 2016年07月, 日本語, 臨床腫瘍学会, 神戸, 国内会議本邦における脊椎転移患者の治療にかかる院内連携の現状の検討 -骨転移キャンサーボードが与える影響について[招待有り]シンポジウム・ワークショップパネル（指名）
- 第14回日本臨床腫瘍学会学術集会, 2016年07月, 日本語, 日本臨床腫瘍学会, 神戸, 国内会議本邦における骨転移治療の現状についてのアンケート結果の報告口頭発表（一般）
- 第14回日本臨床腫瘍学会学術集会, 2016年07月, 日本語, 日本臨床腫瘍学会, 神戸, 国内会議腎障害時のS-1薬物動態試験口頭発表（一般）
- 第14回日本臨床腫瘍学会学術集会, 2016年07月, 日本語, 日本臨床腫瘍学会, 神戸, 国内会議進行性甲状腺癌（放射性ヨウ素治療抵抗性分化型癌，髄様癌，未分化癌）に対する レンバチニブの第2相試験：最終報告口頭発表（一般）
- 第14回日本臨床腫瘍学会学術集会, 2016年07月, 日本語, 日本臨床腫瘍学会, 神戸, 国内会議治癒切除不能な進行・再発結腸直腸癌患者に対するセツキシマブ隔週投与の第II相臨床試験口頭発表（一般）
- 第14回日本臨床腫瘍学会学術集会, 2016年07月, 日本語, 日本臨床腫瘍学会, 神戸, 国内会議甲状腺がんに対するレンバチニブの有害事象と治療効果の関連について口頭発表（一般）
- 第14回日本臨床腫瘍学会学術集会, 2016年07月, 日本語, 日本臨床腫瘍学会, 神戸, 国内会議化学療法及び放射線化学療法に伴う口内炎に対するイブプロフェン含嗽剤の安全性と有効性を検討する非盲検非対照第I/II相試験（ポスター発表）ポスター発表
- 第14回日本臨床腫瘍学会学術集会, 2016年07月, 日本語, 日本臨床腫瘍学会, 神戸, 国内会議化学療法及び放射線化学療法に伴う口内炎に対するイブプロフェン含嗽剤の安全性と有効性を検討する非盲検非対照第I/II相試験口頭発表（一般）
- 第109回近畿皮膚科集談会(第456回大阪地方会・第447回京滋地方会), 2016年07月, 日本語, 大阪地方会, 神戸, 国内会議悪性黒色腫で全身多発転移を伴うもNivolumabとVemurafenibにて長期生存を得た1例口頭発表（一般）
- 第14回日本臨床腫瘍学会学術集会, 2016年07月, 日本語, 日本臨床腫瘍学会, 神戸, 国内会議シスプラチン投与患者におけるeGFR / CKD-EPIの検討口頭発表（一般）
- 第14回日本臨床腫瘍学会学術集会, 2016年07月, 日本語, 日本臨床腫瘍学会, 神戸, 国内会議Next-generation sequencing provides therapeutic targets in advanced biliary tract cancer (aBTC)シンポジウム・ワークショップパネル（公募）
- 第14回日本臨床腫瘍学会学術集会, 2016年07月, 英語, 日本臨床腫瘍学会, 神戸, 国内会議HLA alleles correlate with gemcitabine plus erlotinib-induced ILD in Japanese patients with advanced pancreatic cancer口頭発表（一般）
- 第14回日本臨床腫瘍学会, 2016年07月, 英語, 日本臨床腫瘍学会, 兵庫, 国内会議First-Line Chemotherapy for Recurrent or Metastatic Head and Neck Cancer with or without Cetuximab: A single institution experienceポスター発表
- 第14回日本臨床腫瘍学会学術集会, 2016年07月, 英語, 日本臨床腫瘍学会, 神戸, 国内会議Comparison of 2D- and 3D-cultures in in vitro evaluation of trastuzumab in HER2-overexpressing breast cancer cell lines口頭発表（一般）
- 第14回日本臨床腫瘍学会学術集会, 2016年07月, 英語, 日本臨床腫瘍学会, 神戸, 国内会議Case Report of Two Patients with Pulmonary Artery Intimal Sarcoma Treated with Adjuvant Doxorubicin and Ifosfamide。口頭発表（一般）
- 第40回日本頭頸部癌学会, 2016年06月, 日本語, 日本頭頸部癌学会, Saitama, Japan, 埼玉、ソニックシティー, 国内会議同時併用化学放射線療法を施行した進行期喉頭癌,下咽頭癌症例におけるTalk Score の検討口頭発表（一般）
- 第40回日本頭頸部癌学会, 2016年06月, 日本語, 日本頭頸部癌学会, Saitama, Japan, 埼玉、ソニックシティー, 国内会議当科で放射線治療を施行した下咽頭癌T1・T2症例の検討口頭発表（一般）
- 第40回日本頭頸部癌学会, 2016年06月, 日本語, 日本頭頸部癌学会, 大宮, 国内会議舌癌術後再発症例に対する放射線治療成績口頭発表（一般）
- 2016 ASCO Annual Meeting, 2016年06月, 英語, American Society of Clinical Oncology, Chicago, United States of America, 国際会議Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).ポスター発表
- 2016 ASCO Annual Meeting, 2016年06月, 英語, American Society of Clinical Oncology, Chicago, United States of America, 国際会議Phase II study of lenvatinib in patients with differentiated, medullary, and anaplastic thyroid cancer: Final analysis resultsポスター発表
- 2016 ASCO Annual Meeting, 2016年06月, 英語, American Society of Clinical Oncology, Chicago, United States of America, 国際会議Further evaluations of nivolumab (nivo) versus investigator’s choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141口頭発表（一般）
- 第40回日本頭頸部癌学会, 2016年06月, 英語, 日本頭頸部癌学会, 埼玉, 国内会議First-Line treatment with Cetuximab-based Combination Therapy for Recurrent/Metastatic Head and Neck Cancer: A single institution experience口頭発表（一般）
- 第40回日本頭頸部癌学会, 2016年06月, 日本語, 日本頭頸部癌学会, Saitama, Japan, 埼玉、ソニックシティー, 国内会議First-line Treatment of Recurrent/Metastatic Head and Neck Cancer with or without Cetuximab口頭発表（一般）
- 第113回日本内科学会総会, 2016年04月, 日本語, 日本内科学会, 東京, 国内会議再発転移頭頸部扁平上皮癌1st line化学療法におけるセツキシマブ併用効果。ポスター発表
- 第113回日本内科学会総会, 2016年04月, 日本語, 日本内科学会, 東京, 国内会議再発・転移頭頸部扁平上皮癌におけるプラチナ耐性獲得時の血液学的予後予測因子に関する検討ポスター発表
- 第75回日本医学放射線学会総会, 2016年04月, 英語, 日本医学放射線学会, 横浜, 国内会議radiotherapy for cervical lymph node metastases of unknown primary site口頭発表（一般）
- 第75回日本医学放射線学会総会, 2016年04月, 日本語, 日本医学放射線学会, 横浜, 国内会議Definitive Radiotherapy for T3/T4 Hypopharyngeal Squamous Cell Carcinoma口頭発表（一般）
- 日本放射線腫瘍学会第28回学術大会, 2015年11月, 日本語, 日本放射線腫瘍学会, 群馬, 国内会議RADIOTHERAPY FOR CERVICAL LYMPH NODE METASTASES OF UNKNOWN PRIMARY SITE口頭発表（一般）
- 日本放射線腫瘍学会第28回学術大会, 2015年11月, 日本語, 日本放射線腫瘍学会, 群馬, 国内会議Radiation Induced Hypothyroidism in Squamous Cell Carcinoma of the Head and Neck: a Dose-Volume Histogram Analysis口頭発表（一般）
- 日本放射線腫瘍学会第28回学術大会, 2015年11月, 日本語, 日本放射線腫瘍学会, 群馬, 国内会議Prognostic value of FDG PET imaging in pharyngeal cancer patients treated with radiotherapy alone or chemoradiotherapy口頭発表（一般）
- 日本放射線腫瘍学会第28回学術大会, 2015年11月, 日本語, 日本放射線腫瘍学会, 群馬, 国内会議Outcomes of radiotherapy for oro- or hypopharyngeal cancer with concomitant esophageal cancerポスター発表
- 57th Annual Meeting of ASTRO, 2015年10月, 英語, ASTRO, San Antonio, USA, 国際会議Radiotherapy for T3/T4 squamous cell carcinoma of hypopharynx: retrospective comparison between definitive radiotherapy and surgery followed by postoperative radiotherapyポスター発表
- 57th Annual Meeting of ASTRO, 2015年10月, 英語, ASTRO, San Antonio, USA, 国際会議Radiation Induced Hypothyroidism in Squamous Cell Carcinoma of the Head and Neck: a Dose-Volume Histogram Analysisポスター発表
- European Cancer Congress 2015, 2015年09月, 英語, European Cancer Congress, Vienna, Austria, Austria, 国際会議Radiation Induced Hypothyroidism in Squamous Cell Carcinoma of the Head and Neck: a Dose-Volume Histogram Analysisポスター発表
- 第13回日本臨床腫瘍学会学術集会, 2015年07月, 日本語, 日本臨床腫瘍学会, 札幌, 国内会議アプレピタント併用におけるオキシコドン除法剤の薬物動態研究口頭発表（一般）
- 第13回日本臨床腫瘍学会学術集会, 2015年07月, 英語, 日本臨床腫瘍学会, 札幌, 国内会議Treatment experience of rhabdomyosarcoma in adults at our institution。口頭発表（一般）
- 第13回日本臨床腫瘍学会学術集会, 2015年07月, 英語, 日本臨床腫瘍学会, 札幌, 国内会議Prognostic Value of the Inflammation Markers for Platinum Refractory Recurrent/Metastatic Head and Neck Squamous Cell Carcinomaポスター発表
- 第39回頭頸部癌学会/第4回アジア頭頸部癌学会, 2015年06月, 英語, 日本頭頸部癌学会, 神戸, 国際会議原発不明癌頸部リンパ節転移に対する放射線治療の経験ポスター発表
- The Joint Meeting of 4th Congress of Asian Society of Head and Neck Oncology, 2015年06月, 英語, Asian Society of Head and Neck Oncology, 兵庫, 国際会議局所進行（T3／T4）下咽頭癌の治療成績ポスター発表
- 4th Congress of Asian Society of Head and Neck Oncology 39th Annual Meeting of Japan Society for Head and Neck Cancer, 2015年06月, 日本語, 日本頭頸部癌学会, 神戸, 国内会議Treatment outcomes of definitive radiotherapy in patients with T3N0M0 laryngeal cancerポスター発表
- 2015年6月3日～6日の4th Congress of Asian Society of Head and Neck Oncology, 2015年06月, 英語, 日本頭頸部癌学会, 神戸, 国際会議Treatment outcome of parotid cancers口頭発表（一般）
- 日本頭頸部癌学会, 2015年06月, 英語, Japan Society for Head and Neck Cancer, 神戸, 国際会議Radiotherapy for posterior pharyngeal wall cancer of oropharynx and/or hypopharynxポスター発表
- 日本頭頸部癌学会, 2015年06月, 日本語, Japan Society for Head and Neck Cancer, 神戸, 国際会議Radiotherapy for Head and Neck Cancers with N3 Lymph Node Metastasisポスター発表
- 第39回日本頭頸部癌学会学術集会, 2015年06月, 英語, 日本頭頸部癌学会, 神戸, 国内会議Prognostic value of the Inflammation Scores for Platinum Refractory Head and Neck cancer.口頭発表（一般）
- 第39回頭頸部癌学会/第4回アジア頭頸部癌学会, 2015年06月, 英語, 日本頭頸部癌学会, 神戸, 国際会議Outcomes of radiotherapy for oro and hypopharyngeal cancer with concomitant esophageal cancerポスター発表
- 第39回頭頸部癌学会/第4回アジア頭頸部癌学会, 2015年06月, 英語, 日本頭頸部癌学会, 神戸, 国際会議Definitive radiotherapy for T3/T4 hypopharyngeal squamous cell carcinomaポスター発表
- 15th International Congress of Radiation Research, 2015年05月, 英語, 京都, 国際会議Radioimmunotherapy with 90Y ibritumomab tiuxetan for low grade malignant lymphoma.ポスター発表
- 15th International Congress of Radiation Research, 2015年05月, 英語, International Congress of Radiation Research, 京都, 国際会議Radiation Induced Hypothyroidism in Squamous Cell Carcinoma of the Head and Neckポスター発表
- 第112回日本内科学会総会, 2015年04月, 日本語, 日本内科学会, 京都, 国内会議再発・転移粘膜悪性黒色腫に対するダカルバジン単剤療法の後方視的検討ポスター発表
- 第112回日本内科学会総会, 2015年04月, 日本語, 日本内科学会, 京都, 国内会議化学療法中の固形腫瘍患者に対するインフルエンザワクチン2回接種法の有効性と安全性.口頭発表（一般）
- The 74th Annual Meeting of the Japan Radiological Society, 2015年04月, 日本語, 日本医学放射線学会, 横浜, 国内会議Prognostic value of FDG PET imaging in patients with pharyngeal cancer and who received definitive radiotherapwith radiotherapy or without chemotherapyポスター発表
- AACR Annual Meeting、2015, 2015年04月, 英語, AACR, ペンシルバニア, アメリカ, 国際会議Comparison of 2D- and 3D-culture models as drug-testing platforms in breast cancerポスター発表
- 日本放射線腫瘍学会第27回学術大会, 2014年12月, 日本語, 日本放射線腫瘍学会, 横浜、パシフィコ横浜, 国内会議進行食道癌による通過障害対する緩和的放射線治療の成績口頭発表（一般）
- 56th Meeting of the American Society of Hematology, 2014年12月, 英語, American Society of Hematology, サンフランシスコ, 国際会議Efficacy of the Two-Dose Influenza Vaccine in Cancer Patients Receiving Chemotherapy: A Prospective Study.ポスター発表
- 第54回日本核医学会学術総会, 2014年11月, 日本語, 日本核医学会, 大阪, 国内会議治療前FDG-PETによる喉頭癌の再発予測口頭発表（一般）
- The 15th Asia Oceania Congress of Radiology, 2014年09月, 英語, Asia Oceania Congress of Radiology, Kobe, We retrospectively reviewed 9 cases who underwent radiotherapy with Cetuximab concurrently. Primary tumor response and acute toxicity are reported. Although mucositis was the most remarkable adverse events, one patient developed grade 5 drug-induced interstitial lung disease., 国際会議Retrospective analysis of whole brain radiotherapy for brain metastasesポスター発表
- The 15th Asian Oceanian Congress of Radiology, 2014年09月, 英語, Asian Oceanian Congress of Radiology, Kobe, The purpose of this study was to compare the risk of HT in squamous cell carcinoma of the head and neck undergoing treatment with CCRT or RT alone at our institution, 国際会議Radiation Induced Hypothyroidism in Squamous Cell Carcinoma of the Head and Neckポスター発表
- The 15th Asian Oceanian Congress of Radiology AOCR 2014, 2014年09月, 英語, Asia Oceania Congress of Radiology, Kobe, 国際会議Experience of radiotherapy plus cetuximab for head and neck cancerポスター発表
- 第12回日本臨床腫瘍学会学術集会, 2014年07月, 日本語, 日本臨床腫瘍学会, 福岡, 国内会議再発・転移粘膜悪性黒色腫に対するdacarbazine単剤療法の後方視的検討口頭発表（一般）
- 第12回日本臨床腫瘍学会学術集会, 2014年07月, 英語, 日本臨床腫瘍学会, 福岡, 国内会議Clinicopathological Analysis of Salivary Duct Carcinoma and Salivary Gland Adenocarcinoma, N.O.Sポスター発表
- 第12回日本臨床腫瘍学会学術集会, 2014年07月, 日本語, 日本臨床腫瘍学会, 福岡, 国内会議A prospective study of the efficacy of influenza vaccination for cancer patients receiving chemotherapy口頭発表（一般）
- 第38回日本頭頸部癌学会, 2014年06月, 日本語, 日本頭頸部癌学会, 東京, 国内会議免疫組織化学染色による唾液腺導管癌15例の検討．口頭発表（一般）
- 第38回頭頸部癌学会, 2014年06月, 日本語, 日本頭頸部癌学会, 東京, 国内会議免疫組織化学染色による唾液腺導管癌15例の検討口頭発表（一般）
- 第38回日本頭頸部癌学会, 2014年06月, 日本語, 日本頭頸部癌学会, 東京, 国内会議頭頸部癌に対するセツキシマブ併用放射線治療の初期経験ポスター発表
- 第38回頭頸部癌学会, 2014年06月, 日本語, 日本頭頸部癌学会, 東京, 中咽頭癌に対する化学放射線療法におけるPEG留置患者の栄養投与量と有害事象を検討, 国内会議中咽頭癌に対する化学放射線療法におけるPEG留置患者の栄養投与量と有害事象口頭発表（一般）
- 第38回頭頸部癌学会, 2014年06月, 日本語, 日本頭頸部癌学会, 東京, 国内会議進行期喉頭癌・下咽頭癌に対する治療戦略口頭発表（一般）
- 第38回頭頸部癌学会, 2014年06月, 日本語, 日本頭頸部癌学会, 東京, 国内会議T3N0-1声門癌に対する喉頭温存を目的とした根治的化学放射線治療の検討口頭発表（一般）
- Eur Soc Medical Oncol, 2014年05月, 英語, ESMO, Madrid, スペイン, 国際会議Phase II study of lenvatinib (LEN), a multi-targeted tyrosine kinase inhibitor, in patients (pts) with all histologic subtypes of advanced thyroid cancer (differentiated, medullary and anaplastic).ポスター発表
- Am Soc Clinc Oncol, 2014年05月, 英語, ASCO, シカゴ, アメリカ, 国際会議Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients.ポスター発表
- 第111回日本内科学会総会, 2014年04月, 日本語, 日本内科学会, 東京, 国内会議当院における唾液腺導管癌15例の臨床病理学的検討．ポスター発表
- 第73回日本医学放射線学会総会, 2014年04月, 英語, 日本医学放射線学会, 横浜、パシフィコ横浜, [Objective] The purpose of this study is to evaluate the results of T3 laryngeal cancer with radiotherapy in our institution.[Materials and Methods] Between 2006 and 2013, 20 patients with T3 laryngeal cancer treated with radiotherapy in our institution. Sixteen patients was diagnosed with N0, 2 patients did with N1, 1 patient did with N2, and 1 patient did with N3 disease. Sev, 国内会議当院におけるT3喉頭癌の放射線治療の経験口頭発表（一般）
- 第73回日本医学放射線学会総会, 2014年04月, 日本語, 日本医学放射線学会, 横浜、パシフィコ横浜, 国内会議Treatment outcomes of radiotherapy for T1/T2 supraglottic carcinomaポスター発表
- 第73回日本医学放射線学会総会, 2014年04月, 日本語, 日本医学放射線学会, 横浜、パシフィコ横浜, The purpose of this study was to compare the risk of HT in squamous cell carcinoma of the head and neck undergoing treatment with CCRT or RT alone at our institution., 国内会議Radiation Induced Hypothyroidism in Squamous Cell Carcinoma of the Head and Neckポスター発表
- 第305回公益社団法人日本医学放射線学会関西地方会, 2013年11月, 日本語, 日本医学放射線学会関西地方会, 大阪(ブリーゼプラザ), 国内会議頭頸部癌に対するセツキシマブ併用放射線治療の初期経験口頭発表（一般）
- 第72回日本癌学会学術総会, 2013年10月, 英語, 日本癌学会, 横浜, 国内会議乳癌における新規治療標的としてのTyro3．ポスター発表
- 日本放射線腫瘍学会第26回学術大会, 2013年10月, 日本語, 日本放射線腫瘍学会, 青森（ホテル青森、リンクステーションホール青森）, 国内会議中・下咽頭扁平上皮癌に対する放射線治療後の甲状腺機能低下症に関する検討口頭発表（一般）
- AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 2013年10月, 英語, American Association for Cancer Research, Boston, USA, 国際会議TYRO3 as a potential therapeutic target in breast cancer.ポスター発表
- 日本放射線腫瘍学会第26回学術大会, 2013年10月, 日本語, 日本放射線腫瘍学会, 青森（ホテル青森、リンクステーションホール青森）, 国内会議T1／2声門上癌に対する放射線治療成績の検討口頭発表（一般）
- AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 2013年10月, 英語, American Association for Cancer Research, Boston, USA, 国際会議Reversibility of acquired resistance and "addiction" to MET inhibitors.ポスター発表
- AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 2013年10月, 英語, American Association for Cancer Research, Boston, USA, 国際会議A Phase I study of single-agent BEZ235 (SDS sachet), once- or twice-daily, in Japanese patients with advanced solid tumors.ポスター発表
- 55th Annual meeting ASTRO, 2013年09月, 英語, ASTRO, Atlanta, GA, USA, 国際会議Radiation Induced Hypothyroidism in Squamous Cell Carcinoma of the Head and Neck: Comparison between Concurrent Chemoradiotherapy and Radiation Therapy Aloneポスター発表
- ECCO2013, 2013年09月, 英語, European CanCer Organisation, Amsterdam, Holland, This is one of the largest clinicopathological reports of major SGC from a single institution in Japan. Prognosis and prognostic factors of SGC were in accordance to previous reports., 国際会議25 year experience with primary salivary gland carcinoma at a single institution in Japan European Journal of Cancer 49,ポスター発表
- 第11回日本臨床腫瘍学会学術集会, 2013年08月, 日本語, 日本臨床腫瘍学会, 仙台, 国内会議ｓｕｎｉｔｉｎｉｂを使用し腸管壊死をきたしたACTH産生神経内分泌腫瘍ポスター発表
- 第11回日本臨床腫瘍学会学術集会, 2013年08月, 日本語, 日本臨床腫瘍学会, 仙台, 国内会議乳癌膵転移の1例ポスター発表
- 第11回日本臨床腫瘍学会学術集会, 2013年08月, 日本語, 日本臨床腫瘍学会, 仙台, 国内会議進行胆道癌に対するGC療法が腎機能に与える影響口頭発表（一般）
- 第11回日本臨床腫瘍学会学術集会, 2013年08月, 日本語, 日本臨床腫瘍学会, 仙台, 国内会議再発・転移頭頸部がんに対するドセタキセル・シスプラチン併用（DC）療法口頭発表（一般）
- 第11回日本臨床腫瘍学会学術集会, 2013年08月, 英語, 日本臨床腫瘍学会, 仙台, 国内会議Excessive MET signaling causes acquired resistance to and addiction to METinhibitors MET-amplifed cancer celllineポスター発表
- 第11回日本臨床腫瘍学会学術集会, 2013年08月, 英語, 日本臨床腫瘍学会, 仙台, We hereby reported a clinicopathologic analysis of 15 Japanese patients with SDC., 国内会議Clinicopathologic Analysis of Salivary Duct Carcinoma in 15 Japanese Patientsポスター発表
- 第37回日本頭頸部癌学会, 2013年06月, 日本語, 日本頭頸部癌学会, 新宿、東京（京王プラザホテル）, 原発不明癌頸部リンパ節転移の約80％が扁平上皮癌であり、悪性黒色腫の頻度は0．9％と非常に稀である。今回我々は頸部リンパ節にのみ転移を認めた原発不明悪性黒色腫の2症例を経験した。症例1は72歳男性。2005年9月に左顎下部腫瘤を主訴に来院し、同部よりの穿刺吸引細胞診で悪性黒色腫の診断が得られた。原発巣は明らかでなく、左顎部敦清術を行った。転移リンパ節は1個であったが節外浸潤を認めたため、術後化学療法としてDAV（Dacarbazine, Nimustine, Vincristine)を8コース施行した。現在術後6年経過し、再発・転移を認めない。症例2は61歳男性。症例1と同様に原発不明悪性黒色腫の診断で左顎部敦清術を行った。多発リンパ節転移と節外浸潤を認めたため、術後にDAVを8コース施行した。現在術後2年経過し、再発・転移を認めない。原発不明悪性黒, 国内会議頸部リンパ節転移を認めた原発不明悪性黒色腫の2例口頭発表（一般）
- 第37回日本頭頸部癌学会, 2013年06月, 日本語, 日本頭頸部癌学会, 新宿、東京（京王プラザホテル）, 国内会議頭頸部扁平上皮癌に対する放射線治療後の甲状腺機能低下症に関する検討ポスター発表
- 第37回日本頭頸部癌学会, 2013年06月, 日本語, 日本頭頸部癌学会, 東京, 当院におけるSDC 15例の臨床病理学的特徴を報告した。, 国内会議当院における唾液腺導管癌15例の臨床病理学的特徴ポスター発表
- 第37回日本頭頸部癌学会, 2013年06月, 日本語, 日本頭頸部癌学会, 新宿、東京（京王プラザホテル）, 国内会議当院におけるT3喉頭癌の放射線治療の経験口頭発表（一般）
- 第37回日本頭頸部癌学会, 2013年06月, 日本語, 日本頭頸部癌学会, 新宿、東京（京王プラザホテル）, 国内会議進行舌癌に対する術後放射線治療の経験ポスター発表
- 第37回日本頭頸部癌学会, 2013年06月, 日本語, 日本頭頸部癌学会, 新宿、東京（京王プラザホテル）, 国内会議再発・転移頭頸部がんに対するドセタキセル・シスプラチン併用（DC）療法口頭発表（一般）
- 第37回日本頭頸部癌学会, 2013年06月, 日本語, 日本頭頸部癌学会, 新宿、東京（京王プラザホテル）, 国内会議T1／2声門上癌に対する放射線治療成績の検討ポスター発表
- European Congress of Radiology（ECR, 2013年03月, 英語, European Society of Radiology, Austria,Vienna, Purpose/Objective(s): To assess the efficacy of radiation therapy for Squamous cell carcinomas of oropharynx at Kobe University Hospital retrospectively.Materials/Methods: Between July 2000 and March 2011, 98 patients with squamous cell carcinomas of the oropharynx were treated with radiotherapy at Kobe University Hospital. Patients treated with palliative intent, or who had me, 国際会議Ten Year Experience with Combined Modality Therapy Including Radiotherapy for Squamous Cell Carcinomas of Oropharynxポスター発表
- 日本放射線腫瘍学会第25回学術大会, 2012年11月, 日本語, 日本放射線腫瘍学会, 東京（東京国際フォーラム）, 【目的】当院における中咽頭扁平上皮癌の放射線治療成績を遡及的に検討する。【方法】2000年7月から2011年1月までに当院にて中咽頭扁平上皮癌と診断され、放射線治療を施行した96例を対象とした。年齢の中央値は62歳（31-96歳）、男:女=80:16であった。亜部位は前壁：側壁：後壁：上壁＝24：57：3：12、進展度はT1：T2：T3：T4a：T4b＝6：54：17：10：5、N0：N1：N2a：N2b：N2c：N3＝18：14：6：32：17：9であった。手術は13例に施行され、化学療法の併用は81例（同時併用76例）、処方線量の中央値は70Gy（60-70.8Gy）であった。【結果】経過観察期間の中央値は25.5か月(3-141か月)。3年の全生存割合は76％で、無再発生存割合は66％、局所領域制御割合は70％であった。病期別の3年全生存割合は, 国内会議当院における中咽頭扁平上皮癌に対する放射線治療成績ポスター発表
- 頭頸部がんに対する超選択的動注化学療法の実技, 2012年11月, 日本語, 厚生労働省がん臨床研究事業, 札幌, 上顎洞癌の治療について, 国内会議上顎洞癌の治療総論公開講演，セミナー，チュートリアル，講習，講義等
- 進行頭頸部がんに対する集学的治療としての薬物療法と放射線療法, 2012年11月, 日本語, 厚生労働省がん臨床研究事業, 東京, 術後化学放射線療法の有用性について, 国内会議術後ハイリスク症例に対する化学放射線療法公開講演，セミナー，チュートリアル，講習，講義等
- 24rh EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, 2012年11月, 英語, EORTC-NCI-AACR, Dublin, Ireland, Excessive MET signaling causes acquired resistance to and addiction to MET inhibitors in MKN45 gastric cancer cell line, 国際会議Excessive MET signaling causes acquired resistance to and addiction to MET inhibitors in MKN45 gastric cancer cell lineポスター発表
- 第50回日本癌治療学会学術集会, 2012年10月, 日本語, 日本癌治療学会, 横浜, 頭頸部がんの分子標的薬の適正使用, 国内会議頭頸部がん治療の過去と未来 頭頸部がんの分子標的治療について[招待有り]シンポジウム・ワークショップパネル（指名）
- 54th ASTRO Annual Meeting, 2012年10月, 英語, ASTRO, U.S.A , Boston, 国際会議Patterns of Local Recurrence and Metachronous Malignancy Following Radiation Therapy for Stage I or II Hypopharyngeal Carcinoma: Role of Close Observation and Multidisciplinary Approachポスター発表
- European Society of Medical Oncology, 2012, 2012年10月, 英語, European Society of Medical Oncology, Viena, A randomized phase II trial comparing standard pain control with or witout gabapentin for the treatment of pain related radiation-induced mucositis head and neck cancer, 国際会議A randomized phase II trial comparing standard pain control with or witout gabapentin for the treatment of pain related radiation-induced mucositis head and neck cancerポスター発表
- 第71回日本癌学会学術総会, 2012年09月, 英語, 日本癌学会, 札幌, MCF-7乳癌細胞株における insuylin-like growth factor 1 receptor受容体阻害薬に対する獲得耐性機構, 国内会議MCF-7乳癌細胞株における insuylin-like growth factor 1 receptor受容体阻害薬に対する獲得耐性機構ポスター発表
- 37th Congress of the European-Society-for-Medical-Oncology (ESMO), 2012年09月, 英語, Vienna, AUSTRIA, 国際会議A RANDOMIZED PHASE II TRIAL COMPARING STANDARD PAIN CONTROL WITH OR WITHOUT GABAPENTIN FOR THE TREATMENT OF PAIN RELATED TO RADIATION-INDUCED MUCOSITIS IN HEAD AND NECK CANCERポスター発表
- 第10回日本臨床腫瘍学会学術集会, 2012年07月, 日本語, 日本臨床腫瘍学会, 大阪, 頭頸部がんの薬物療法のトピックの紹介, 国内会議頭頸部がん：頭頸部がん薬物療法のトピック[招待有り]口頭発表（招待・特別）
- 第10回日本臨床腫瘍学会学術集会, 2012年07月, 日本語, 日本臨床腫瘍学会, 大阪, cancer related VTEの現状, 国内会議当科における悪性腫瘍に伴う静脈血栓塞栓症（VTE）の検討ポスター発表
- 第10回日本臨床腫瘍学会学術集会, 2012年07月, 日本語, 日本臨床腫瘍学会, 大阪, 当科においける静脈血栓塞栓症(VTE) 症例の検討, 国内会議当科においける静脈血栓塞栓症(VTE) 症例の検討ポスター発表
- 第10回日本臨床腫瘍学会学術集会, 2012年07月, 日本語, 日本臨床腫瘍学会, 大阪, 切除不能神経内分泌腫瘍に対するダカルバジン単剤療法：後方視的解析, 国内会議切除不能神経内分泌腫瘍に対するダカルバジン単剤療法：後方視的解析ポスター発表
- The 6th S.Takahashi Memorial Symposium & The 6th Japan-US Cancer Therapy International Joint Symposium, 2012年07月, 英語, 高橋信次記念三次元原体照射国際学会, 広島県（広島国際会議場）, Purpose: To assess the efficacy radiation therapy for Squamous cell carcinomas of oropharynx at Kobe University Hospital retrospectively.Methods: Between September 1990 and January 2011, 138 patients with Squamous cell carcinomas of the oropharynx were treated with radiotherapy at Kobe University Hospital. The median age was 61 years (range 31-96) with 117 male and 21 female pa, 国際会議Radiotherapy for Squamous Cell Carcinomas of Oropharynxポスター発表
- The 6th S.Takahashi Memorial Symposium & The 6th Japan-US Cancer Therapy International Joint Symposium, 2012年07月, 英語, 高橋信次記念三次元原体照射国際学会, 広島県（広島国際会議場）, 国際会議Chemoradiotherapy in Patients with Locally Advanced Unresectable Esophageal Squamous Cell Carcinomaポスター発表
- 第10回日本臨床腫瘍学会学術集会, 2012年07月, 日本語, 日本臨床腫瘍学会, 大阪, 国内会議A Pilot Randomized Trial Comparing Standard Pain Control with or without Gabapentin for the Treatment of Pain Related to Radiation-induced Mucositis in Head and Neck Cancer口頭発表（一般）
- 第36回日本頭頸部癌学会, 2012年06月, 日本語, 日本頭頸部癌学会, 島根県松江市（島根県民会館）, 国内会議頸部リンパ節転移を認めた原発不明悪性黒色腫の2例口頭発表（一般）
- 第36回日本頭頸部癌学会, 2012年06月, 日本語, 日本頭頸部癌学会, 松江, 頭頸部がんの分子標的薬の適正使用, 国内会議分子標的薬の適正な使用について 頭頸部がん領域における分子標的薬の適正な使用について[招待有り]シンポジウム・ワークショップパネル（指名）
- 第36回日本頭頸部癌学会, 2012年06月, 日本語, 日本頭頸部癌学会, 松江, 放射線粘膜炎に対するガバペンチンの有用性, 国内会議頭頸部癌患者における放射線性粘膜炎による疼痛に対するガバペンチンのパイロット・ランダム化比較試験口頭発表（一般）
- 第36回日本頭頸部癌学会, 2012年06月, 日本語, 日本頭頸部癌学会, 島根県松江市（島根県民会館）, 【目的】当院における中咽頭扁平上皮癌の放射線治療成績を遡及的に検討する。【方法】1990年9月から2011年1月までに当院にて中咽頭扁平上皮癌と診断され、放射線治療を施行した138例を対象とした。年齢の中央値は61歳（31-96歳）、男:女=117:21、経過観察期間の中央値は27か月(3-209か月)であった。亜部位は前壁：側壁：後壁：上壁＝39：77：4：18、進展度はT1：T2：T3：T4＝8：71：26：33、N0：N1：N2：N3＝23：21：80：14であった。手術は33例に施行され、化学療法の併用は112例（同時併用91例）、処方線量の中央値は70Gy（50-76.8Gy）であった。【結果】経過観察期間の中央値は27か月(3-209か月)。3年の全生存割合は73％で、無再発生存割合は65％、局所領域制御割合は73％であった。病期別の3年, 国内会議当院における中咽頭扁平上皮癌に対する放射線治療成績口頭発表（一般）
- 第66回日本食道学会学術集会, 2012年06月, 日本語, 日本食道学会, 軽井沢, 国内会議当院における高齢者食道癌の内科的治療の成績と戦略についてポスター発表
- 第36回日本頭頸部癌学会, 2012年06月, 日本語, 日本頭頸部癌学会, 松江, 多診療科連携にて治療した頭頸部肉腫の検討, 国内会議多診療科共同で集学的治療を行った頭頸部原発骨軟部肉腫の2例ポスター発表
- 2012 ASCO Annual Meeting, 2012年06月, 英語, ASCO, Chicago, 国際会議Phase II trial of chemoradiotherapy concurrent with S-1 plus cisplatin in patients with unresectable, locally advanced squamous cell carcinoma of the head and neck (SCCHN): Results of the Japan Clinical Oncology Group study, JCOG 0706ポスター発表
- 第109回日本内科学会講演会, 2012年04月, 日本語, 日本内科学会, 京都, 切除不能高分化神経内分泌腫瘍に対するダカルバジン療法, 国内会議切除不能高分化神経内分泌腫瘍に対するダカルバジン療法ポスター発表
- 第109回日本内科学会講演会, 2012年04月, 日本語, 日本内科学会, 京都, 抗がん薬投与におけるeGFRの有用性の検討, 国内会議抗がん薬投与におけるeGFRの有用性の検討ポスター発表
- 第109回日本内科学会講演会, 2012年04月, 日本語, 日本内科学会, 京都, Extra-pulmonary neuroendocrine carcinoma (EP-NEC) に対する救済化学療法としてのアムルビシン（AMR）の効果, 国内会議Extra-pulmonary neuroendocrine carcinoma (EP-NEC) に対する救済化学療法としてのアムルビシン（AMR）の効果ポスター発表
- 第24回日本放射線腫瘍学会, 2011年11月, 日本語, 日本放射線腫瘍学会, 神戸ポートピアホテル（神戸市）, 国内会議再建遊離空腸に対する術後(化学)放射線療法の検討口頭発表（一般）
- 第35回日本頭頸部癌学会, 2011年06月, 日本語, 日本頭頸部癌学会, ウインク愛知（名古屋市）, 国内会議遊離空腸再建後の高リスク頭頸部癌に対する術後放射線治療の検討口頭発表（一般）
- 第35回日本頭頸部癌学会, 2011年06月, 日本語, 日本頭頸部癌学会, ウインク愛知（名古屋市）, 国内会議当科における喉頭機能温存手術の検討口頭発表（一般）
- 第35回日本頭頸部癌学会, 2011年06月, 日本語, 日本頭頸部癌学会, ウインク愛知（名古屋市）, 国内会議切除不能頭頸部癌に対するSequential therapyの安全性に関する後向き研究口頭発表（一般）
- 第35回日本頭頸部癌学会, 2011年06月, 日本語, 日本頭頸部癌学会, ウインク愛知（名古屋市）, 国内会議局所進行外耳道扁平上皮癌に対する3剤(TPF)併用化学放射線療法の経験口頭発表（一般）
- 第70回日本医学放射線学会総会, 2011年05月, 日本語, 日本医学放射線学会, 震災の影響によりWEB開催, 国内会議原発不明頸部リンパ節転移に対する治療経験口頭発表（一般）
- 第70回日本医学放射線学会総会, 2011年05月, 日本語, 日本医学放射線学会, 震災の影響によりWEB開催, 国内会議局所進行外耳道扁平上皮癌に対する3剤（TPF）併用化学放射線療法の経験口頭発表（一般）
- 第33回日本造血細胞移植学会総会, 2011年03月, 日本語, 日本造血細胞移植学会, 松山, 国内会議臍帯血移植前にﾎﾞﾘｺﾅｿﾞｰﾙ水晶体内投与が有効であった真菌性眼内炎ポスター発表
- 第33回日本造血細胞移植学会総会, 2011年03月, 日本語, 日本造血細胞移植学会, 松山, 国内会議急性GVHD予防薬ﾐｺﾌｪﾉｰﾙ酸ﾓﾌｪﾁﾙ（MMF)使用下における移植後G-CSF至適投与量の検討ポスター発表
- シンポジウム「頭頸部がんに対する化学放射線療法の適応と実践」, 2010年12月, 日本語, 日本対がん協会「がん医療水準均てん化推進事業」, 東京, 国内会議局所進行頭頸部癌に対する化学放射線療法の実践的管理口頭発表（招待・特別）
- 日本放射線腫瘍学会第23回学術大会, 2010年11月, 日本語, 東京, 国内会議局所進行外自動扁平上皮癌に対する3剤（TPF）併用化学放射線療法の経験口頭発表（一般）
- 22nd EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics 2010, 2010年11月, 英語, EORTC, NCI, AACR, ベルリン, ドイツ, 国際会議Foretinib (GSK1363089) inhibits growth of gastric cancer cell lines through blockade of inter-receptor tyrosine kinases networks.ポスター発表
- 第72回日本血液学会総会, 2010年09月, 日本語, 日本血液学会, 横浜, 国内会議Therapy-related pure erythroid leukemia with hemophagocytic syndromeポスター発表
- 第35回 神戸放射線腫瘍懇話会, 2010年08月, 日本語, 神戸, 国内会議原発不明癌頸部リンパ節転移に対する治療経験口頭発表（一般）
- 第34回日本頭頸部癌学会, 2010年06月, 日本語, 日本頭頸部癌学会, 東京, 国内会議本邦における頭頸部癌化学療法の展望 化学療法臨床研究の現状での問題点と対策口頭発表（招待・特別）
- 第34回頭頚部癌学会, 2010年06月, 日本語, 東京（新宿）, 国内会議原発不明癌頚部リンパ節転移に対する治療経験口頭発表（一般）
- 第34回日本頭頸部癌学会, 2010年06月, 日本語, 日本頭頸部癌学会, 東京, 国内会議局所進行頭頸部扁平上皮癌術後再発High-Risk群に対するHigh-dose CDDP+RTの実施可能性試験口頭発表（一般）
- 第34回頭頚部癌学会, 2010年06月, 日本語, 東京（新宿）, 国内会議下咽頭癌に対する術後放射線治療の遡及的検討口頭発表（一般）
- 第107回日本内科学会講演会, 2010年04月, 日本語, 日本内科学会, 東京, 国内会議結腸直腸がんに対するmFOLFOX6/FOLFIRI±Bevacizumab療法における甲状腺機能の評価ポスター発表
- 臨床腫瘍学会, 2010年03月, 英語, 日本臨床腫瘍学会, 東京, 国内会議Effect of axitinib (AG-013736) on thyroid function and biomarkers in Japanese patients with advanced solid tumors.ポスター発表
- 21st EORTH-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, 2009年11月, 英語, AACR, Boston, 米国, 国際会議Effect of axitinib (AG-013736) on thyroid function and biomarkers: results form phase I studies in Japanese patients.ポスター発表
- 21st EORTH-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, 2009年11月, 英語, AACR, Boston, 米国, 国際会議A phase I study of sorafenib (BAY 43-9006) in combination with S-1 plus cisplatin in patients with advanced gastric cancer.ポスター発表
- 第48回日本医学放射線学会生物部会学術大会, 2009年07月, 日本語, 日本医学放射線学会生物部会, 富山, 国内会議頭頚部癌に対する集学的治療の取り組み中での放射線生物学の役割口頭発表（一般）
- 第33回日本頭頸部癌学会, 2009年06月, 日本語, 日本頭頸部癌学会, 東京, 国内会議頭頸部癌患者に対する化学放射線療法に嚥下リハビリテーションを導入した症例の検討口頭発表（一般）
- 第33回日本頭頸部癌学会, 2009年06月, 日本語, 日本頭頸部癌学会, 東京, 国内会議頭頸部がん治療における多職種医療普及のためのサテライト講演会 その成果と課題ポスター発表
- Am Soc Clin Oncol, 2009年06月, 英語, 米国臨床腫瘍学会, Orland, 米国, 国際会議Final results of a phase I trial of chemotherapy combination with docetaxel, cisplatin ,and S-1 (TPS) in patients with locally advanced or recurrent metastatic head and neck cancer.ポスター発表
- 第5回日本臨床腫瘍学会学術総会, 2007年03月, 日本語, 日本臨床腫瘍学会, 札幌, 国内会議根治切除不能局所進行頭頸部扁平上皮癌(LASCCHN)に対する5-FU、Cisplatin同時併用化学放射線療法の有用性に関する後ろ向き検討ポスター発表
- 1. Relationship between tumor burden to growth rate and treatment outcomes of nivolumab for patients with head and neck squamous carcinoma.
- 日本学術振興会, 科学研究費助成事業, 基盤研究(B), 東海大学, 2024年04月01日 - 2028年03月31日難聴発症および重症化に関わる遺伝的素因と後天的要因の解明研究
- 日本学術振興会, 科学研究費助成事業, 基盤研究(B), 神戸大学, 2023年04月01日 - 2027年03月31日B細胞を軸とした免疫チェックポイント阻害の有害事象の包括的機序解明と効果の推定
- 日本学術振興会, 科学研究費助成事業, 基盤研究(C), 神戸大学, 2023年04月01日 - 2026年03月31日唾液腺癌における免疫微小環境の特徴と免疫関連バイオマーカーの探索
- 日本学術振興会, 科学研究費助成事業 基盤研究(C), 基盤研究(C), 神戸大学, 2020年04月01日 - 2023年03月31日鼻副鼻腔神経内分泌悪性腫瘍の遺伝子変化と免疫チェックポイント分子発現に関する研究令和２年度の検討において、当院における鼻副鼻腔悪性腫瘍データベースの137例中、鼻副鼻腔神経内分泌悪性腫瘍の60例を抽出し、主たる組織型は嗅神経芽細胞腫（ONB）が利用可能な組織検体を有する症例に絞り込みを行った。その結果、本研究の中心である腫瘍の体細胞遺伝子変異の程度と免疫多重染色による腫瘍内及び腫瘍周囲免疫細胞の関係を検討する上で十分な症例数を確保できるのはONB 27例であった。組織型別に進行期及び転帰は、Kadish A/B/C/D/unkown（2/3/17/1/4）であり、ONB全症例における観察期間中央値は4.9年で全体での5年生存割合は92%であった。本研究に十分利用可能な組織検体については、ONB 27例中26例で手術検体が利用可能であり、病理診断科の協力の下に組織型の再レビューを行った。また、次世代シーケンサー（NGS）を用いた遺伝子変異解析及び、免疫多重染色については、研究協力者である近畿大学医学部ゲノム生物学教室及びがん研究会有明病院先端医療センターと検討を重ねた。この結果、免疫多重染色を行う上で重要な腫瘍細胞を標識する抗体を決定することができた。また、組織検体の研究協力機関への移送には本研究に関するプロトコール作成と倫理審査（神戸大学での一括審査）が必要であり、プロトコール作成を行い神戸大学大学院医学研究科等医学倫理委員会に提出した。NGS及び免疫多重染色を行うために必要な腫瘍組織標本の作製は、耳鼻咽喉・頭頸部外科の協力の下に行うことが決定した。
- 国立研究開発法人日本医療研究開発機構, 革新的がん医療実用化研究事業, 国立大学法人神戸大学, 2019年04月 - 2023年03月, 研究代表者がん患者における患者報告アウトカム尺度開発に関する研究
- 日本学術振興会, 科学研究費助成事業 基盤研究(C), 基盤研究(C), 神戸大学, 2017年04月01日 - 2020年03月31日, 研究代表者Stage III/IVの唾液腺癌術後症例で粘表皮癌（low grade/high grade)、唾液腺導管癌、腺癌、腺様のう胞癌の各7例合計35例を解析した。遺伝子変化は、Oncomine Tumor Mutation Load Assayを使用、免疫多重染色はCD3/CD4/CD8/CD204/FOXP3/PD-L1/PD-L2を用いて行った。Tumor Mutation Load（TML）は粘表皮癌(High grade)、唾液腺導管癌及び腺癌で高い傾向を認めた。免疫多重染色からは、組織型に関係なく腫瘍内Treg密度とPD-L1陽性細胞が予後不良因子である可能性が示唆された。競争的資金
- 日本学術振興会, 科学研究費助成事業 基盤研究(C), 基盤研究(C), 神戸大学, 2014年04月01日 - 2017年03月31日, 研究代表者唾液腺腺癌の中には唾液腺導管癌と免疫組織学的に類似したアンドロゲン陽性唾液腺腺癌が存在し予後不良であった。また、AR陰性唾液腺腺癌はAR陽性唾液腺腺癌及び唾液腺導管癌とは全く異なる免疫組織学的特徴を有し、遺伝子学的特徴も全く異なる疾患であることが見いだされた。 また、アンドロゲン陽性唾液腺腺癌はHER2陽性例が多く、唾液腺導管癌と共に今後はこうアンドロゲン療法や抗HER2療法の対象として治療開発を行えることが見いだされた。さらには、唾液腺腺癌の中にはflt3やRETのような既存の分子標的薬で治療可能な遺伝子変異が存在することも判明し今後症例数を増やして検討を進める。競争的資金
- 国立研究開発法人国立がん研究センター, 革新的がん医療実用化研究事業, 2017年, 研究代表者（AMED）進行頭頸部がんに対する術後補助療法の標準治療確立のための多施設共同研究/頭頸部癌に対する新たな術後補助療法の開発競争的資金
- 国立大学法人北海道大学, 革新的がん医療実用化研究事業, 2017年, 研究代表者（AMED）進行上顎洞癌に対する超選択的動注化学療法を併用した放射線治療による新規治療法開発に関する研究競争的資金
- 公立大学法人大阪市立大学, 革新的がん医療実用化研究事業, 2017年, 研究代表者（AMED）甲状腺未分化癌の標準的治療法の開発に向けた全国的組織を用いた医師主導臨床試験の企画/（４） 術前化学療法臨床試験のプロトコール作成（５） 化学放射線療法のプロトコール作成競争的資金
- 国立大学法人北海道大学, 臨床研究・治験推進研究事業(CRT事業）, 2017年, 研究代表者（AMED）HER2陽性再発転移の唾液癌に対する個別化治療の開発競争的資金
- 革新的がん医療実用化研究事業, 2016年, 研究代表者（AMED）頭頸部腫瘍に対する強度変調放射線治療の確立と標準化のための臨床研究/頭頸部癌に対するIMRTの有用性に関する研究競争的資金
- 革新的がん医療実用化研究事業, 2016年, 研究代表者（AMED）進行頭頸部がんに対する術後補助療法の標準治療確立のための多施設共同研究/頭頸部癌に対する術後補助療法の開発競争的資金
- 革新的がん医療実用化研究事業, 2016年, 研究代表者（AMED）進行上顎洞癌に対する超選択的動注化学療法を併用した放射線治療による新規治療法開発に関する研究競争的資金
- 革新的医療技術創出拠点プロジェクト（早期探索的・国際水準臨床研究事業）, 2016年, 研究代表者（AMED）新規医薬品・医療機器等の創出、難治性疾患の治療法の開発および最適な治療法の確立に関する研究/HER2過剰発現・遺伝子増幅腫瘍あるいはHER2遺伝子変異陽性腫瘍に競争的資金
- 国立がん研究センター研究開発費, 2016年, 研究代表者成人固形がんに対する標準治療確立のための基盤研究/頭頸部がんに対する標準治療確立のための多施設共同研究競争的資金
- 2010年, 研究代表者厚生科研「進行頭頸部がんに対する科学放射線療法を中心とした集学的治療の開発に関する研究」競争的資金